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ABSTRACT
NMR-BASED AND AUTOMATED DOCKING CHARACTERIZATION OF
PROTEIN STRUCTURE, DYNAMICS, AND LIGAND BINDING

Andrew L. Olson
Marquette University, 2010

NMR-based methods used in conjunction with a technique called docking are
used to characterize ligand binding to proteins. Standard NMR methods were used to
study the backbone dynamics of substrate binding to phosphomevalonate kinase (PMK)
and it was observed that ligand binding caused PMK to undergo large conformational
changes. These changes were reflected by the appearance of many chemical shift
changes upon binding of the natural substrates of PMK (both the binary and ternary
complexes) in 1H-15N HSQC NMR titration experiments. The same process was used to
characterize the effect ligand binding has on the many arginines in the active site (and
distal to the active site) to determine the effect of long-range coulombic interactions on
ligand binding. While studying the backbone dynamics of PMK it was discovered that
the N-terminal tail of PMK consisting of 10 residues was very disordered which is unlike
every other monphosphate kinase. The function of this N-terminal tail was investigated
by attempting to find other proteins in human liver cells that bind this peptide, monitored
by ESI mass spectrometry.
The thioredoxin system of Mycobacterium Tuberculosis consists of a thioredoxin
reductase and three thioredoxins. To help facilitate the understanding of this mechanism
the solution structures of the oxidized and the reduced forms of thioredoxin C (TrxC)
were solved by NMR and modeled with the crystal structure of the thioredoxin reductase
complex. The two redox states of TrxC are very similar to each other with most of the
differences coming from subtle changes in the active site of TrxC.
Automated docking is the process of computationally determining how a ligand
binds to a protein and the correct orientation. A large scale docking study, termed virtual
screening, was carried out by docking 10,590 compounds into three proteins to find
inhibitors for each protein, and those predicted to bind best were tested experimentally.
For each protein there were 3 compounds found to bind with reasonable affinity.
When ligands bind to a protein they can undergo dynamic changes. To explore
this phenomenon, 15N labeled NAD+ cofactor (and other derivatives) was synthesized
and bound to oxidoreductases. Relevant binding motions were monitored using CPMG
relaxation NMR experiments.
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CHAPTER I. Introduction to the Methods Used to Characterize Protein Structure,
Function, and Ligand Binding.

2
1.1

Introduction
To study a protein and its interactions with substrates can be a difficult task since

one needs knowledge of the protein structure as well as how the protein behaves upon
binding its specific ligand. To help facilitate this task we employ standard NMR methods
to study the protein structure and the dynamical properties associated with ligand
binding. NMR is special in this way because we can observe ligand binding and residual
dynamics information site specifically, since 15N-labeled protein gives us information
about each amino acid residue (amide bond) in the protein (except prolines) in the 1H-15N
HSQC (Heteronuclear Single Quantum Correlation) experiment (Figure 1). After we
have a structure and relevant dynamical information we can begin to assess how ligands
bind to the protein, not only its natural substrates but also inhibitors, and other proteins.
This can be done computationally, using a method called automated docking.

Figure 1.1. Heteronuclear single quantum correlation experiment (1H-15N HSQC) of
Thioredoxin C protein with amide (N-H) crosspeaks labeled with amino acid residue
numbers.
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1.1.2

Protein Structure Determination using NMR
Protein structures, due to their size, can be difficult to solve. The two common

methods for this are x-ray crystallography and NMR. The advantage of using NMR is
that the protein is in its native state (being in solution) and not packed into a solid crystal.
There are limitations however, mostly due to the size of the protein, in that for proteins >
25 kDa crosspeak overlap is an issue. To solve protein solution structures using NMR,
an extensive set of experiments are acquired on 13C-15N-(2D) labeled protein (Scheme
1.1). The backbone amides of the 1H-15N HSQC are generally assigned first using 6 3-D
NMR experiments, which are 1) HNCO and HN(CA)CO, 2) CBCA(CO)NH and
HNCACB, 3) HNCA and HN(CO)CA. Briefly, magnetization starts on the amide proton
and transfers to the nitrogen, which then transfers to the following atoms in the sequence
(for example, to Cα and Cβ carbons, in the HNCACB experiment), which are described
in the title of the experiment. These experiments are run in the pairs stated above, in
which one experiment’s chemical shifts will align themselves in the exact same chemical
shift as its partner experiment, allowing for that chemical shift to be assigned (Figure
1.2). This is done until every chemical shift in the 1H-15N HSQC is assigned.
The backbone assignments are then used to aid in the assignment of the sidechain
protons and carbons of all the residues that appear in the 1H-15N HSQC (Figure 1.1). We
do this with the 3-D experiments CBCA(CO)NH and CC(CO)NH which are used to
assign the carbons of the side chains, HBHA(CO)NH and HCC(CO)NH which are used
to assign all the protons in the side chains, and with HCCH-TOCSY which correlates all
protons and carbons together. Getting as many assignments made as possible is very
important as this will lead to more distance constraints for structure generation. These
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constraints come from 13C-NOESY (aromatic and aliphatic) and 15N-NOESY spectra.
These experiments are also 3-D experiments that have the heteroatom chemical shift as
the third dimensions, and are directly used in structure calcuation. The NOESY
experiments are based on the Nuclear Overhauser Effect in which cross peaks arise if
there are protons in proximity of each other (< 5 Å). Since there are many residues in a
protein, all whose protons “see” other protons through the NOE (cross peak), it is
common to have up to 5000-6000 cross peaks for a (~12 kDa protein) amongst the three
NOESY spectra. These cross peaks are used to determine the structure of the protein
since they all provide distance restraints, which the program CYANA1, 2 uses to calculate
an ensemble of protein structures based on torsion angle dynamics, a molecular dynamics
simulation that uses only torsion angles of the backbone as degrees of freedom instead of
Cartesian coordinates. CYANA only calculates the proper folding of the protein based
on these NOE-derived, TALOS (chemical shifts)3, and covalent bonding (connectivity)
constraints. To get the correct geometry of the side chains with full consideration of
inter-atom energetic effects (ex. H-bonds and Van der Waals interactions), the calculated
structure undergoes water refinement which is a simulated annealing protocol using the
AMBER molecular force field where the protein is heated rapidly to overcome any local
minima barriers, it is then allowed to explore higher energy states, and is then cooled
slowly so that it finds its lowest energy minima. This is done repeatedly (ex. 100 times)
to generate an “ensemble” of structures that are consistent with all constraints. Precision
of the calculated structures is quantified using a RMSD (root mean squared deviation) for
atoms in the protein backbone and again for all heavy atoms.

5

Scheme 1.1. Flow chart detailing the steps to solving protein structure using NMR.

6

Figure 1.2. Illustration of sequential assignment process using 3D HNCACB and
CBCA(CO)NH spectra. Residues are i (amino acid of interest), i-1 (amino acid
proeceeding i), and i+1 (amino acid after i). Shown are pairs of strips from 1H-13C planes
at a particular 15N chemical shift. Typically, there would be one such pair of strips (15N
planes) per amino acid, in a protein (except for prolines and the N-terminus)
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Figure 1.3. Representation of a A) random secondary structure, B) random secondary
structure with all the restraints from the 13C and 15N NOESY experiments applied, and C)
the experimental restraints turned into distance restraints in CYANA calculations, used to
define the secondary and tertiary structure. Figures taken from NMRFAM Workshop.
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1.1.3

Relaxation Dynamics Studies of Protein Backbone N-H’s
Protein motions are critical for various biological functions and occur over a wide

range of timescales. There is a strong correlation between structural dynamics and
molecular function, and studying these dynamic processes can give site-specific
information on motions that span timescales from psec to msec4. We can characterize
these dynamic processes by use of NMR with 15N-labelled protein and relaxation
experiments (measure longitudinal relaxation rate R1 (1/T1), transverse relaxation rate R2
(1/T2), and the heteronuclear NOE for the amide N-H bond) in conjunction with a
Modelfree analysis. The Modelfree analysis utilizes the R1, R2, and NOE values obtained
from the relaxation dynamics experiments, and the spectral density equations:
R1= 1/4 d2[3J(ωN) + 7J(ωh) + c2J(ωN)

Eq. 1.1

R2= 1/8 d2[4J(0) + 3J(ωN) + 13J(ωh)] + 1/6c2[4J(0) + 3J(ωN)]

Eq. 1.2

NOE = 1 + ¼ T1d2(γH/γN)[5J(ωh)]

Eq. 1.3

J(ω) = 2/5[(S2τm/1+ (ωτm)2) + ((Sf 2 − S2)τ/1+ (ωτm)2

Eq. 1.4

in which the spectral density equations are fitted at each Larmor frequency ω (nitrogen
and proton) and at given field strength using experimentally measured values of

relaxation parameters (R1, R2, and NOE ) to find S2 and τm. In the above equations, c
and d are both constants; γ is the gyromagnetic ratio for nitrogen or proton; S2 is the
generalized order parameter for movement of the N-H bond vector; Sf is the generalized
order parameter on the sub-nsec timescale; τm is the isotropic rotational correlation time
for the whole protein, and τ = τm τe / (τe + τm) where τe is the effective correlation time for
internal motions within the protein (ex. Loop motions)5-8. This allows us to quantify any
changes to the fast timescale motion (psec-nsec) of the protein backbone, especially for
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catalytically relevant regions, by solving to find the generalized order parameter S2 (S2 =1
means completely restricted and immobile, S2 =0 means no restriction and completely
mobile). The Modelfree analysis can also provide insight into the state of the overall
conformational motions of the protein, and how they change upon substrate addition, by
measuring the correlation time (τm) for each complex (high τm means the protein tumbles
slower and behaves like a larger protein; low τm means the protein tumbles faster and
behaves like a smaller protein).8

1.1.4

Automated Docking and Virtual Screening
Docking is the process of positioning a ligand into the binding site of a protein, by

computationally exploring different translations, orientations, and conformations until a
lowest energy structure and “pose” orientation is found. There are many programs that
are fully capable of virtual screening such as DOCK9, FlexX10, Glide11, and AutoDock12.
AutoDock is currently the docking program that is in use for virtual screening at
Marquette University. AutoDock uses a genetic algorithm (GA) to sample multiple
conformations of a ligand when binding to a protein. AutoDock will use those
coordinates and make derivations to the ligand structure based on the “fitness” level of
the previous generation of ligands, meaning if a certain ligand binds poorly the
coordinates of that ligand will not be used for further “generations.” However, if a ligand
binds well, AutoDock will keep those coordinates and then optimize the binding by
sampling other torsions of the ligand. “Fitness” is calculated using a target function that
is similar to a forcefield equation that describes energy of interactions between the
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protein and ligand. The GA optimizes the ligands pose to obtain the lowest energy
function.
To quantitatively assess how well a ligand binds, AutoDock employs an
“expanded” version of the free energy equation shown below,

ΔG = ΔGvdw + ΔGhbond + ΔGelec + ΔGconform + ΔGtor + ΔGsol

Eq. 1.5

Where the first four terms are for the free energy terms for Van der Waals forces,
hydrogen bonding, electrostatics, and deviations from covalent geometry and are typical
for molecular mechanics free energy equations. The latter two terms are the expanded
portion of the equation and are the free energy terms for rotation of internal torsions
(internatl entropy) and desolvation upon binding (modeling hydrophobic effects and
solvent entropic changes upon binding)12.
The experimental information that AutoDock provides is written out at the end of
the docking session in a docking log file (dlg file). After the docking is finished and the
50 poses are generated (Figure 1.4), AutoDock then puts them through a clustering
analysis to define which poses are similar enough to each other to cluster them together
(within an RMSD of 2 Å). Clustering offers an additional verification of the likelihood
that a certain pose is the correct pose for the ligand binding to the protein. Figure 1.5
shows examples of this clustering analysis where A) had a very low energy of binding
compound at (-10.11 kcal/mol) but there are many different clusters with few poses in
each cluster. In practice, this indicates a low probability of binding. Figure 1.5B shows a
cluster histogram for a compound with a slightly higher binding energy, but the
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probability of this being an accurate pose is higher since there are fewer number of
sparsely populated clusters, yet in the lowest energy cluster there are nearly half the
number of poses clustered together. In general, an accurate pose (and prediction that a
compound binds to a protein) is more likely if there is one populated cluster.

Figure 1.4. A docking experiment where AutoDock generated 50 poses (all 50 are
shown) of a structure in the active site of phosphomevalonate kinase. An example
structure clustering is shown in the circle.
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Figure 1.5. Clustering histograms from docking program AutoDock used to detail
similarites between docked poses. Panel A is an example of poor clustering and B is an
example of good clustering.
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1.1.5

Protein Binding Analysis using Chemical Shift Perturbations
In NMR analysis, a change of chemical environment will cause the chemical shift

(any nuclei used to detect NMR signal) of some compound or molecule to change or
perturb, either upfield or downfield depending on the nature of the new environment. For
example, when a protein binds a ligand, those residues that are involved in binding (or
are causing a structural change in the protein such as domain movement) are perturbed as
shown in Figure 1.6.
These changes in chemical shift can be monitored as a function of ligand
concentration to give information about ligand binding, such as the affinity of the ligand
(i.e. inhibitor or substrate) for the protein. This technique is also useful for screening of
compounds that are thought to inhibit a certain protein. Multiple compounds can be
screened at a time to determine if any of the compounds bind to the protein, by
monitoring any chemical shift changes that arise in the 1H-15N HSQC. NMR-based
titrations are usually complemented with a secondary assay for binding, to detect protein
inhibition (or activation). For example, an enzyme kinetic assay can be executed
utilizing fluorescence or UV spectroscopy, for detection of enzyme reaction at various
inhibitor concentrations.

14

Figure 1.6. Overlay of 1H-15N HSQC titration experiments where Mg-ATP is being
titrated onto phosphomevalonate kinase. Chemical shift changes are shown with the
color change from red (free PMK) to blue (Mg-ATP saturated PMK). Note that the large
number of chemical shift changes is an indication of domain reorientation to accept the
new ligand, since the number of cross peaks (amino acid residues) that are perturbed is
greater than those in the active site.
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CHAPTER II. Substrate Induced Structural and Dynamics Changes in Human
Phosphomevalonate Kinase and Implications for Mechanism

16
2.1

Introduction

2.1.1

Phosphomevalonate Kinase and Rationale for Dynamics Study
Protein motions are critical for various biological functions and occur over a wide

range of timescales. There is a strong correlation between structural dynamics and
molecular function, and studying these dynamic processes can give site-specific
information on motions that span timescales from psec to msec4. One class of enzymes
that undergoes large structural and associated motional changes is the kinases. These
changes occur due to the binding of their two ligands (substrates) and the need for
reactive groups to move into close proximity for catalysis. A model kinase in this regard
is adenylate kinase, which consists of two domains that adjust to bring their phosphate
donor and acceptor ligands into proximity for reaction to occur13.
To better understand the molecular mechanism of enzymatic catalysis, structural
characterizations of protein-ligand complexes are required. Of particular interest are
conformational and dynamic changes that are needed to bring the two highly charged
substrates of PMK in proximity to react. To facilitate these studies (at the time of the
study there was no crystal structure), a homology model for human phosphomevalonate
kinase (PMK) had been generated using the PHYRE homology model method (≈24%
overall sequence identity between PMK model and template), because there is no
experimental structure yet available for this protein14. Our recent NMR chemical shift
assignments and subsequent secondary structure analysis has largely validated this
model, based on chemical shift index values that match helical and sheet regions in the
model. But, the presence of disordered regions and loops has made it impossible to
pursue a complete structure determination. Currently, 77% of the backbone atoms have
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been assigned, excluding two unassigned gaps that may be disordered regions (residues
56–72 and 99–111). As such, studies herein refer to the homology model. This model
consists of two domains. The larger ATP (adenosine triphosphate)-binding domain is
comprised of a five-stranded parallel β-sheet interweaved with three α-helices. The
smaller M5P (mevalonate 5-phosphate) domain is comprised of loop regions and two αhelices. In the model, two hinge regions, analogous to adenylate kinase, tether the ATP
and M5P domains together. These may be involved in opening and closing motions to
permit binding and release of substrates15. Also, recent site-directed mutagenesis studies
have identified a ‘‘Walker A’’ ATP binding motif (K17, R18, K19, and K22)16.
Mutagenesis of some of these residues can decrease catalysis up to 10,000-fold14, 17,
suggesting this as the active site location for catalysis of phosphoryl transfer. ‘‘WalkerA’’ loop residues that are most important for catalysis include K22 and R18. Outside the
‘‘Walker-A’’ catalytic loop, R110 is also important14, 17. The reaction catalyzed by PMK
is shown in scheme 2.1.
To characterize the effects of substrate addition on protein dynamics, we have
used NMR relaxation experiments in conjunction with a Modelfree analysis8 to quantify
any changes to the fast timescale motion (psec-nsec) of the protein backbone, especially
for catalytically relevant regions. We also report on the conformational effects of
substrate addition by comparing chemical shift changes and backbone 15N relaxation data
for various complexes of PMK: (a) Apo-PMK, (b) the binary complex with Mg-ADP
(adenosine diphosphate), (c) the binary complex with M5P, and (d) the ternary complex
with Mg-ADP and M5P.

18

Scheme 2.1: Mevalonate Pathway with PMK catalyzed reaction shown in black box. P
represents phosphate (-PO32-) and E.C. is “Enzyme Commission.”
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2.2

Materials and Methods

2.2.1

Docking of M5P and ATP into Human PMK Homology Model
The homology model used in our studies was that which was previously prepared

and reported by Herdendorf and Miziorko14. The binding orientation of ligands in this
PMK (human) homology model was determined using Autodock412. Gasteiger charges
and hydrogens were added using AutoDock Tools (ADT). The docking grids were also
prepared using ADT, with a grid size of 60 x 60 x 60 Å and a spacing of 0.375 Å. These
grids were centered on the ligands (AMP and GMP) of the homology model template,
bacteriophage T4 deoxynucleotide kinase18. The homology model and template were
superimposed on each other, in order to obtain coordinates for the grid box used to dock
the ligands. The overlay was done using Sybyl 5.8 (Tripos Inc., St Louis, MO, USA).
Default docking parameters were used, except that 50 genetic algorithm runs were used
with 2,500,000 as the maximum number of evaluations. The docking of both ligands was
done separately, due to inter-ligand repulsion from the negative charges on M5P and the
ATP triphosphate, even after neutralization of two charges (as would be the case with
bound Mg2+). This repulsive interaction was recognized based on earlier docking
attempts to form the ternary complex, which produced erroneously distorted structures
with the phosphate groups on the two ligands as far apart as possible in the docking box.
This led us to do independent docking of ATP and M5P to produce the separate binary
complexes, and these pdb coordinate files were then merged to create the ternary
complex. This approach positioned the phosphate groups on ATP and M5P in close
proximity, as required for the phosphate transfer reaction, and therefore provides strong
validation for the docking poses that were generated.
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2.2.2 Protein Expression and Purification
PMK is normally a 192 residue 22.0 kDa protein, although it was expressed with
an N-terminal histidine tag and additional linker residues, giving a total molecular weight
of 24.2 kDa. Uniformly 15N labeled PMK samples were prepared using 15NH4Cl as the
sole source of nitrogen in minimal media and protein was expressed and purified as
described previously14, 17. Briefly, E. coli BL21-(DE3) Rosetta cells were transformed
with a pET15b(+) expression construct which encoded human PMK with an N-terminal
His6 affinity tag. The transformed cells were plated onto LB (Luria Bertani) agar
containing ampicillin (amp) and chloramphenicol (chl) antibiotics. Plates were incubated
overnight at 37 °C, and a single colony was picked to inoculate 2 mL of media, and
grown to A600 ~ 0.3. This culture was then used to inoculate 20 LB-amp-chl plates. The
plates were incubated overnight at 37 °C, and resulting bacterial lawns were used to
inoculate 500 mL of LB-amp-chl to give A600 ~ 1.0. The liquid culture was then
incubated at 30°C for 1 h prior to induction with 1 mM IPTG. The culture was harvested
4 h post induction at A600 ~2.0. Bacterial pellets were resuspended in 100 mL of a 50
mM KPi (potassium phosphate) buffer containing 100 mM KCl, 5 mM imidazole, and 0.5
mM DTT at pH 7.8. Lysis was accomplished by passage through a microfluidizer at ~17
kpsi. The lysate was clarified by centrifugation at ~100,000 g and the supernatant was
loaded onto ~0.5-1.0 mL of Ni-Sepharose Fast Flow resin. The column was washed with
lysis buffer until A280 < 0.005, and the protein was eluted with lysis buffer supplemented
with 300 mM imidazole. The fractions containing PMK were pooled and the
concentration was determined spectrophotometrically using an extinction coefficient of
€280 = 32,290 M-1 cm-1.
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2.2.3 NMR Sample Preparation
All protein samples were buffer exchanged, using ultrafiltration with an Amicon
(YM10) membrane, into 5 mM DTT, 20 mM KH2PO4, 10% D2O, and 0.02% NaN2, and
concentrated to 400-600 µM. ADP was complexed with Mg2+ by adding a 1:1 ratio of
MgCl2. Mg-ADP and M5P were both concentrated to 50 mM prior to titration, with pH’s
of 5.0 for ADP and 7.0 for M5P. All experiments were performed at pH 6.5.

2.2.4 NMR Spectroscopy
All NMR experiments were performed on a 600 MHz Varian NMR System at
599.515 MHz using a triple resonance cryoprobe with z-axis gradients at 25 °C.
Titrations were performed using 100 µM increments for both ligands, until saturation was
achieved based on 1H-15N HSQC chemical shift changes (1 mM for M5P and 2 mM for
MgADP). There were two sets of titrations performed, first starting with M5P then
adding Mg-ADP. To assess binding order and synergy, the second titration started with
Mg-ADP followed by M5P.
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N relaxation experiments were performed on free PMK,

PMK saturated with M5P (2 mM), PMK saturated with Mg-ADP (20 mM; higher
concentration was needed due to slow hydrolysis of ADP), and then the ternary complex
(using the same saturation concentrations).

15

N-T1, 15N-T2, and {1H}-15N NOE

experiments were all performed using the BioPack pulse sequences from Varian, Inc
(Palo Alto, CA). Delay times for the T1 experiment were 10.8, 108.3, 215.8, 379.2,
541.7, 758.4, 1083.4, 1515.8, and 2165.8 ms and 4.31, 8.62, 12.9, 17.2, 21.6, 30.2, 38.8,
47.4, 55.1 ms for T2. T1 experiments employed the standard inversion-recovery pulse
sequence19, while T2 experiments employed the CPMG (Carr-Purcell-Meiboom-Gill)
sequence, as implemented previously20, 21. NOE’s were obtained by measuring HSQC
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spectra with and without 1H saturation for a time of 3 s (same for both), with an interscan
delay of 1 sec. An interleaved approach was used for the T1 and T2 experiments, to
average out any potential instability over time22, 23.

2.2.5 NMR Spectroscopy Data Analysis
NMR data were processed using NMRPipe/NMRDraw24, and analyzed using
NMRView.25 For all experiments, 1H-15N spectra were processed using a 90° shifted sine
function in the 1H and 15N dimensions. For 15N-T1 and 15N-T2 experiments, the spectra
with the shortest relaxation delay were peak picked using NMRView. For {1H}-15N
NOE measurements only one spectrum was peak picked, and for each subsequent
spectrum the peak ellipses were manually adjusted to fit each peak.
The R1 and R2 relaxation rates were determined by fitting the T1 and T2 curves to
Equation 1:
It= Io*e(-Rt)

Eq.2.1

where It is the peak intensity after time t, Io is the intensity at time t=0, and R is either R1
or R2. Fitting was done using the Rate Analysis package included in NMRView. NOE
values were obtained by taking the ratio of the intensity versus the control. This was
done with two sets of experiments in order to obtain an error for the analysis. T1 and T2
values were measured for PMK at various concentrations and used to calculate τm values,
to demonstrate that PMK remains monomeric under the conditions of our NMR studies
(previous analytical gel filtration studies also established that PMK is monomeric).14
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Dissociation constants were obtained by measuring the chemical shift changes in
going from free to various bound states, monitoring peaks in fast exchange in both 1H and
15

N dimensions. These changes were then combined using Equation 2:

Δshiftobs = [(1H shift)2+(15N shift/5.51)2](1/2)

Eq. 2.2

The chemical shift change (Δshiftobs) as a function of the concentration of the ligand, at
fixed concentration [Po] were fitted to a quadratic equation, to determine the dissociation
constant Kd:

Δshiftobs = (Δshiftmax/(2[Po]))*{([Lo] + [Po] + Kd) –{([Lo] + [Po] + Kd)2 – 4[Lo][Po]}1/2}

Eq. 2.3

using Sigmaplot8, where Lo is the total ligand concentration at a particular titration point,
Po is the total protein concentration, and Δshiftmax is the maximum chemical shift change
observed for the particular peak in question. Fitting to the quadratic equation was
required because [Po] > Kd. Standard deviations resulted from the non-linear least squares
fitting process (note: as Kd gets very small relative to [Po], errors will become larger
because Kd become less well-defined in the fitting process).

2.2.6 Modelfree Analysis
The parameters of internal motion were determined from the NMR relaxation data
according to the model-free formalism established by Lipari and Szabo5-7 using
Modelfree4 software (version 4.20, A. G. Palmer, Columbia University). The residues
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were optimized with an isotropic diffusion model using an initial estimate derived from
the R2R1_diffusion program (A. G. Palmer, Columbia University). Backbone dynamics
calculations were performed with 300 Monte Carlo simulations per run using an
internuclear distance rNH of 1.02 Å and a chemical shift anisotropy (CSA) for the 15N
nucleus of -172 ppm. Five models were used to fit our experimental data and were
iteratively tested in order of increasing complexity (M1= S2; M2= S2, τe; M3= S2, Rex;
M4= S2, Rex, τe; M5= S2f, S2s, τe) until an acceptable fit was achieved. S2 is the
generalized order parameter, τe is the internal correlation time, Rex is the exchange
contribution term, and S2f and S2s are for sub-nanosecond and nanosecond motions
respectively. These models were tested until they could reproduce the experimental
relaxation data within 90% confidence limits using appropriate χ2 and F-tests8, and this
was done for each crosspeak (amino acid).

2.3

Results and Discussion

2.3.1 Docking of M5P and ATP to Human PMK
The docking of M5P and ATP (Fig. 2.1) seems reasonable based on the proximity
of the reactive phosphate groups to each other, and also their location within 4.0 Å of the
“Walker A” catalytic loop (which is a peptide motif found in proteins known to bind
nucleotides, such as ATP), which includes Lys17, Arg18, Lys19, and Lys22 as well as
other basic residues, especially Arg110. It is striking that the independent docking of
M5P into PMK positioned its phosphate group within 2.7 Å of the ATP γ-phosphate and
2.8 Å from Arg110 and Arg138.
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Figure 2.1. Ternary complex structure of docked ligands ADP and M5P in the active site,
near the “Walker A” loop, of PMK. Catalytically important amino acids are labeled,
including Lys’s 17, 19, and 22, as well as Arg’s 18, 138, and 110.

In our docked complex of human PMK with M5P and ATP (Fig. 2.1), the key
catalytic residues identified by Herdendorf and Miziorko14, 17 (Arg18, Lys22, and
Arg110) are all reasonably well positioned for catalysis. The only possible exception is
Lys22, which is in the active site but is pointed away from the phosphate; while this may
reflect an inaccuracy of the homology model, it is noteworthy that a simple side chain
rearrangement could easily position its ε-amino group near the ATP γ-phosphate. Arg18,
Lys22, and Arg110, along with the other basic residues in Fig. 2.1, may be important for
forming the ternary complex by neutralizing the negative charges on the two substrates,
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so that their phosphate groups can move into proximity for phosphoryl transfer.
Additional charge stabilization (from Lys22?) may also be needed to stabilize the
transition state if it goes by an associative-type mechanism, which would place added
charge density on the γ-phosphate. An important feature of the model in Fig. 2.1 is that
the γ-phosphate of ATP is ideally positioned for nucleophilic attack by the M5P
phosphate (separated by only 2.7 Å). This provides further validation that this structural
model of the ternary complex is reasonably accurate.

2.3.2 Chemical Shift Perturbation Studies to Make the Binary and Ternary
Complexes
To determine how different ligands affect the residues of the protein, titrations of
the ligand to the protein can be performed by monitoring 1H-15N HSQC NMR spectra.
The HSQC experiment monitors the magnetization transfer from the proton to the
nitrogen on the amide group of the backbone of the protein. The spectra show crosspeaks
for all the amide groups in the protein, one for each residue, except for proline. Addition
of specific ligands that bind to protein can cause these amide groups to change their
chemical shift due to environmental changes, giving rise to chemical shift perturbations.
For chemical shift perturbation studies, a dead-end (i.e. non-reactive) complex with PMK
was created, to ensure that there would be no catalytic turnover during the NMR
measurements. AMP-PNP (Fig. 2.2 and 2.3b) is often used to create such dead-end
complexes in kinases, but it binds only weakly to PMK and causes few structural changes
in PMK compared to ATP (Fig. 2.3a) or ADP (Fig. 2.3c). As a result, ADP was used to
make the dead end complex (Fig. 2.3c) in our studies.
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Figure 2.2. Structures of adenine nucleotides ATP, AMP-PNP, and ADP with
corresponding Kd values.
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Figure 2.3. Chemical shift perturbations due to binding of nucleotides a) Mg-ATP titrated to
saturation onto Apo-PMK, b) Mg-AMP-PNP titrated to saturation onto Apo-PMK, and c) MgADP titrated to saturation onto Apo-PMK. All experiments begin at the red cross-peaks, with
additions in 100 µM increments to saturation, which is indicated by the transition to the blue
cross-peaks. The corresponding chemical shift changes are mapped on to the human PMK
homology model, where the red indicates a large chemical shift change (>0.09 ppm) and pink
indicates a medium chemical shift change (0.05-0.09 ppm), while blue indicates a small or no
chemical shift change (or no data).
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To justify the use of ADP as a suitable replacement for ATP, an ATP titration
experiment was carried out and is shown in Fig. 2.3a. Comparing these spectra, it is clear
that they show the same chemical shift changes for the same residues, which infers that
the two protein-ligand complexes undergo very similar structural changes. From the
HSQC spectra for the Mg-ADP titration (Fig. 2.3c), a pronounced conformational change
is observed upon substrate addition, due to multiple residues that are affected when the
complex is formed. Fig. 2.4a shows the chemical shift perturbations due to Mg-ADP
binding mapped onto the PMK model, and is consistent with Mg-ADP causing the
protein to undergo a gross conformational change; that is, the whole protein appears to
adjust structurally in order to accommodate the addition of Mg-ADP. Notable changes
are observed in the loops near the substrate phosphate groups, as well as the region where
the two ATP-domain helices contact each other. The Mg-ADP addition was then
followed by further titration with M5P to form the ternary complex (Fig. 2.4b). To
determine if there is a preferred sequence for binding, due to synergy, M5P was then
titrated first to Apo-PMK (Fig. 2.4c).
Based on the chemical shift perturbations that occurred during titration to form
binary and ternary complexes, it can be seen that the largest changes occur in forming the
binary complex, whether it is ADP or M5P that binds first (Fig. 2.4). The chemical shift
changes include residues outside the binding site, such as hinge regions between
domains, suggesting that a conformational change has occurred.
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Figure 2.4. Chemical shift perturbations due to: a) Mg-ADP added to saturation to Apo-PMK b)
M5P added to saturation to Mg-ADP/PMK c) M5P added to saturation to Apo-PMK and d) MgADP added to saturation to PMK/M5P. All experiments begin with the red cross-peaks and
titrations occur at 100 µM increments to saturation, which is indicated by transition to the blue
cross-peaks. The corresponding chemical shift changes are mapped on to the human PMK
homology model, where the red indicates a large chemical shift change (>0.09 ppm) and pink
indicates a medium chemical shift change (0.05-0.09 ppm) while blue indicates small or no
chemical shift change (or no data). Note: Gly21 is visible in panel (a) at a lower threshold.
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In terms of adenine nucleotide binding, it is interesting that while the γ-phosphate
of ATP seems to not be important for binding or inducing structural changes, based on
comparisons of ATP and ADP (Figs. 2.2 and 2.3), the situation is actually more
complicated - because simple O=>NH substitution of the bridging heteroatom between
the β and γ phosphates has a dramatic effect on binding. This suggests there may be
important interactions with the β-γ bridging heteroatom, which might be important for
stabilizing this leaving group during phosphate transfer. It is also noteworthy that ADP
(and ATP) binding causes chemical shift perturbations in the Walker A loop (ex. Arg18)
and the lid that covers the Walker A loop, as well as the hinge residue for the lid (D163).
Opening of this lid should only produce a modest change in size of the protein, and so
would not be expected to produce a change in correlation time. In contrast, domain
movement between ATP and M5P binding domains would be expected to produce a
much larger change in size and correlation time, as had been observed in adenylate
kinase, and appears to also occur in human PMK (vide infra).

2.3.3 Binding Affinity and Synergy
To quantitatively assess binding affinity and binding synergy, if any, cross-peak
perturbations (Figs. 2.3 and 2.4) were fitted to obtain Kd values for each binding event.
Monitoring chemical shift changes and fitting to the quadratic equation (Eq. 2.3)
permitted determination of dissociation constants (Kd) for the various nucleotides (Fig.
2.2) and for all four complexes (Fig. 2.5). The Kd for the Mg-ADP titration to Apo-PMK
is 19 ± 9 µM and <20 µM for subsequent M5P binding to form the ternary complex. For
the titration of M5P to Apo-PMK the Kd is 6 ± 3 µM and 56 ± 16 µM for the subsequent
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Mg-ADP addition to form the ternary complex. These values are consistent with the
previously reported Km values of 47 ± 5 µM for ADP and 34 ± 3 µM for M5P,26 keeping
in mind that Km values can often deviate from Kd values due to kinetic effects.

Figure 2.5. Thermodynamic box for the formation of the dead-end ternary complex of
human PMK with corresponding Kd and τm values for each complex. Cartoon
representations of each complex are shown, with the circles representing M5P and the
squares representing ADP.

Based on chemical shift perturbations, it appears that binding of either M5P or
ADP to apo PMK can induce a large conformational change. Kd values obtained from
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fitting spectral changes are consistent with their being no preferred binding sequence or
synergy for the ligands. This is in contrast to the report of an ordered sequential
mechanism (M5P binding first and ADP released last) for the pig liver PMK enzyme,26
but is consistent with recently reported steady state kinetics on human PMK, where
competitive inhibition was observed using mevalonate 5-diphosphate as a product
inhibitor versus M5P.17 If anything, our data suggest there is a modest (~3-fold) antisynergy, such that affinity for the second ligand is weakened due to presence of the first,
which could be due to the charge/charge repulsion by the phosphate groups on both
ligands. But, this anti-synergy could be unique to our dead-end complex (MgADP/M5P),
and does not necessarily reflect the situation for the catalytically competent Michaelis
complex (MgATP/M5P).27

2.3.4 Relaxation Dynamics
To obtain dynamic information on the psec-nsec time scale motions, longitudinal (R1)
and transverse (R2) relaxation rates as well as {1H}-15N NOE values were obtained, and
are summarized in Fig. 2.6 for Apo-PMK, Mg-ADP bound PMK, M5P bound PMK, and
the ternary (Mg-ADP/M5P) complex. All of the complexes have relatively rigid
structures (high S2), indicative of a well-ordered protein backbone on the psec-nsec
timescale (Fig. 2.6). Trends in R1 and R2 values in Table 2.1 can best be explained based
on changes in the overall correlation time of the protein in the different complexes. It
should again be noted that PMK remains in a monomeric state in our NMR studies (Fig.
2.7), so changes in correlation time are not associated with aggregation effects.
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Figure 2.6. NMR dynamics data including R1, R2, NOE, and S2 values, where blue is the
Apo-PMK complex, red is the M5P saturated complex, yellow is the Mg-ADP saturated
complex, and green is the ternary complex.

35

Figure 2.7: Representative 1-D spectra from T2 relaxation measurement at A) 500 µM,
B) 250 µM, and C) 125 µM PMK. The rotational correlation time τm for A) is 12.9 ± 1.2
ns, B) is 13.5 ± 0.9 ns, and C) is 12.0 ± 0.6 ns.

Table 2.1. Summarization of relaxation dynamics parameters of apo and ligand induced
states of PMK.
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The changes in PMK correlation time were verified and quantified in the
Modelfree analysis, where it was found that relaxation data could not be properly fitted
for the different PMK complexes using the same correlation time. The correlation times
obtained from the Modelfree analysis of each complex are summarized in Fig. 2.5. These
correlation time changes are consistent with there being a ligand-induced change in
overall shape of PMK in the different complexes, as had been previously observed in
analogous NMR studies of adenylate kinase.
Based on Modelfree analysis of NMR dynamics parameters (Fig. 2.6),
generalized order parameters were obtained. These clearly indicate that PMK adopts a
fairly rigid structure (S2 values >0.8) for all the binary and ternary complexes.
Furthermore, the average S2 values remain largely unchanged upon formation of the
binary complex with either ADP or M5P, indicating that the local dynamics for all the
complexes are virtually the same (Table 2.1) on the psec-nsec timescale. The large S2
values, which are consistent with a rigid, highly ordered backbone, are not unexpected
given the well-structured core of the protein, which includes a 5 stranded parallel β-sheet.
One might have expected some ordering in the M5P domain upon ligand binding, given
the high content of extended and loop regions, but this does not appear to be occurring.

2.3.5

Inter-domain and loop motion: ligand binding domains, lid and “Walker A”

catalytic loop
Although the protein core may be largely rigid, it is possible that there is some
motion of domains relative to each other, and of other defined regions. Indeed, chemical
shift perturbation studies suggested there was a large substrate-induced conformational
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change (Fig. 2.4). In fact, there were a small number of residues with small or negative
NOE’s that gave rise to small S2 values (H55, R93, and D163), and these are located in
loop and potential hinge regions in the homology model (vide infra). Interestingly, the
“Walker A” ATP binding loop shows the same S2 values as the rest of the protein (i.e. it
is rigid), indicating that if there is any catalytically relevant change in dynamics, it might
only occur during turnover with the actual Michaelis complex,27 rather than with the
“dead-end” complex used in our studies. One important exception is Gly21, which is
adjacent to Lys22, the catalytically most important residue in PMK.14 Gly21 undergoes
an increase in S2 in going from the apo (blue) to the M5P (red) complex, indicating it
becomes less mobile in the binary complex (Fig. 2.6), perhaps as Lys22 moves into
position for catalysis (note: Lys22 was not assigned, so changes to its dynamic state are
not known). Interestingly, Gly21 exchange broadens in the ternary complex, suggesting it
undergoes msec timescale motion. But, in the conversion of apo PMK to the PMK-M5P
binary complex, one can see a slow exchange process for Arg18, and a fast exchange
process for Gly21 (Fig. 2.4c, and expansions in Fig. 2.8).

38

Figure 2.8: Expansions of HSQC spectra, showing crosspeak changes used to calculate
exchange rates. R18 is in slow exchange between two states, while G21 is in fast
exchange between two states. Crosspeak seperation, in sec-1, therefore defines the
exchange rate between these two states, for the loop containing R18 and G21.

Assuming the same motion occurs for these two “Walker A” loop residues, this
timescale flanking permits an estimation of the rate constant for the “Walker A” catalytic
loop exchanging between the two states associated with M5P binding as kex = 100-600
sec-1 (see Fig. 2.8). This is likely to be due to a lid opening/closing motion, which would
be coupled to “Walker A” loop motion, based on analogy to adenylate kinase where a
flexible lid caps the catalytic “Walker A” loop. 28-31
It should be noted that while there doesn’t appear to be significant motion of
“Walker A” catalytic loop residues on the psec-nsec timescale (besides Gly21), there
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does appear to be motion on slower (ex. msec) timescales. For example, in the ADP
binary and ternary complexes, most crosspeaks for residues in the loop were no longer
visible, due to exchange broadening (Fig. 2.4). For this reason, S2 for ADP complexes
could not be measured. Accordingly, it is simply not known in these complexes what
motion might be occurring on the psec-nsec timescale.
Overall, the psec-nsec timescale dynamics data indicate that M5P binding drives
the immobilization of catalytic residues (with Gly21 as our “Walker A” reporter), but
there still appears to be msec timescale motion, especially when ADP is bound. This
motion might be important for catalysis, but could also be unique to the particular deadend inhibitory complex used in our study. There is certainly literature precedent for
kinase active site loop dynamics being very sensitive to the nature of the inhibitory
complex. For example, residual dipolar coupling and 15N relaxation measurements of
various ABL kinase complexes indicated that inhibitors differed significantly in their
ability to immobilize the catalytic/activation loop.32

2.3.6

Ligand-induced changes to protein size: inter-domain conformational

change?
The chemical shift perturbation studies indicated that binding of either ADP or
M5P may cause a large conformational change (Fig. 2.4), but the above analysis of S2
values indicated this did not correspond to any significant changes in dynamics within the
two ligand binding domains, other than some changes to the “Walker A” catalytic loop,
and the lid that covers it. What about inter-domain motion? The Modelfree analysis
provided some insights in this regard. As mentioned in the Methods section, relaxation
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data fitting was optimized for each complex to find the rotational correlation time τm for
that complex, since it was not possible to fit all complexes using a single τm. Changes to
fitted τm values for all the complexes (Fig. 2.5) reveal that the ADP binary complex has
the largest τm of 17.6 nsec while the M5P binary complex has the smallest, with a τm of
13.5 nsec. The Apo-PMK and the ternary complex fall in between these two extremes,
with similar τm values of ~15.7 nsec (Fig. 2.5). This suggests that both ADP and M5P
binding induce conformational changes, but in opposite directions. That is, M5P causes a
compression of the structure (so PMK tumbles faster), while ADP causes an opening up
of the structure (so PMK tumbles slower). Such changes would be consistent with a
movement of the two ligand binding domains relative to each other, as occurs in the
nucleoside monophosphate kinases. 28-3133
Why ADP binding causes the structure to open up is not clear. Since the product
of the PMK reaction is ADP, it could be that the open conformation reflects the protein
trying to release ADP. However, the chemical shift perturbation study with ATP (Fig.
2.3a) shows the same chemical shift perturbations as with ADP, arguing against there
being a dramatically different conformation in the ATP vs. ADP binary complexes. The
changes in τm for the various complexes indicates that protein closure occurs upon
binding to M5P, with or without ADP present. This tightening/closure of the structure
induced by M5P binding might be associated with domain movement around a
His55/Arg93 hinge (Figs. 2.4 and 2.6). The chemical shift perturbation studies of PMK
bound to M5P, with subsequent addition of Mg-ADP, demonstrate that the protein may
open back up to bind ADP/ATP for catalysis.
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2.3.7

Hinge regions for lid and domain movement
The previous discussion presented data in support of ligand-induced structural

changes, which may be related to inter-domain (ATP/M5P) motion as well as to motion
of the “Walker A” catalytic loop and the lid that covers it. Regarding movement of the
lid, it is noteworthy that data on adenylate kinase indicates lid movement occurs on the
same timescale as catalysis. This is consistent with the lid controlling access to the active
site, as well as its packing up against the catalytic “Walker A” loop. In adenylate kinase,
a key catalytic residue in the ATP binding site is Lys21, 33 which twists into an
unfavorable double gauche rotamer in order to interact with the ATP phosphate, just as
Lys22 would in the human PMK homology model (Fig. 2.1) if its sidechain were
adjusted to permit interaction with the ATP phosphate. This lysine may cycle into a
catalytically useful orientation in the transition state to stabilize the increasing negative
charge on the γ-phosphate, which would be created in the associative mechanism that is
thought to be operative for nucleoside monophosphate kinases.33 Such a mechanism
would permit selective stabilization of the transition state, and would require motion of
the “Walker A” loop as the transition state is approached. So, lid motion is potentially
relevant to catalysis. How does lid motion occur in PMK?
As noted earlier, a number of potential hinge residues had unusually small S2
values (H55, R93, and D163), which indicates they are mobile on the psec-nsec timescale
(note: often, fast timescale motion occurs along with msec timescale motion, which
would be more relevant for a hinge region). Specifically, residues H55 and R93 are
positioned (Fig. 2.4) such that they could operate as hinge residues that allow movement
between the core ATP domain and the M5P domain, possibly for enabling an opening
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and closing motion upon substrate binding3. Likewise, Asp163 is located in a potential
hinge region for the “lid” loop region that is analogous to the “lid” that is present in the
nucleoside monophosphate kinases. 28-3133, 34 This lid caps the catalytic “Walker A” loop
in the PMK model. The potential hinge residue, Asp163, also underwent dramatic
chemical shift changes upon ligand binding (Fig. 2.4), as would be expected if there were
motion around this hinge region induced by ligand binding. Motion around this hinge
region would permit movement of the “Walker A” catalytic loop, which could be coupled
to lid motion, as in adenylate kinase. The full extent to which catalytic loop and lid
motions are coupled, and what role this motion might have in catalysis in human PMK, is
not known, and will be the topic of future studies. But, extensive NMR studies on
nucleoside monophosphate kinases,33 and especially adenylate kinase as a prototype, 283134

provide a rich literature that describes coupled motions between these loops, and their

role in catalysis. These studies have also identified ligand-induced changes in protein
correlation times (due to inter-domain movement; opening/closing), as we have now
observed in human PMK. It will be interesting to see if human PMK follows the example
of the adenylate kinase prototype, or whether it will provide unique and new insights into
the role of such loop and domain motions in kinase-mediated phosphate transfer
reactions. The studies reported herein provide a foundation for such future studies.

2.4

Conclusion
PMK is a very dynamic protein with large structural changes that occur upon

ligand addition, especially the first ligand addition. However, as shown from the
Modelfree analysis, we see that the protein conformation changes with different ligands
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being added upon M5P binding, the protein goes to a closed conformation (τm of 13.5
nsec) and upon ATP/ADP binding, the protein opens up (τm of 17.6 nsec). The
Modelfree analysis has also identified a few potential hinge regions, specifically R93 and
H55, which may be involved in moving of the M5P binding domain to permit closure of
the protein. This analysis has also indicated that D163 may be involved in the lid region
movement. This lid caps the “Walker A” ATP binding site, like many other
monophosphate kinases. Finally the Kd’s determined from chemical shift perturbation
studies were very similar to the Km’s previously reported4, and we have determined that
all ligands bind with similar dissociation constants: 6 +/- 3 µM for M5P binding to free
PMK and 56 +/- 16 uM for subsequent ADP binding; 19 +/- 9 µM for ADP binding to
free PMK and <20 µM for subsequent binding of M5P.
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CHAPTER III. NMR Dynamics Investigation of Ligand-Induced Changes of Main
and Side Chain Arginine N-H’s in Human Phosphomevalonate Kinase
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3.1

Introduction

3.1.2

Phosphomevalonate Kinase and Arginine Dynamics
Studies of the dynamical properties of proteins using NMR spectroscopy is an

emerging field that has largely been limited to backbone N−H or side-chain methyl
motions. It is often but not always true that changes to the dynamic state of the backbone
reflect changes in the side chains. The NMR techniques for quantifying fast-time-scale
motion involve measuring the longitudinal (R1) and transverse (R2) relaxation rates as
well as the heteronuclear nuclear Overhauser effect (NOE) for each amino acid backbone
N−H (or side-chain C−H) bond vector in the protein.4, 7, 8, 35 These values can then be
used to calculate the generalized order parameter (S2), which is a measure of protein
flexibility on the psec to nsec timescale.
We have recently reported on the ligand-induced structural and dynamical
changes of human phosphomevalonate kinase (PMK).(4) PMK is the fifth enzyme in the
mevalonate pathway in humans and is involved in steroid biosynthesis.26, 36 PMK
catalyzes phosphoryl transfer from adenosine triphosphate (ATP) to mevalonate 5phosphate (M5P) to form adenosine diphosphate (ADP) and mevalonate 5-diphosphate.
To permit phosphoryl transfer, the substrates are brought close together, resulting in a
significant and repulsive buildup of negative charge. To facilitate this difficult task, PMK
contains 17 arginines (Figure 3.1) and eight lysines, many of them in the active site to
help neutralize the negative charge on the phosphates.
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Figure 3.1. Ternary complex of human PMK, with M5P and ATP docked independently
into the apo crystal structure (3CH4).9 After docking, structure was optimized using
molecular dynamics (50 ps at 300 K). All arginines are shown, and those known to be
important for substrate binding or catalysis are labeled. Inter-phosphate distance is 7 Å,
so phosphate transfer will require additional domain movement.

The most important arginines, on the basis of site-directed mutagenesis studies, are R18,
R48, R73, R84, R110, R111, and R141.14, 17 Here we describe the use of NMR dynamics
methods to characterize changes in the mobility of arginine side chains upon ligand
binding. NMR dynamics methods, which have recently been applied to arginine side
chains,35, 37, 38 allow study of the role that arginine side chains play in ligand binding and
catalysis. Our studies provide surprising insights into ligand effects on arginine side
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chains that are remote from the active site, perhaps due to long-range Coulombic
attractions.

3.2

Methods and Materials

3.2.1

Docking of M5P and ATP into the Human PMK Crystal Structure

The binding orientation of ligands in the PMK (human) crystal structure (3CH4) was
calculated using Autodock4.12 Gasteiger charges and hydrogens were added using
AutoDock Tools (ADT). The docking grids were also prepared using ADT, with a grid
size of 60 x 60 x 60 Å and a spacing of 0.375 Å. These grids were centered on the
ligands (AMP and GMP) of the homologous protein, bacteriophage T4 deoxynucleotide
kinase.18 The PMK crystal structure (apo) and template were superimposed on each
other, to determine coordinates for the grid box used to dock ligands. Default docking
parameters were used, except 50 genetic algorithm runs were used with 2,500,000 for
maximum number of evaluations. The docking of both ligands was done separately, due
to inter-ligand repulsion from the negative charges on M5P and the ATP triphosphate,
even after neutralization of two ATP charges (as would be the case with bound Mg2+).
This repulsive interaction was recognized based on earlier docking attempts to form the
ternary complex, which produced distorted structures with the phosphate groups on the
two ligands as far apart as possible. This led us to do independent docking of ATP and
M5P to produce the separate binary complexes, and these pdb coordinate files were then
merged to create the ternary complex. The crystal structure of PMK has the R141
positioned in the proposed binding site of ATP, so that docking of ATP into that site
caused the ATP to adopt a highly strained conformation with a steric clash involving
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R141. So to achieve a proper docking, with minimal perturbation to the crystal structure,
R141 was temporality changed to glycine. This allowed a proper docking of ATP into
the active site. Then the R141 sidechain was added back and, as expected, there was still
a steric clash with the R141 sidechain and ATP. This merged ATP/PMK pdb file was
then minimized using Amber 99, as implemented by HyperChem 7.5 (Gainesville, FL).
The minimized structure was then further refined by performing a brief molecular
dynamics (MD) run (again using the Amber 99 force field, as implemented in
HyperChem 7.5) to determine any lid motion that may be required to permit ATP
binding. MD was performed using a 1 fsec step size, with a heating time of 10 ps and a
production time at 300K of 50 ps. At the end of the dynamics run, the structure was again
minimized to produce the final ATP/PMK complex. During the MD, motion was only
permitted for residues 120 to 160, which included the lid that contains R141. This
approach to docking, with subsequent MD-based refinement, positioned ATP and M5P in
their respective binding sites, is positions that are consistent with previous binding
studies. In the end, there were no dramatic changes to the lid. Rather, there was mostly
just an adjustment in the orientation of R141 sidechain, with modest lid rearanegement.

3.2.2

Protein Expression and Purification
PMK is normally a 192 residue 22.0 kDa protein, but it was expressed herein with

an N-terminal histidine tag and additional linker residues, giving a total molecular weight
of 24.2 kDa. Mutated PMK constructs (R84M, R111M, R130M, and R141M) were
described previously.14, 17 Briefly, E. coli BL21-(DE3) Rosetta cells were transformed
with a pET15b(+) expression construct of wild type and mutant PMK. The transformed
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cells were plated onto LB (Luria Bertani) agar plates containing ampicillin (amp) and
chloramphenicol (chl). Plates were incubated overnight at 37 °C, and a single colony
was picked to inoculate 2 mL of media, which was then grown to A600 ~ 0.3. This culture
was then used to inoculate 20 LB-amp-chl plates. The plates were incubated overnight at
37 °C, and resulting bacterial lawns were used to inoculate 500 mL of M9 minimal
media-amp-chl with 14NH4Cl and 13C-glucose, as the sole sources of nitrogen and carbon,
except media was supplemented with .25g/L [13C6, 15N4]-L-Arginine (Isotec Inc.), to give
A600 ~ 1.0. The liquid culture was then incubated at 30°C for 1 h prior to induction with
1 mM IPTG. The culture was harvested 4 h post induction at A600 ~2.0. Bacterial pellets
were resuspended in 100 mL of a 50 mM KPi (potassium phosphate) buffer containing
100 mM KCl, 5 mM imidazole, and 0.5 mM DTT at pH 7.8. Lysis was accomplished by
passage through a microfluidizer at ~17 kpsi. The lysate was clarified by centrifugation
at ~100,000 g and the supernatant was loaded onto ~0.5-1.0 mL of Ni-Sepharose Fast
Flow resin. The column was washed with lysis buffer until A280 < 0.005, and the protein
was eluted with lysis buffer (stated above) supplemented with 300 mM imidazole. The
fractions containing PMK were pooled and the concentration was determined
spectrophotometrically using an extinction coefficient of €280 = 32,290 M-1 cm-1.

3.2.3

NMR Sample Preparation
All protein samples were buffer exchanged, using ultrafiltration with an Amicon

(YM10) membrane, into 5 mM DTT, 20 mM KH2PO4, 10% D2O, 10% d6-glycerol, and
0.02% NaN3, and concentrated to 400-600 µM. All experiments were performed at pH
6.5 and 298 K.
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3.2.4

NMR Spectroscopy
All NMR experiments were performed on a 600 MHz Varian NMR System at

599.515 MHz using a triple resonance cryoprobe with z-axis gradients at 25 °C.
Titrations were performed using 100 µM increments for M5P addition, until saturation
was achieved based on 1H-15N HSQC chemical shift changes (1 mM for M5P).
15

15

N-T1,

N-T2, and {1H}-15N NOE experiments were all performed using the BioPack pulse

sequences from Varian, Inc (Palo Alto, CA). Delay times for the T1 experiments were
10.8, 108.3, 215.8, 379.2, 541.7, 758.4, 1083.4, 1515.8, and 2165.8 ms, and delay times
for the T2 experiments were 4.31, 8.62, 12.9, 17.2, 21.6, 30.2, 38.8, 47.4, 55.1 ms. T1
experiments employed the standard inversion-recovery pulse sequence,34 while T2
experiments employed the CPMG sequence, as implemented previously.32, 33 NOE’s
were obtained by measuring HSQC spectra with and without 1H saturation for a time of 3
s (same for both), with an inter-scan delay of 1 sec. An interleaved approach was used
for the T1 and T2 measurements, to decrease effects of field instability over long
experiment times.21
The 3D HNCO spectrum was acquired on the same 600 MHz instrument, using
16 transients, with 24 13C and 16 15N increments, using 13C and 15N spectral widths of
2250 and 1200 Hz, respectively. In addition to HNCO, we attempted CC(CO)NH and
related TOCSY experiments, in an effort to obtain sidechain assignments, but very little
TOCSY transfer was observed due to relaxation. A 3D HNCA was acquired using 16
transients, and 13 13C and 16 15N increments, with 13C and 15N spectral widths of 2100
and 1200 Hz, respectively. Processing of the 2D planes was performed using 90° shifted
sine bell window functions in 1H and 15N dimensions. In an another attempt to assign
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sidechain NH’s to backbone NH’s, 3D 15N-NOESY experiment were also acquired on
apo-PMK with mixing times of 80 and 150ms using 16 transients, with 70 13C and 79 15N
increments.

3.2.5

NMR Data Analysis
NMR data were processed using NMRPipe/NMRDraw,24 and analyzed using

NMRView.25 For all experiments, 1H-15N spectra were processed using a 90° shifted sine
function in the 1H and 15N dimensions. For 15N-T1 and 15N-T2 experiments, the spectra
with the shortest relaxation delay were peak picked using NMRView. For {1H}-15N
NOE measurements only one spectrum was peak picked, and for each subsequent
spectrum the peak ellipses were manually adjusted to fit each peak.
The R1 and R2 relaxation rates were determined by fitting the T1 (1/R1) and T2
(1/R2) curves to Equation 3.1:
It= Io*e(-Rt)

Eq. 3.1

where It is the peak intensity after time t, Io is the peak intensity at time t=0, and R is
either R1 or R2. Fitting was done using the Rate Analysis package included in NMRView.
NOE values were obtained by taking the ratio of the intensity versus the control. This
was done with two sets of experiments in order to obtain an error for the analysis.

3.2.6 Modelfree Analysis
The parameters of internal motion were determined from the NMR relaxation data
according to the model-free formalism established by Lipari and Szab5-7o using
Modelfree4 software (version 4.20, A. G. Palmer, Columbia University). R2/R1 values
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were calculated for each complex for those assigned main chain residues and were used
as the starting point for optimization of τc values. The optimized τc values (Table 3.1)
were then fixed for each model afterward. Main chain and side chain dynamics
calculations were performed with 300 Monte Carlo simulations per run using an
internuclear N-H distance rNH of 1.02 Å and a chemical shift anisotropy (CSA) for the
15

N nucleus of -172 ppm for backbone and -114 ppm for sidechain38. Five models were

used to fit our experimental data and were iteratively tested in order of increasing
complexity (M1= S2; M2= S2, τe; M3= S2, Rex; M4= S2, Rex, τe; M5= S2f, S2s, τe) until an
acceptable fit was achieved. S2 is the generalized order parameter, τe is the internal
correlation time, Rex is the exchange contribution term, and S2f and S2s are for subnanosecond and nanosecond motions respectively. These models were tested until they
could reproduce the experimental relaxation data within 90% confidence limits using
appropriate χ2 and F-tests. Sidechain N-H’s predominantly fit to model 5 for apo-PMK,
while the three ligand bound complexes fit best to model 4 in most cases.
To address the concern of anisotropic rotation affecting the transverse relaxation
of sidechain residues, we used our data from a previous dynamical study performed on
the backbone residues of PMK. In this study, we assessed ligand binding and dynamic
properties of PMK and at the time there was no structure (axial-anisotropic model needs a
structure to optimize Dratio for correlation time, which is the reason we could not use it in
the current study of arginines as they are unassigned) so we could only use an isotropic
model to assess correlation times of rotation (ns). Using the isotropic model and average
R2/R1 as an initial estimate of τc, the correlation times were estimated for each complex
(Table 3.1).
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Table 3.1.
τc (ns)

Apo-PMK
15.6

M5P
13.5

MgADP
17.6

M5P/MgADP
15.8

To test whether anisotropic rotation affects the correlation times of the previous study, we
will rely on the crystal structure of human PMK and use the axial model of diffusion,
which relies on the structure of the protein in which a global axially symmetric diffusion
tensor is used for all spins. From the structure we have the calculated Dratio for human
PMK (0.88), giving it somewhat of a disc shape. This input as well as the data from the
previous study gives us new estimated correlation times based on the anisotropic rotation
of PMK (Table 3.2).
Table 3.2.
τc (ns)

Apo-PMK
15.4

M5P
13.9

MgADP
19.1

M5P/MgADP
17.0

The S2 values from these data are nearly the same as the reported values of the previous
study, validating that the use of the isotropic model in calculating the dynamic properties
of PMK.

3.3

Results and Discussion

3.3.1

Arginine Assignment and Chemical Shift Perturbation
Since PMK is a rather large protein (24 kDa), in terms of NMR studies, samples

were prepared with only arginines having the 15N label (Figure 3.2A). This allowed us to
make sure that every arginine backbone residue was considered, without concern for
signal overlap, along with the ε-N−H’s of the side chain. Other arginine side-chain
N−H’s, though labeled, exchange too rapidly to be observed. Because PMK has
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significant resonance overlap in the backbone N−H region and also because of significant
relaxation that precluded side-chain assignments via TOCSY experiments, only half of
the arginine residues could be assigned. The assigned arginines are labeled accordingly
on the spectra, and the rest of the arginine backbone N−H’s are labeled R-A through R-I.
The ε-N−H’s of the arginine side chains are shown at the top of Figure 3.2A and
expanded in Figure 3.2B.

Figure 3.2. 1H-15N HSQC spectra of (A) 15N-Arg-PMK with backbone residues labeled
and (B) expansion of arginine sidechain region with cross-peaks labeled and spectra of
mutational assignments (boxes). Spectra were of 500 µM PMK (20 mM potassium
phosphate, 5 mM DTT, 10% D2O, 10% d6-glycerol) acquired at 298K on a 600 MHz
Varian NMR System.
Many attempts were made to assign the arginine ε-N−H’s to their respective
backbone amides using various NMR spectroscopy experiments including HNCO,
HNCA, HNCACB, CC(CO)NH, and 15N-NOESY. Displayed in Figure 3.3 is the HNCA
experiment of 15N/13C-Arg and U-13C PMK to assign the CHd of the arginine side chain.
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Figure 3.3. HNCA of 15N/13C-Arg and U-13C PMK. Spectra are of PMK that is
uniformly 13C labeled, and has 15N label present only in arginines. Spectra are 2D 1H-13C
(top) and 1H-15N (bottom) planes from the 3D HNCA experiment.

These spectra provide confirmation for arginine specific labeling, versus metabolic
scrambling of label into other amino acids. Sidechain crosspeaks show connection of the
NHe proton to the CHd of the sidechain. Partnering experiments HNCACB and
CC(CO)NH to assign the CHd of the side chain with the b and g protons as well as the
amide N-H gave little signal; not enough to resolve assignments. Spectra in panels (A)
and (B) of Figure 3.4 are standard 1H-15N HSQC spectra, of backbone and sidechain
regions of 15N-Arg labeled PMK, and are provided for comparison with HNCO 2D
planes (panels (C) and (D)). The 1H-15N plane from the 3D HNCO spectrum (panel (C))
shows crosspeaks for arginine backbone 15NH’s, adjacent to 13C=O carbonyls, but also
for arginine sidechain 15NHe’s, adjacent to 13C=NH2 iminos, of the guanidinium groups.
Panel (D) shows the corresponding 1H-13C HNCO plane, that correlates proton shift of
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the arginine backbone or sidechain epsilon 15NH with 13C chemical shift of the adjacent
carbonyl or imino carbon. Imino 13Cz shifts are identified with red lines. In panel (C), the
R150 backbone and all NHe sidechain crosspeaks are folded, as are the sidechain 13Cz
crosspeaks in panel (D).
The last attempt to assign the arginines using NMR was to use a 15N-NOESY
experiment in which magnetization starts on the backbone amide and transfers to any
proton within 5 Å, including the ε-N-H of the arginine side chain allowing for
assignment. This experiment was run with two isotropic mixing times of 80 and 150 ms
with both experiments giving good signal to noise for the backbone amides however the
signal on the ε-N-H of the arginines are very weak (Figure 3.5). This is likely due to the
fact that magnetization, when on the ε-NH, was transferred rapidly to water and was
subsequently destroyed with water suppression, which led to a decrease in signal
intensity (red box in Figure 3.5) as compared to backbone NH intensity. Attempts to
solve this issue using various forms of water suppression proved unsuccessful.
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Figure 3.4. HNCO and HSQC spectra of 15N/13C-Arg and U-13C PMK. Spectra are of
PMK that is uniformly 13C labeled, and has 15N label present only in arginines.
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Figure 3.5. 15N-1H plane from a 15N-NOESY experiment of 500 uM apo-PMK in 20
mM potassium phosphate at pH 5.5. 15N-NOESY was run with a mixing time of 150 ms,
ε-NH signal was weak (shown in red box) compared to backbone NH’s, due to increased
exchange with water. These data are shown, to demonstrate the infeasibility of arginine
sidechain assignment using the NOESY experiment. Similar problems were encountered
with TOCSY experiments as well.
We had to then resort to assigning these arginines using point mutations. The
mutants R18M (arginine # 18 mutated to a methionine), R84M, R110M, R111M,
R130M, and R141M proteins were all expressed in 15N minimal media so that these
mutated arginine side chains could be identified in 1H-15N HSQC based on perturbed
chemical shifts. Figure 3.6 shows four of the mutant PMK 1H-15N HSQC spectra (R84M,
R111M, R141M, and R130M) with the black spectra being native apo-PMK chemical
shifts and red being the corresponding mutant PMK. In the R84M and R111M panels,
notice that mutation causes the 3 crosspeaks on the left to be perturbed, broadening or
shifting, suggesting that these arginine sidechains are likely to be in some proximity to
each other. This is consistent with the titration of M5P onto apo-PMK (Figure 3.7), that
showed these same 3 cross peaks broaden upon binding. The R141M mutant causes
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some cross peaks to change slightly, however one crosspeak (SC-12) clearly disappears,
suggesting it is most likely from the ε-NH of R141. As with the R141M mutant, the
R130M mutant causes cross peaks to change slightly, however SC-5 completely
disappears, implying this is probably the ε-NH of R130.
To monitor arginine involvement in the binding of PMK’s substrates, chemicalshift titration experiments were performed (Figure 3.7). Increasing amounts of M5P and
MgADP were added to PMK, and the arginine backbone and side chains were monitored
using 1H−15N HSQC spectra. The majority of the arginine N−H’s showed very small
chemical shift changes, indicating little change in chemical environment for residues
labeled SC-2 and SC-5−13. For residues labeled SC-1, -2, and -4, the chemical shifts
were exchange-broadened, indicating some change in environment and motion due to
binding of M5P (Figure 3.7C). This experiment was duplicated using MgADP (Figure
3.7D), monitoring chemical shift changes as before. Only SC-1, -2, and -4 showed large
chemical shift changes, suggesting that they are involved in binding.
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Figure 3.5. Assignment by site-directed mutagenesis. Overlaid 1H-15N HSQC spectra of
the arginine ε-NH region where black indicates apo-PMK arginine chemical shifts, and
red is for mutant (R84M, R141M, R111M, and R130M) PMK chemical shifts.
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Figure 3.7. (A) 1H-15N HSQC spectrum showing Arg-PMK chemical shifts, including side chains
(top) and backbone (bottom). (B) Expanded region of side chain chemical shifts. (C) Chemical
shift titration showing effect of increasing amounts (100 uM increments) of M5P added to apoPMK (red) to saturation (1 mM) shown in gray. (D) Chemical shift titration of increasing
amounts of MgADP added to apo-PMK (red) to saturation (1 mM), shown in gray. (E) Chemical
shift titration of increasing amounts of M5P added to the MgADP/PMK complex (red), forming
the ternary complex (1 mM) shown in gray. Backbone and sidechain 15N-H atoms, monitored in
the spectra, are identified on the arginine structure (blue) shown in the inset in panel A, although
the ε-N-H is the only observable sidechain NH, since it is the least acidic (least prone to exchange
with solvent). Spectra were taken at 600 MHz at 298 K. Arginine backbone assignments are
indicated, when available. SC-1 to SC-13 are unassigned arginine side chain N-H’s (no side
chains have been assigned). R-A to R-I are unassigned arginine backbone N-H’s.
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3.3.2

Arginine Dynamics
Dynamics experiments were performed as before, where we showed that

substrate-induced domain movement occurs in PMK.39 The longitudinal relaxation rates
(R1) were generally the same for the backbone and side chains for each particular
complex and agreed with previous results39 (Figure 3.8 and Table 3.3). The transverse
relaxation rates (R2) of the backbone N−H’s also correlated with our previous studies.39
The side chains, however, showed a decrease in transverse relaxation rates relative to the
backbone. This difference in R2 values for the apo-PMK arginine side chains was
significant (half relative to backbone) while the difference in R2 between backbone and
sidechain was small for the M5P/PMK complex, with the other two complexes showing
an intermediate decrease (Figure 3.8). The 1H−15N NOE values for the side chains varied
from residue to residue, but this variability was consistent between complexes.

R1 (s-1)
R2 (s-1)
1
H-15N NOE
S2
τc (ns)

Free
0.78 ± 0.06
14.0 ± 1.3
0.30 ± 0.11
0.47 ± 0.04
20.1

M5P
1.1 ± 0.13
15.6 ± 1.5
0.15 ± 0.08
0.67 ± 0.09
15.5

MgADP
0.89 ± 0.07
15.6 ± 2.1
0.28 ± 0.10
0.64 ± 0.04
22.0

MgADP/M5P
0.82 ± 0.09
15.2 ± 1.9
0.23 ± 0.11
0.75 ± 0.06
18.4

Table 3.3. Average dynamic parameters for the ε-NH’s of arginine sidechains, with the
correlation time (τc) of the backbone arginine residues used for calculating S2 values of
the arginine sidechain N-H’s. Note: These are only averaged in those cases where all
four complexes have data for a particular sidechain residue.
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Figure 3.8. NMR dynamics data including R1, R2, and 1H-15N NOE values, where blue
is apo-PMK, red is the M5P/PMK binary complex, yellow is the MgADP/PMK binary
complex, and green is the M5P/MgADP/PMK ternary complex. The sections are divided
into assigned backbone N-H’s, unassigned backbone N-H’s and side chain guanido NH’s. These are the data that were used to calculate order parameters in Figure 3.9.
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As in previous studies,39 a model-free analysis(2) was used to generate the
generalized order parameter, S2. The S2 value is a measure of rigidity (where S2 = 1.0
indicates complete rigidity and S2 = 0.0 complete fluidity) on the nanosecond-topicosecond time scale for the bond of interest,(1, 2) in our case the arginine backbone and
side-chain N−H bond vectors. Model-free analysis can also differentiate between global
and local motions. In our previous work on PMK, we showed that domain movement
(global motion) was affected by ligand binding, with little attenuation of local motions. In
the side-chain studies presented herein, it was observed that ligand binding causes the
arginine ε-N−H’s to increase S2 on average from 0.47 in apo-PMK to 0.64−0.75 in the
binary and ternary complexes (Figure 3.9 and Table 3.3). As a control to test whether it
is coulombic attraction that is causing these arginines to rigidify upon ligand binding, the
same dynamics experiments were repeated as before except in 100 mM KCl buffer
(Figure 3.10). Addition of KCl into the buffer causes the R2 values the MgADP bound
PMK to decrease on average from 15 sec-1 to 10 sec-1 which subsequently seems to cause
the S2 values to decrease in every arginine NH (except SC-12/R141).
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Figure 3.9. Generalized order parameters (S2 values) for all assigned and unassigned
arginine backbone and sidechain ε-N-H’s, where blue is apo PMK, red is M5P/PMK
complex, yellow is MgADP/PMK complex, and green is the M5P/MgADP/PMK ternary
complex. Using mutant forms of PMK, we have identified SC-3 and 4 belonging to
either R84 and R111, and SC-12 as probably belonging to R141. Nearly all arginine
sidechain residues undergo a significant increase in S2 (i.e. rigidification) upon binding
either ligand.

Residue
Number

Tentative
Assignment

SC-3

R84

SC-4

R111

SC-5

R130

SC-12

R141

Distance to Nearest
Neg. Charge (ε-NH)
Distance
Atom
3.0 Å
Carboxyl
of M5P
2.6 Å
Carboxyl
of M5P
14 Å
γphosphate
of ATP
14 Å
αphosphate
of ATP

S2 Values of PMK Complexes
Apo
0.588

M5P
-----

ADP
0.875

Ternary
0.648

0.593

-----

-----

-----

0.417

0.618

0.730

0.734

0.418

0.597

0.667

0.802

Table 3.4. Distance from arginine sidechain NH (for those that were tentatively assigned
using site-directed mutagenesis) to the nearest negatively charged atom on either
substrate. Also shown are changes in order parameter, when available. Note that while
R141 is close to substrate, it is still distal from any charged atom on the substrate.
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Figure 3.10. Effect of adding 100 mM KCl. NMR dynamics data of arginine side chain
ε-NH’s of PMK including the R1and R2 relaxation rates, 1H-15N NOE, and the
generalized order parameter (S2), where blue is Apo PMK, red is Apo PMK in NMR
buffer including 100 mM KCl, yellow is MgADP bound PMK, and green is MgADP
bound PMK in NMR buffer including 100 mM KCl.
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It should be noted that MgADP bound PMK without salt was able to fit to model
4 while addition of salt seemed to cause the dynamical changes to fit only model 5. It
should also be noted that the backbone NH’s of MgADP bound PMK with in high salt
behaved the same way as with regular NMR buffer (in terms of S2 values), suggesting
that only the ε-NH’s are affected by the high salt. This leads to the conclusion that ligand
binding causes arginine side chains to rigidify throughout the protein, even distal to the
binding site, perhaps as a result of long-range Coulombic interactions with the substrates.
The S2 values for the arginine backbones corresponded to our previous results39 on fully
15

N labeled PMK, where we reported changes in τc due to domain motion, analogous to

those in adenylate kinase where the differences are attributed to different buffer
conditions. Surprisingly, the backbone dynamics changes were minimal, in stark contrast
to the side-chain effects.

3.4

Conclusion
It has been noted in studies of side-chain methyl groups that changes in the

dynamic state of side chains may not be well-reflected in changes observed in the
backbone.40, 41 We also have observed quite large differences between the backbone and
side-chain responses to substrate binding. Whether such dramatic differences between
side-chain and backbone dynamics changes are common in arginines (vs aliphatic side
chains) and/or in interactions with highly charged substrates (multiple phosphate groups)
cannot be concluded until more arginine side-chain dynamics studies on other proteins
are reported.
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While it is possible that substrate binding simply causes a global rigidification of
side chains in PMK, this seems unlikely. We propose that side chains rigidify because of
Coulombic attraction from the highly charged substrate(s); in support of this hypothesis,
the ADP-induced S2 effect is abolished in high salt (Figure 3.10). This must be a longrange effect, since only four arginines are within 4 Å and only six arginines are within 8
Å, even though 10 arginine side chains rigidify (Figure 3.9).
In summary, we have shown that substrate binding to PMK causes arginine side
chains to undergo a transition from a flexible to a rigid state. The magnitude and global
nature of this effect is significant. Besides providing mechanistic insights, such studies
will facilitate computational docking by identifying flexible side chains that can be
allowed to sample conformational space during the docking calculations.
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CHAPTER IV. Proteomic Investigation of the N- Teriminal Disordered Region of
Unknown Function in Human Phosphomevalonate Kinase
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4.1

Introduction

4.1.1

N-terminal Peptide of PMK and Aims to Discover Function
The most noticeable feature of the order parameter profile (Figure 4.1) of

backbone amides in PMK is in the N-terminal region, which has no homology to
adenylate kinase or to the T4 deoxynucleotide kinase template, upon which the homology
model was based. But, there is a dramatic and sharp change in S2 from a disordered state
(S2≈ 0.4) to an ordered state (S2 > 0.8), occurring immediately after Arg9 where the
homology model starts. The fact that these nine residues are completely disordered in apo
Phosphomevalonate Kinase (PMK), and all binary and ternary complexes, combined with
the fact that organisms such as C. elegans lack this N-terminal segment entirely, suggests
it is not an integral part of the PMK structure.14 Indeed, inspection of the homology
model reveals no potential structural role for these nine N-terminal residues. This led us
to speculate that these residues may be part of a signal or regulatory peptide, which might
be cleaved off by an as-yet unidentified protease (note: this region shows no homology to
membrane-binding peptides, and there are no data suggesting PMK is membrane bound).
To determine the function, if any, of this N-terminal region, we mixed human
liver proteins with 15N-PMK to determine if any proteins in liver tissue bind to or cleave
PMK. We also attempt to identify those proteins that do bind by purifying them using an
affinity column with just the N-terminal disordered region (synthesized peptide)
covalently attached to a column. Proteins that bind to the affinity column, and are eluted
by free peptide, will be identified by mass spectrometry (MS). Finally, to ensure that
those proteins that are identified do actually bind to the peptide, saturation transfer
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difference STD NMR binding studies are performed with the liver proteins and the PMKderived peptide.

Figure 4.1: S2 values of the backbone amide N-H’s of human PMK with the hinge
regions and domains labeled. Note the 9-residue signal peptide S2 values at amino acid
number 1-9.

4.2

Methods and Materials

4.2.1

Instruments and Materials
All NMR experiments were performed on a 600 MHz Varian NMR System

instrument equipped with a triple resonance cryoprobe and z-axis gradients. Peptides
were synthesized at the Medical College of Wisconsin where they were prepared with the
N-terminus acetylated. All NuPage and Novex products used for SDS-PAGE
experiments were purchased from Invitrogen. All other chemical reagents, including
activated CH Sepharose 4B, as well as human liver proteins (cytoplasmic) were
purchased from Sigma Aldrich.
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4.2.2

15

N-1H HSQC Spectra of PMK with Human Liver Proteins Added

15

N-PMK was exchanged into a buffer containing 20 mM potassium phosphate

and 5 mM DTT at pH of 5.5. Liver proteins and 500 uM PMK was combined into equal
volumes in an NMR tube to attain 400 uL total volume. HSQC spectra were acquired
after liver protein addition, at 6 hours, and at 24 hours to assess if any changes in
chemical shifts occur with time. HSQC spectra were then processed using NMRPipe and
NMRDraw using a 90° shifted sine bell function in 1H and 15N dimension.

4.2.3

Peptide Affinity Column Preparation and Purification of Liver Proteins
Both peptides were prepared for coupling to the column resin the same way. One

gram of CH Sepharose was added to 200 mL of 1 mM HCl solution and the resin was
allowed to swell for 15 minutes. This solution was then filtered into a column and
washed with 500 mL of 1 mM HCl. The resin swelled to a volume of around 3 mL. To
couple the ligand to the resin, 10 mg of ligand (1.7 mM) was dissolved into 3 mL of
coupling buffer that consisted of 0.1 M NaHCO3 and 0.5 M NaCl at pH 8.0. The 3 mL of
peptide ligand solution was added to the resin in the column and shaken at room
temperature for 2 hours, to permit chemical coupling by reaction of ligand amino groups
with the N-hydrosuccinamide groups on the resin. After two hours, the residual ligand
was washed with 30 mL of coupling buffer. The remaining active groups of the resin
were blocked with 0.1 M Tris buffer at pH 8.0 by washing the resin with buffer and
letting the resin incubate in the buffer for 1 hour. The resin was washed with alternating
washes of 0.1 M acetic acid with 0.5 M NaCl at pH 4.0, then with 0.1 Tris-HCl with 0.5
M NaCl at pH 8.0. This was done to ensure that no free peptide ligand remained bound
via ionic interactions. The column was then packed using a Pharmacia LKB peristaltic
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pump with 50 mM phosphate buffer with the same pH as the human liver proteins, pH at
7.4. It was packed until the bed volume stabilized. 100 uL of human liver proteins were
then added to 100 uL of phosphate buffer, and then added to the top of the resin. The
resin was then washed with the phosphate buffer, and fractions were monitored by UVVis until A280< 0.005, indicating that there was no more protein being eluted from the
column. Competitive elution was used to elute any bound protein from the column: 20
mg of peptide (control or N-terminus) was dissolved into 5 mL of phosphate buffer with
0.5 M NaCl at pH 5.0 to give a 2 mM peptide solution, and all 5 mL of the peptide
solution was added to the resin and phosphate/salt buffer was added to the column after
the 5 mL went through, and all eluent was collected in a single fraction. The eluent was
then filtered using a Millipore Amicon-4 Centrifugal Filter with a 10,000-dalton cutoff.
This solution was concentrated down to approximately 100-200 uL and a SDS-PAGE gel
was used to determine the molecular weights of the eluted proteins (Figure 4.4). To get a
more precise MW value, the log value of all the MW marker proteins vs. the Rf values of
protein bands was plotted and fitted. This gave a fitted equation of y=-1.815x + 2.444,
where y is the log of MW and x is the Rf of the unknown protein in the eluent. The
samples were then sent to the Medical College of Wisconsin Protein and Nucleic Acid
Facility for tandem MS (ESI) based identification, based on sequencing of tryptic
peptides from the eluted protiens. The trypsin digested peptides derived from the whole
proteins were searched against a database of human protein mass spectra fingerprints to
then identify the eluted proteins, using standard methods.
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4.2.4 Saturation Transfer Difference (STD) of Hemoglobin with Peptide
Fragments Present
STD NMR studies were recorded at 298 K with 1 mM N-terminal peptide and
100 µM hemoglobin, and using the Varian cyclenoe pulse sequence. 1D-1H NMR
spectra were taken in advance, for both protein and peptide, to select the proper
frequency for irradiation. During the STD experiment, alternating on-resonance
irradiation of the protein methyl region (around -2.5 ppm), and off-resonance irradiation
at a region far from any protein or peptide signals (-10 ppm) was used. The spacing and
pattern values were set to 20 and 5, while cycle was set to y and tau to 100 ms, with the
saturation power at -10 dB. The total irradiation time was set to 4 s, with 512 transients
collected for each experiment. All 1D-1H NMR spectra and 1D STD spectra were
processed using iNMR on a Mac workstation. Exponential multiplication was used with
2 Hz line broadening for all spectra.

4.3

Results and Discussion

4.3.1

Signal Sequence Database Search
To begin exploring the hypothesis that the 9 N-terminal residues of PMK have a

functional/signaling role, and to identify which protease might cleave this N-terminal
peptide, an exhaustive search of signal sequence databases was performed, searching
only against the peptide sequence in question (i.e. Met1 to just past Arg9). While none of
these searches yielded a strongly scoring motif hit, one did give a modest scoring
prediction of cleavage immediately after Arg9:
∨

PLGGAPR LV
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This site was identified using the ProP 1.0 server, using a neural network model trained
using literature sequence data.42 While the score for the cleavage site was relatively low
(0.112; scores in the 0.5-1.0 range are considered high probability), it is the best scoring
motif hit obtained thus far, and should be interpreted in the context of NMR data that
indicate cleavage, if it occurs, is expected at exactly this site (after Arg9). The enzyme
predicted to cleave here is a furin-like protease, which belongs to a family of proteases
broadly classified as “proprotein convertases.”43-46 Interestingly, there is growing
evidence in recent years that proprotein convertases affect cholesterol levels and lipid
metabolism, largely by undefined mechanisms.47, 48 Furthermore, data have indicated
that inhibiting the proprotein convertase PCSK9 may be an effective means to treat
hypercholesterolemia and associated cardiovascular disease, as a complement to statin
treatment,45, 46 based on the observation of synergistic lipid lowering effects. Many of the
newly discovered proprotein convertases, including PCSK9, do not have any known
substrates, and therefore have poorly defined peptide recognition motifs. As such, we are
now pursuing studies to identify which, if any, proprotein convertase might cleave the
disordered PMK N-terminal peptide, and what affect this cleavage might have. Likewise,
it is possible that a protein other then a proprotein convertase may recognize this 9 amino
acid sequence, and our studies endeavor to identify this protein.

4.3.2

Human Liver Proteins Binding to PMK
A 15N-1H HSQC 2D NMR spectrum was acquired before human liver protein

addition and at each time point after. If any protein binds to or cleaves the N-terminal
region of PMK, then we should notice chemical shift changes in the N-terminal amino
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acid residues, especially residues 1-9. As shown in Figure 4.2 there are no chemical shift
changes in any residues when comparing purified PMK (black) to PMK after the liver
proteins have been added (red), then after 4 hrs. (green), and after 24 hrs. (blue). So,
HSQC data suggest that no liver proteins bind to or cleave PMK. This could be for any
of several reasons, the first being that the concentration of the protein that may be doing
the binding or cleaving is not in high enough concentration to produce any chemical shift
changes. The approximate PMK concentration was 250 µM when mixed with liver
proteins. To see any chemical shift changes, the protein(s) that bind would have to be
close to that concentration (at least > 25 µM) to produce any detectable chemical shift
changes. Another reason that we may not see binding is due to the additional 20 amino
acid chain on the N-terminal region of PMK. This chain contains the histidine tag region
that was engineered onto PMK to facilitate purification, and this tag may block binding to
other proteins. Finally, it is of course possible that no human liver proteins bind to and/or
cleave this N-terminal sequence.
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Figure 4.2: 1H-15N HSQC 2D spectra of human PMK (black) and PMK incubated with
human liver proteins directly after addition (red), 4 hrs. after addition (green), and 24 hrs.
after addition (blue).

4.3.3

Purification of Human Liver Proteins That Bind to the Synthesized Nterminal Peptide Sequence
Activated CH-Sepharose 4B resin is designed to be specific for reaction with

primary amino groups. At lower pH, the NHS (N-hydroxysuccinimide) ester becomes
available for attack (Figure 4.3) by ligands with active primary amino groups. As stated
in the previous section, the disordered N-terminal region starts at Met1 and ends with
Arg9, so we had this peptide sequence synthesized with those 9 residues with an
additional 4 residues from the sequence and 7 more amino acids added as a flexible and
hydrophilic linker, with the two-lysine residues at the C-terminal end to react with the
NHS ester on the resin:
Acetyl-MAPLGGAPRLPLLGSGSKSK
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These lysine residues (KSK) have the primary amino groups needed to react with the
resin. To ensure that the amino group of Met1 does not react with the resin, we had the
N-terminal residue acetylated.

Figure 4.3: Chemical reaction of activated CH sepharose 4B with the primary amine of
the amino acid lysine.

The column purification and subsequent concentration of the eluent yielded seven
clear bands on the SDS-PAGE gel (Figure 4.4). The molecular weights, as determined
by the measuring Rf values of the bands in the gel, are 13.7, 43.7, 52.4, 61.3, 65.1, 73.3,
142.8 kDa. Some of the proteins that correspond to the molecular weights, determined
by mass spectrometry (MS), are represented in Table 4.1.
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Figure 4.4: SDS-PAGE gel of eluted human liver proteins from the affinity column with
covalently attached A) N-terminal PMK peptide and B) scrambled N-terminal PMK
peptide. Note: Gel B is much darker due to longer staining time, to make sure that every
band is resolved.
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Table 4.1. Human liver proteins with the highest probability of being bound to the Nterminal region of human PMK. These proteins were bound to the N-terminal peptide
that was covalently attached to the affinity column.

In this MS anaylsis, protein probability is the likelihood that the peptides that
were sequenced are for the “identified” protein. Peptide count is the number of
sequenced peptides in the sample that are present in the “identified” protein; scan count
represents the number of times the peptide was identified in the MS-scanning process
(reflects S/N); percent coverage is the percent of the total protein sequence covered by
the sequenced peptides, and MWT is the molecular weight of the identified protein. Of
all the categories, probably the most important is percent coverage, along with score.
According to these criteria, the highest rated proteins are hemoglobin subunits α (52.4%
coverage) and β (37.1% coverage) as well as L-xylulose reductase (25.5% coverage).
Hemoglobin is a tetramer with two α subunits and two β subunits that are used for
oxygen transport from the lungs to the rest of the body, where the oxygen is released for
cell uptake.49 L-xylulose reductase is involved in the uronate cycle of glucose
metabolism and catalyzes the reduction of xylulose into xylitol.50 Currently, we have no
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reason to suspect that either of these proteins would interact with PMK, however we are
testing to determine whether hemoglobin binds the N-terminal peptide fragment (vida
infra).
To make sure that the human liver proteins are not binding non-specifically to
something else in the column, such as support material, we had another peptide
synthesized using the same procedure as the first, except the amino acids that comprise
the PMK signal peptide were scrambled. We did this by assigning a number to each
amino acid then used a random number generator to scramble the order of the amino
acids. To make sure there were no important amino acids still together in the sequence
(Arg9 and those residues before and after it) we manually adjusted the sequence, as
needed. This led to the following peptide, which was synthesized at MCW:
Acetyl-LARGPMLGLLAPVGSGSKSK
We preserved the final 7 amino acids so that they still bind the peptide to the sepharose
support. Figure 4.4B shows the concentrated eluent from the scrambled N-terimanl
region peptide of PMK. The bands look nearly the same between the two gels, however
at 15 kDa, there appears to be no band present for the scrambled peptide indicating that
there was no binding of any protein to affinity column at that molecular weight. This
indicates that something does indeed bind to the natural N-terminal region of PMK
(Figure 4.4A) with the molecular weight of 15 kDa. This strongly supports the MS data
(Table 4.1) that hemoglobin (with a molecular weight of approx 15 kDa) could be the
protein that binds to PMK’s N-terminal disorderd region.
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3.3.4

Saturation Transfer Difference STD NMR Binding Assay to Determine if
Hemoglobin Binds to the N-terminal Disordered Region of PMK
Saturation transfer difference (STD) is a relatively new NMR technique in which

a certain frequency region of the NMR spectra is irradiated; mainly the methyl region and
difference spectra are measured. This irradiation of protein methyl protons leads to
magnetization transfer via spin diffusion from the methyl protons to the rest of the
protein.51 If a ligand binds to the protein in fast exchange, magnetization is then
transferred to the ligand, giving rise to a 1-D difference NMR spectrum for that ligand
(the “NOE difference spectrum”). As mentioned in methods and materials, a 1-D 1H
NMR spectrum was taken of both the peptide and the hemoglobin, to determine the best
spectral region for irradiating (Fig. 4.5). As shown, there is signal as low as 0.6 ppm for
the ligand and -2.5 ppm for the protein. The STD experiment (Figure 4.6B) with
hemoglobin and peptide, with irradiation of the methyl region at -2.5, gave only a modest
increase in STD signal at 0.6 ppm, for peptide. To determine if we are observing
artifactual STD of just the peptide, a control experiment was run in which only the
peptide (no hemoglobin) was subjected to an irradiation at -2.5 ppm (Figure 4.6A).
When the spectra are overlaid on each other using the same noise level as
reference what is observed is that the STD signal with hemoglobin present is roughly
twice the signal for the control STD experiment with peptide alone. This doesn’t
necessarily mean that peptide binds to hemoglobin, as generally the STD signal is much
larger. It is possible that STD signal is attenuated because binding is too tight (STD
signal requires fast exchange binding). If a ligand binds to tightly, no STD signal will be
observed, as the ligand won’t be released before the magnetization that was transferred
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from the protein decays. More experiments will have to be done to confirm whether the
N-terminal peptide does in fact bind to hemoglobin.

Figure 4.5. 1-D 1H NMR spectra of hemoglobin to determine methyl irradiation for STD
NMR spectra. Note: methyl regions extends to -2.4 ppm.

84

Figure 4.6: 1-D STD NMR spectra of A) the N-terminal region peptide and B) the Nterminal region peptide with 100 µM hemoglobin. An expanded overlay of the possible
STD signal in the upper right corner.

4.3.4

Conclusion
The N-terminal region of PMK was synthesized and used in NMR and affinity

column binding experiments to determine if there are proteins in the human liver
proteome that bind to it and/or cleave it. We have identified proteins from human liver
tissue that may bind to the N-terminal peptide of PMK, using tandem mass spectrometry
(ESI), with hemoglobin being the most likely binding partner. Hemoglobin was then
used in NMR STD binding experiments to determine if binding of hemoglobin to peptide
does actually occur. However, it is still unclear if such binding does occur. An
alternative strategy to verify binding is to have the peptide synthesized with one of the
amino acids in the sequence labeled with 15N, which will then give a signal in 1H-15N
HSQC spectra, and which will permit monitoring of binding of the peptide to protein
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based on chemical shift changes. The peptide could also be synthesized with a
fluorescence tag, and we could monitor binding to hemoglobin based on fluorescence
changes.
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Chapter V. Solution Structures of Oxidized and Reduced forms of
Thioredoxin C, and Models to Describe the Intact Thioredoxin System from
Mycobacterium tuberculosis
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5.1

Introduction
Mycobacterium tuberculosis (M. tb) is the causative agent of the infectious

disease tuberculosis, and is a devastating pathogen that has affected (new and previously
occurring infection) nearly 11 million people and a mortality rate of 1.3 million people in
2008.52 It is also thought that a third of the population is infected, with a latent form of
the disease, which is not infectious.53 The pathogen resides in the alveolar phagocytes
and can resist the oxidative killing of the cell however this mechanism is still unclear.54
The method by which phagocytes kill the invading microbes is by the production of
reactive oxygen and nitrogen species, including superoxides and hydrogen peroxide,
which can create free radicals that become toxic to the microbe.55 One method that M. tb
uses to resist this oxidative killing is by the same process that eukaryotic cells use to
combat oxidative stress. In other prokaryotes, this is done by the thioredoxin system,
which keeps the cell in a reduced state, based on it’s ability to control the redox state of
cellular thiols/disulfides.56, 57
Thioredoxins are well-studied proteins, and found in almost every organism.58
They share common features such as a similar three-dimensional structure, a conserved
catalytic motif of WCXXC in the active site of the protein, and a molecular weight of
about 12 kDa.59 Thioredoxins catalyze thiol-disulfide exchange reactions using redox
active cysteine thiols to reduce oxidized disulfide cysteines of other essential proteins,
including metabolically essential enzymes.60, 6162 Oxidized thioredoxins are then reduced
by thioredoxin reductase in an NADPH dependant reaction, via redox active cysteine
thiols.63 Disulfide reductions occur via hydride transfer from NADPH to a bound FAD
cofactor, followed by electron transfer from FADH2 to bound thioredoxin. The
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interaction and reaction between the thioredoxin reductase and the thioredoxin substrates
are essential to keep the cell in a reduced state, and define what is called the thioredoxin
system. While the thioredoxin system of E. coli is well characterized, that of M.
tuberculosis is not.64 If this system were disrupted, the M. tuberculosis pathogen would
be more vulnerable to the oxidative attacks of our immune cells (neutrophils,
macrophages).
The thioredoxin system in M. tb is comprised of three thioredoxins (TrxA, TrxB,
and TrxC) and one thioredoxin reductase (TrxR).54, 64, 65 Many organisms have multiple
genes encoding thioredoxins, which is probably a function that enables coping with the
amount and perhaps type of oxidative stress in a cell. It has been shown that TrxB and
TrxC behave as general disulfide reductases with near equal reduction potential, while
TrxA is observed to have a weak capacity to act as a disulfide reductase, and was found
to not be a substrate of TrxR.64 It was also observed that the ability of M. tb to survive
redox stress isn’t dependant on the expression of one thioredoxin over another, which
suggests that having multiple thioredoxins may be a “redundant system” to ensure
survival under oxidative conditions.64
It is for these reasons, and the severity of the tuberculosis disease, that make the
thioredoxin system of M. tb a suitable target for drug inhibition, as long as a drug could
be designed knock out the whole thioredoxin system (ex. inhibit TrxR binding).66 There
has been some work done on the inhibition of TrxC signaling.67 The crystal structure of
TrxC in the oxidized state has been solved to help facilitate those studies.65 Previous
studies of the different redox states of prokaryotic thioredoxins have shown that there are
subtle changes in structure in going from oxidized to the reduced state.68-70 Most of the
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changes are occuring in the active site, around the redox active cysteines, with some
conformational flexibility observed in the active site loop.68, 71 The secondary structure
of the whole protein remains the same, as the thioredoxin goes from oxidized to reduced
state. Whether this is also true in M. tb is not known, since there is no structure of
reduced TrxC (or of any TrxA or B).
Here we report the NMR solution structures of Mycobacterium tuberculosis
thioredoxin C in both the oxidized and reduced states, with discussion of structural
changes that occur in going between redox states. The NMR solution structure of the
oxidized TrxC, when compared to the crystal structure, corresponds very closely.
However, crystal packing may have caused an artifactual shift in the α4 helix in the
reported crystal structure, compared to the solution structure. With the previous report of
the crystal structure of M. tb’s thioredoxin reductase (not bound to a Trx), we have
modeled the complete thioredoxin system in the mechanism (catalytic cycle) for disulfide
exchange. This was based on existing structures of M. tb TrxR and both redox states of
TrxC (our solution structures), and using the E. coli TrxR/Trx complex as a template for
model building.72

5.2

Methods and Materials

5.2.1

Protein Expression and Purification
The plasmid containing the gene Rv3914 (TrxC) in the pET vector pET22b and

gene Rv3913 (TrxR) in pET vector pET23a was obtained from Tuberculosis Vaccine
Testing and Research Materials at Colorado State University and Shkhar C. Mande from
the Center for DNA Fingerprinting and Diagnostics in Hyderabad, India.73 The plasmid
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containing the expression constructs (with a C-terminal histidine tag) was transformed
into E. coli BL21-(DE3) Rosetta cells from Novagen and grown overnight at 37° C,
which was then used to inoculate 2 L of LB (Luria Bertani) media. The media was
closely monitored at O.D. 600 nm until the cell density reached an absorbance of 0.7, at
in which point, the media containing the cells for expression of TrxR were induced with 1
mM IPTG and the cells containing TrxC, the cells were then spun down at 4000 rcf and
washed with M9 minimal media salts at pH of 7.0. The cell pellets were transferred to
0.5 L of M9 minimal media containing 0.5 grams 15NH4Cl and 2.0 grams of 13C-glucose
as the only sources of nitrogen and carbon, to yield uniformly labeled protein.74 The cells
were allowed to acclimate for 1 hour and then induced with 1 mM IPTG for an additional
4 hours at 37° C, then cells were harvested. The bacterial pellet was resuspended in 50
mM Tris base, 300 mM NaCl, 5 mM imidazole, and 10% glycerol at pH of 7.8, and lysed
using sonication. The lysate was clarified by centrifugation at 15,000 RPM for 30
minutes and the supernatant loaded onto 1 mL of nickel-Sepharose (Amersham Scienes)
resin at 1 mL/minute. The bound proteins (TrxC/R) were then washed with lysate buffer,
then with lysate buffer containing 25 mM imidazole, and then eluted using lysate buffer
containing 300 mM imidazole. The eluted protein was than dialyzed with 40 mM
potassium phosphate buffer at pH of 6.3 (NMR structures) and pH of 7.0 (TrxC/R
binding experiments) and concentrated to 1 mM, with protein concentration determined
by the absorbance at 280 nm using extinction coefficients of 11,000 and 14,440 L/molcm for TrxC and TrxR respectively by using the resource ProtParam
(http://expasy.org/tools/protparam.html). To reduce the disulfide, 5 mM DTT was added
to the protein samples.
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5.2.2

NMR Spectroscopy and Structure Calculation
All NMR experiments were performed on a 600 MHz Varian NMR System at

599.515 MHz using a triple resonance cryoprobe with z-axis gradients at 25 °C.
Backbone assignments were obtained using 2D 1H-15N HSQC, and 3D HNCO,
HN(CA)CO, HNCA, HN(CO)CA, CBCA(CO)NH, and HNCACB spectra (Figure 5.1).
The side chains were assigned using CC(CO)NH, HBHA(CO)NH, HCC(CO)NH, and
HCCH-TOCSY spectra. Distance restraints were obtained from 3-D 15N-NOESY, 13C
aliphatic NOESY, and 13C aromatic NOESY experiments which were obtained using 150
ms mixing times. Structures were calculated using these distance restraints with the
program CYANA1, 2, in conjunction with backbone phi and psi angle restraints as
predicted from TALOS3 based on chemical shifts of Cα, Cβ, Hα, Hβ, HN, and CO atoms.
Initial structures were obtained using the noeassign macro of CYANA2, followed by
manual refinement using the calibration of peaklists by the CYANA function caliba,75
with the disulfide bond added as a restraint for the oxidized structure. A final ensemble
of 500 structures was calculated, and the 100 conformers with the lowest target function
were then selected for water refinement using AMBER. Using implicit solvent (which
treats the solvent as a high dielectric continuous medium surrounding the protein near its
van der Waals surface so it can interact with the charges on the low dielectric protein), a
500 step energy minimization was first performed on the 100 structures (no restraints)
followed by two cycles of 30 ps simulated annealing from 1000K to 0K, with distance
and dihedral restraints applied. After the MD simulated annealing, a 2000 step
minimization with restraints was applied in implicit solvent and analyzed for distance and
dihedral penalties and rank ordered by lowest AMBER energy. The 20 lowest energy
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Figure 5.1. Selected strips from CBCA(CO)NH (left strip of residue) and HNCACB
(right strip of residue where red peaks are Cβ and black peaks are Cα) spectra of residues
30-38. Blue lines indicate peaks used in sequential assignment of backbone residues.
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structures were then selected for the final ensemble, and were subjected to analysis using
the PSVS (http://psvs-1_4-dev.nesg.org/) server. NMR spectra were processed using
NMRPipe24 and analyzed using NMRView25 and Sparky (T. D. Goddard and D. G.
Kneller, SPARKY 3, University of California, San Francisco). In general, processing
was performed with a cosine bell window function in the direct and indirect dimensions.
All calculations were done using Pere and Condor submission process (NSF OCI0923037).

5.2.3

Modeling of M. tb Thioredoxin Oxidoreductase Activity
The M. tb thioredoxin reductase structure (pdb code 2A87)54 had been solved in

the oxidized state. To create a model TrxR of in the reduced state, where the disulfide is
converted to surface free thiols, available to react with and reduce thioredoxins, the
coordinates of the E. coli homolog of TrxR bound to a thioredoxin (pdb code 1F6M)72
were used as template. The M. tb TrxR (oxidized) structure was superimposed on the E.
coli TrxR (reduced) structure; but, the reduced E. coli TrxR is known to have a 66°
domain rotation relative to the oxidized TrxR,54, 72 so this rotation was created in the M.
tb structure. To do this, the pdb file of M. tb TrxR was split at amino acids 117 and 241
so that the FAD and NADPH domains could be separated. The separated NADPH and
FAD domain coordinates were then superimposed onto the coordinates of the E. coli
NADPH and FAD domain using Pymol (The PyMOL Molecular Graphics System,
Version 1.2r3pre, Schrödinger, LLC.), rejoined and then minimized using AMBER. To
model the various oxidation states of the TrxR/TrxC complexes, including the mixed
disulfide bond between TrxR and TrxC, structures were minimized with a restrained
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disulfide bond between the cysteines (oxidized) or left with no restraint (reduced). All
AMBER minimizations were performed with 2000 steps in implicit solvent.
5.2.4

Thioredoxin System NMR Binding Experiments
Concentrated TrxC and TrxR solutions were buffer exchanged in 50 mM

potassium phosphate at pH 7.0, to 1 mM each. TrxC was diluted to 320 µM in the
absence of DTT, so that it was in the oxidized state. TrxR was then added to the TrxC
NMR sample, so that both proteins were at equal concentrations of 250 µM. NADPH
was then added to the sample at 1 mM so that TrxR would reduce the disulfide of TrxC.
As a control to test for binding in the presence of the different redox states of the
cofactor, NADP+ was added to the sample at 1 mM.

1

H-15N HSQC experiments were

taken after every step, and pH was measured to ensure that it remains at 7.0. As a control
for the reduced state, 1H-15N HSQC spectra were acquired of TrxC in the oxidized state,
and then reduced by DTT at pH 7.0.

5.3

Results and Discussion

5.3.1

NMR Structures of Oxidized and Reduced Thioredoxin C
The solution structures of M. tb Thioredoxin C were solved by NMR, with 2036

unique NOE derived restraints and 168 angle restraints in the oxidized state and 2114
NOE restraints in the reduced state with 169 angle restraints. Statistics describing the
restraints used in calculation, precision to average coordinates, and quality of the
structures are summarized in Table 5.1. The ensemble of structures for oxidized TrxC
has a backbone RMSD of 0.54 Å, and 0.50 Å for the reduced conformer (Figure 5.2A-D).
To ensure that the cysteines were reduced, 5 mM DTT was added to the protein sample
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and chemical shifts were monitored before and after each experiment, using a 1H-15N
HSQC (Figure 5.3A-B) spectrum, to ensure there was no disulfide reformation. Further
confirmation of the reduction of the active site cysteines is provided by the decrease in
the 13Cβ chemical shift from 44.6 to 26.9 ppm and 35.1 to 27.6 ppm for Cys37 and Cys40
respectively. The HSQC spectrum of TrxC shows good dispersion of chemical shifts.
After addition of DTT, those residues that are affected the most are located along that
active site loop, including F32, A34, T35, C37, G38, and C40.

Table 5.1. NMR and structure refinement statistics for the NMR solution structures of
the oxidized and reduced states of M. tb TrxC, obtained using the program pdbstat.
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Figure 5.2. Solution NMR structures of A) the ensemble of oxidized TrxC with a
backbone RMSD of 0.54 and B) is the median structure for this ensemble with the
disulfide of C37 and C40 shown. Panel C shows the ensemble of the reduced state of
TrxC with a backbone RMSD of 0.50 and D) is the median structure for this ensemble
with the free thiols shown.
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Figure 5.3 2D 1H-15N HSQC spectra of A) the oxidized state of TrxC (red) with all the
backbone N-H chemical shifts assigned, and B) the reduced state of TrxC (black) with
the large chemical shift changes associated with going from the disulfide to free thiols
labeled.
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Analogous to the situation with the solution structures of the E. coli
thioredoxins,68 the oxidized and reduced forms of TrxC are very similar to each other,
showing only small differences between oxidized and reduced states, with a pairwise
RMSD of 0.53 (calculated using Pymol) between ensembles (Figure 5.2A-D). Compared
to other thioredoxins, TrxC in both forms has the characteristic folding pattern of 4 αhelices surrounding a 5 stranded beta sheet core, consisting of three parallel strands and
two antiparallel. The redox active cysteine residues C37 and C40 are located in the
conserved active site loop (C37-G-P-C40) that leads into the α2 helix, which in both states
is a bent helix. The active site of TrxC includes a predominately hydrophobic core
including two Ala (34 and 44), two Pro (39 and 81), an Ile (80), and a Val (43) residue.
Both Trp (33 and 36) indole rings are all within 6 Å of the two Cys’s, with W36 forming
the interface with the thioredoxin reductase. The disulfide in the oxidized state has the
typical 90° χ1 angle between the C-S-S-C linkage, and keeps roughly the same χ1 angle
going to the free thiols. The most drastic change is the distance of the Cys residue
sidechains, with the S-S distance in the oxidized state of the median structure in the
ensemble having a distance of 2.0 Å, and 3.5 Å in the reduced state (Figure 5.4).
Although the α1 helices are nearly identical between the two states, it is
somewhat of an irregular helix. It is also present in the crystal structure of M. tb TrxCox65
as well both E. coli Trx solution structures. The α4 helix spans residues 101-111
however it begins to show disorder at L108, while still keeping its secondary structure.
There is some degree of difference between the two states in the random coil and turn
region linking the α1 helix to the β3 sheet (22-26), and the α3 helix connecting to the β4
sheet (75-81). The latter region closely contacts the active site region. These regions are
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probably dynamic in nature, and are also evident in the E. coli solution structures of the
different redox states, which resemble the M. tb solution structures (Figure 5.5).

Figure 5.4. The overlay of backbones for the median structures from the solution
structures of TrxC in both redox states (with active site cysteines shown), where blue is
the oxidized form and wheat is the reduced form. Thiol and disulfide atoms from
cysteines 37 and 40 are shown.
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Figure 5.5. Overlays of both redox states of solution structures from E. coli Trx and M.
tb TrxC, where A) is the overlay for the oxidized states, with blue being from M. tb and
green from E. coli and B) is the overlay for the reduced states, with wheat being from M.
tb and purple from E. coli.

5.3.2

Comparison to M. tb TrxC Crystal Structure
The M. tb TrxC crystal structure (pdb code 2i1u)65 was solved in the oxidized

state, and is nearly identical in secondary structure to our solution structure, with a
pairwise rmsd of 0.83 Å between the crystal structure and the median structure from the
ensemble (Figure 5.6). The major differences and the source of the high RMSD, is the
orientation of the α4 helix. It was noted in the crystal structure study that the protein
crystals packed such that the C-terminal residues (110-114) in the α4 helix rested in the
active site groove of an adjacent protein in the crystal lattice. Based on our solution
structure, this crystal packing seems to have caused the α4 helix to be pushed up 2.7 Å
towards the β5 strand, and rotated in towards the β4 strand (Figure 5.6). Residues 108115 in the crystal structure are disordered, perhaps so that those residues can occupy the
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active site neighboring protein. However, residues 108-111 still retain helical shape (as
mentioned above) before becoming disordered at residues 112-115 in our solution
structure.

α4	
  

α4	
  

Figure 5.6. Overlay of the median structure of the NMR solution structure of oxidized
TrxC (blue) and the crystal structure of oxidized TrxC orange with the active site
disulfides shown.

5.3.3. Oxidoreductase Activity of M. tb Thioredoxin Reductase and Thioredoxin C
To complete the redox cycle, after having reduced other proteins in the cell, TrxC
itself must be regenerated to the reduced state. As previously mentioned, it does this by
serving as the substrate of thioredoxin reductase. Figure 5.7 shows our models of
TrxR/TrxC in different redox states, depicting the complete redox cycle between TrxR
and TrxC, using the M. tb TrxR crystal structure54 and our TrxC structures (oxidized and
reduced). It has long been known that bacterial TrxR’s undergo a large conformational
domain rearrangement, to place the reactive cysteines in a position so that they are able to
react with the disulfide on its thioredoxin substrate. The crystal structure of the M. tb
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TrxR is in the oxidized state (FO), with it’s disulfide buried in the protein interior, near
the isoalloxazine ring of FAD so the reduced state of M. tb TrxR (FR), with the cysteines
at the surface and the NADPH close to the FAD, was modeled using the E. coli
thioredoxin reductase structure, which was crystallized in complex with thioredoxin (pdb
code 1f6m).72 This E. coli structure was used as a template for proper positioning of the
M. tb TrxR FAD and NADPH domains. All the steps in the reaction sequence have
corresponding structures or models (Figure 5.7), and are based on previous kinetic and
structural studies of the E. coli system.76, 77
As shown in Figure 5.7A the catalytic cycle for the M. tb thioredoxin system is
shown starting out in a conformation described as the “FR” state, so that the active site
cysteines have just reduced TrxC and there are bound NADP+ and FADH2 cofactors in
TrxR. It is called the FR state because of the relative orientation of the NADPH and FAD
domains such that the NADPH binding site is close to the FAD (and the thiol/disulfide is
distal). Assuming M. tb TrxR behaves as the E. coli reductase, it will then undergo a 66°
rotation around the NADPH binding domain to bring the disulfide bonded cysteines
(C145 and C148 with a bond length of 2 Å) closer to the isoalloxazine ring of FADH2,
while the NADPH binding pocket moves away from the FADH2. This positions the
isoalloxazine ring within 3.7 Å of the S atom of Cys 148 (now TrxR is in the “FO” state),
while releasing NADP+. The FADH2 then reduces the disulfide by electron transfer
(Figure 5.7B-C), now giving a sulfur inter-atom distance of 3.7 Å between the two
cysteine thiols, although giving a slightly smaller χ1 angle. After reduction, a general
base (thought to be D149 which is 5.3 Å from the thiol of C148) abstracts the proton
from C148 to produce a thiolate ready for attack to the oxidized cysteines of the
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thioredoxin.77 NADPH then binds to TrxR, and the NADPH domain undergoes another
66° rotation to bring the reduced active site cysteines away from the FAD isoallxazine
ring, and back to the surface (back to the FR state) of the protein in the TrxC binding
pocket (Figure 5.7D). At the same time, the NADPH nicotinamide ring is brought to
within 3.4 Å of the isoallooxazine ring of FAD so that it can reduce the cofactor back to
FADH2. The FADH2 can once again reduce the disulfide of TrxR, later in the catalytic
cycle.
The TrxR is now in a conformation that can bind TrxC (Figure 5.7E), where the
two proteins come together in a complex that is stabilized by hydrophobic interface
produced by the FR state of TrxR residues F142 and F143 in TrxR, interacting with TrxC
residues A34, P39, V43, A44, A72, V78, I80, and P81. Figure 5.8 shows an expanded
view of this binding interface, between the two proteins, with surface rendering showing
the hydrophobic pocket. Notice how Trp36, which is conserved in all thioredoxins, has
its indole ring situated in the middle of this hydrophobic pocket, with the indole ring
nitrogen NH hydrogen bonding to the carboxyl group of Asp66, at a distance of 1.9 Å.
Such interactions with TrxC’s Trp36 are likely to be important for proper positioning of
the TrxC C37 for reaction with the TrxR thiol/disulfide (C45,C148). The thiolate of
C148 in TrxR is 4.9 Å from the disulfide linked cysteine (C37) of TrxC (Figure 5.7E).
Attack of C37 on C148 (disulfide) produces the mixed disulfide between the two proteins
(Figure 5.7F), which is analogous to the mixed disulfide structure of E. coli TrxR/Trx
that was recently reported. During mixed disulfide formation, a proton is abstracted from
C146, producing the thiolate that is capable of forming the disulfide with C148, and
releasing the C37 leaving group of the thioredoxin. This ultimately leaves TrxC in the
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thiol reduced state (Figure 5.7G). The newly reduced TrxC is released from TrxR, which
is in the same state as panel A, completing the catalytic cycle.
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Figure 5.7. The complete redox and catalysis cycle of M. tb thioredoxin system of reduced TrxR reducing
and oxidized TrxC. FR and FO refer to the reduced or oxidized conformations of TrxR, which are related by
a 66° domain rotation. TrxC (ox and red) structures are those reported herein, TrxR (FO) is the previously
reported crystal structure, while models for the various complexes were constructed based on structural and
functional data for the E. coli thioredoxin system. Each modeled complex was minimized with AMBER.
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Figure 5.8. Expansion and surface rendering (white) of the hydrophobic interface
formed when TrxR reduces an oxidized TrxC (from Figure 5.7F).
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5.3.4

NMR Evidence for Binding Interactions between M. tb TrxC and TrxR
It has been proposed that the E. coli TrxR, in solution, exists in a dynamic

equilibrium between the two conformations (FO and FR),76 no matter what the state of
oxidation is for the flavin or cysteines. The hypothesis is that changing redox state or
binding complex merely shifts the FO/FR equilibrium. While are studies are not directed
to testing this hypothesis, NMR binding and chemical shift perturbation measurements
can be used for various catalytically competent and dead-end complexes, related to those
shown in Figure 5.7. This can establish that binding occurs, and can define the
interaction surface on TrxC. To determine what oxidation state the proteins (TrxC and
TrxR) must be in order for binding to occur, a series of 1H-15N HSQC experiments were
performed so that changes to the state of the proteins in different oxidative states could be
monitored (Figure 5.9). Chemical shift changes could be due to binding or to
conformational/structural changes induced by redox changes. The TrxC protein was
partially reduced, so that we could track the changes that occur upon full reduction and
binding, amongst the different redox states in the experiments. When oxidized TrxR in
the absence of NADPH, was added to TrxC (Figure 5.9A), there were no chemical shift
changes. Interestingly, the small amount of TrxC that was present in a reduced state was
converted to a fully oxidized state, shown by the absence of red peaks over the reduced
black peaks of TrxC. When the reducing agent (NADPH) for the thioredoxin system was
added in excess (4-fold), all of the oxidized TrxC is converted to the reduced state
(Figure 5.9B). But, there is no chemical shift changes from this reduced state of TrxC,
and that observed in Figure 5.9C when of fully reduced TrxC is produced by adding the
reducing agent DTT in 4-fold excess.
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Figure 5.9. 2D 1H-15N HSQC spectra where the black cross peaks in all panels are for
oxidized/reduced TrxC and A) TrxR has been added to the sample (red), B) TrxR has
been added to the sample and the redox activity initiated by addition of with NADPH to
reduce TrxC (green), and C) DTT is added to the sample to fully reduce TrxC as a control
experiment (blue). Protein concentration is 250 µM for both TrxC and TrxR.
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Figure 5.9 continued. 2D 1H-15N HSQC spectra where D) black cross peaks are for
oxidized/reduced TrxC and TrxR is added to the sample along with the oxidized cofactor
NADP+. E) The overlay of the DTT reduced sample (blue) and the NADPH reduced
sample (green), and F) is the same as panel E with the oxidized sample from panel D and
DTT added to it (orange).
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This indicates that while NADPH binds and reduces FAD, and subsequently reduces
TrxC, that protein products of this reaction do not have high affinity for each other. In an
effort to trap a dead-end complex, NADP+ was added. But, when NADP+ is added to the
sample of TrxC/R there appears to be no chemical shift changes from the oxidized state
of TrxR (Figure 5.9D).
When the spectra for TrxC that has been reduced using NADPH and DTT are
overlaid onto each other (Figure 5.9E), there are no distinguishable chemical shift
changes. However there are a few residues that broaden indicating an intermediate
exchange process, perhaps due to binding interactions between TrxC and TrxR. To see
whether binding was a function of the oxidation state of the flavin, the sample used in
Figure 5.9D was reduced with DTT, so that both proteins were reduced, the flavin was
still oxidized, and the cofactor NADP+ was still bound. The results from this experiment
are shown in Figure 5.9F, and are analogous to the results when both proteins were being
reduced using NADPH, there were no distinguishable chemical shift changes, but some
residues were exchange broadened. The residues that were in intermediate exchange in
the complex with TrxR in Figures 5.9B and 5.9F, were mapped onto the reduced state
solution structure of TrxC in Figure 5.10. The majority of the residues that were
exchange broadened are in the active site region of the protein (F32, A34, T35, W36,
C37, T67, V78), which is consistent with expectations from the modeling of the
thioredoxin system in Figure 5.7E and 5.8, where the proteins interacting via a
hydrophobic interface. These residues’ are still present in Figure 5.9A (with no
significant chemical shift change). The dead-end complex has both proteins in the
oxidized state, with flavin being oxidized too. Based on these results, although the
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protein may be sampling both FO and FR states, TrxC will only be bound to the reduced
(free thiol) form of TrxR, no matter the state of oxidation of the flavin. And, the identity
of the residues that exchange-broaden provide some confirmation of the protein-protein
interface suggested in the model (Figure 5.7).

Figure 5.10. Solution structure of reduced TrxC with those chemical shifts that have
exchanged broadened upon binding to TrxR mapped on it (blue spheres).

5.4

Conclusion
We have determined the solution structures of both redox states of thioredoxin C

from Mycobacterium tuberculosis using NMR with high-resolution (backbone RMSD of
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0.54 and 0.50 Å for TrxCox and TrxCred, respectively). Like the E. coli thioredoxins,68 the
secondary structure and folding of the different redox states of TrxC are nearly identical,
with only subtle changes around the active site the protein, and with some dynamic loop
regions. In the presence of the thioredoxin reductase from M. tb, it appears that TrxC
binds to TrxR only when TrxR has a reduced disulfide. This was demonstrated by the
disappearance of cross peaks for residues in the active site of TrxC. Using these data,
and previous structures of the thioredoxin system from E. coli organism,72 structural
models depicting the steps of the oxidoreductase catalytic cycle of the thioredoxin system
was developed to facilitate future mechanistic studies of this system, and perhaps aid in
design of inhibitors as potential drug leads.
Further studies will include more experiments to define the binding interactions of
TrxC and TrxR, with potential point mutations to trap mixed disulfide intermediates the
proteins. This can help to determine whether TrxR really needs to be reduced for the
proteins to bind to each other. The NMR solution structures of TrxA and B are also in
the process of being solved, to provide a complete understanding of the M. tb thioredoxin
system, and to aid in the drug design process. Inhibitors of the M. tb thioredoxin system
may also help us to better understand this pathogen’s ability to survive intracellular redox
stress.
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CHAPTER VI. Discovery of Inhibitors of Protein Drug Targets by Automated
Docking: PMK, SDF1, and DUSP-5
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6.1

Introduction

6.1.1

Docking and Virtual Chemical Libraries
Docking is the process of positioning a ligand into the binding site of a protein, by

computationally exploring different translations, orientations, and conformations until a
lowest energy structure and “pose” orientation is found. Virtual screening is the process
of automated docking of a compound library into a known binding site of a protein, with
the goal of discovering inhibitors with high affinity for the protein.78 This method
reduces time, cost, and material of high-throughput ligand screening processes such as
random screening and structure based drug design.79 Virtual screening is used in the early
phase of drug discovery, since it can substantially reduce the number of compounds to be
screened, so one can focus on the most relevant compounds which will go on to further
testing.80
Chemical libraries are computational databases of chemical structures often
broken down by specific needs (i.e. small fragments or larger chemical structures) and
generally there are physical compounds accompanying the library for experimental
testing. The first of two chemical libraries used in this study were a database of 2,000
Thai natural products coming from 7 plants from ChemieBase, which is a molecular
database of 2D bioactive compounds developed by the Cheminformatic Research Unit at
Kasetsart University in Bangkok, Thailand. This database houses approximately 30,000
compounds in 2D structure format and are grouped by the plants from which they come.
There were no physical compounds associated with this database but if the virtual
screening hits were strong enough, compounds similar in structure or the actual
compound (if available) was purchased for testing. The second database is an in-house
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physical collection of 10,590 compounds that contain numerous kinds of compound dyes,
including sulfonates that had been selected or designed for binding dehydrogenases and
kinases.
Automated docking, on average, takes approximately an hour per compound,
which becomes very computationally expensive when trying to dock whole
computational databases. To increase the speed of virtual screening the databases, we
use a workload management system called Condor.81, 82 Condor essentially provides a
job queuing system that distributes jobs to computers, monitors progress, and compiles
the data sent to those computers to a central location. Condor was set up on 400
computers throughout campus that are capable of running 400 jobs simultaneously which
significantly decreases computational time for virtual screening of the compounds into
our drug target proteins: phosphomevalonate kinase (PMK), dual specificity phosphotase5 (DUSP-5), and stromal cell derived factor 1 (SDF1).

6.1.2

PMK as a Drug Target
Phosphomevalonate kinase (PMK) is a good drug target for such a docking study,

as it relates to cardiovascular disease since it is in the mevalonate biosynthetic pathway.
This pathway is a mammal’s only route to biosynthesis of steroids and isoprenoids,
including cholesterol.26, 83 Much work has been done already on the inhibition of this
pathway using statin drugs, which target the HMG-CoA Reductase enzyme.84 However,
PMK offers similar advantages to HMG-CoA Reductase inhibitors, in that the active site
has been characterized and a structure is currently available for it (Figure 6.1).85 In this
study both chemical libraries were docked into the whole active site of PMK. Good
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binding ligands, as predicted by AutoDock calculations,12 were then tested
experimentally for binding using both NMR and fluorescence-based titrations.

Figure 6.1. Crystal structure of PMK (pdb code 3ch4)85 with natural substrates, ATP and
M5P, docked into the active site. Nearby interactions from ligands to residues are shown
in the black and yellow box, which indicates the site that was docked in to using
AutoDock.

6.1.3

DUSP-5 as a Drug Target
Dual-specificity phosphatase 5 (DUSP-5) is part of a class of proteins that

dephosphorylate phospho-serine/threonine and phospho-tyrosine substrates (DSPs) on
proteins called mitogen-activated protein kinases (MAPKs).86 MAPKs are involved in
the mediation of cell signaling that is directly involved in diseases such as cancer,
diabetes, and autoimmune disorders.87-89 MAPKs are fully activated when the tyrosine
and threonine in their active loops are both phosphorylated. As such DSPs counteract
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such activity and if over expressed or the activity of DSPs were to increase, the cell
signaling brought on by MAP would cease. In effect, the phosphorylation state of
proteins such as MAPKs acts as an on/off switch for the proteins signaling activity.

Figure 6.2. Crystal structure of the catalytic domain of DUSP-5 (pdb code 2g6z) is
shown with the active p-loop residues displayed. The green box indicates the site that
was docked into by the in house library of compounds.

DUSP -5 specifically dephosphrylates a MAPK called extracellular signal
regulated kinase (ERK). It has also been shown that over expression of DUSP-5
suppresses the growth of several types of human cancer cells, by “shutting off” ERK (i.e.
dephosphorylation).86 There is also some interest in inhibition of DUSP-5, which would
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lead to increased levels of phosphorylated ERK2, leading to angiogenesis (growth of
blood vessels). Inhibition of DUSP-5 could, for example, be used to treat retinal
diseases. Figure 6.2 shows the crystal structure of the catalytic domain of DUSP-5 as
well as the binding site into which we docked.90 The residues shown are those involved
in binding the phosphorylated substrates, located in what is called the p-loop (residues
232, 263-269).91 The in house library was docked into this site and the top binding
compounds with good clustering information were used by our collaborators; Dr. Ramani
Ramchandran (Medical College of Wisconsin) in cell-based assays to see whether these
compounds inhibited or activated ERK. Of the 10 compounds that were tested, 1 of them
showed promise as a potent in inhibitor.

6.1.4

SDF1 as a Drug Target
Stromal cell-derived factor 1 (SDF1) is a cytokine, a small protiein secreted by

cells to carry signals to and from other neighboring cells, which in adulthood, plays an
important role in angiogenesis (blood vessel growth).92 Because of this, SDF1 is also
important in the initial creation of tumor cells and formation of networks of blood
vessels, which leads to tumor progression.93 Figure 6.3 shows the dimer that SDF1 forms
to permit signal transduction, with Arg 47 which is important for binding.94, 95 The inhouse chemical library was docked into the active site of SDF1, and then screened by
NMR to verify the binding of compounds. Any compounds that were determined to bind
by this screening assay were then sent to our collaborator on this project, Dr. Brian
Volkman (Medical College of Wisconsin), to be further tested for binding affinity and
inhibition.
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Figure 6.3. Shows one of the structures in the ensemble of solution structures of SDF1
(pdb code 2k05)94. Relevant side chains (Arg 47 and Val 49) are shown and the orange
box shows the site into which the in-house chemical library was docked.

6.2

Methods and Materials

6.2.1

Ligand Preparation
Ligands were received as 2D MDL MOL files and were converted to 2D SDF

MOL files using Babel, as CORINA was not equipped to handle 2D MDL MOL file
extensions. The newly converted SDF MOL files were then converted to 3D PDB
coordinate files by using CORINA (Molecular Networks, Erlangen, Germany), which
generates low energy 3D structures. The files were then processed with the python script
prepare_ligand4.py, which comes with AutoDock12, 96 molecular modeling package. This
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script generates a pdbqt file, and adds partial charges to the ligand, sets all torsions in the
ligand to active (to permit rotation), as well as merging all non-polar hydrogen’s.

6.2.2

Docking Protocol
The protein pdb files and grid maps were all prepared using the AutoDock Tools

suite.96 Grid maps are used in the energy calculations performed by AutoDock. The
protein was treated just as the ligands were (done manually on AutoDock), adding partial
charges and merging all non-polar hydrogens and saved as a pdbqt file. The 13 different
grid maps, one needed for each of the different atoms in the chemical libraries (ex. C, H,
F, Cl, etc.) were generated using AutoGrid415 with the grid box, the site used to dock the
ligands, placed over the active sites of the protein (the colored boxes in Figures 6.1-6.3).
Calculations are then limited to the region defined by the grid box.
The docking parameter file (dpf), which contains the parameters that AutoDock
uses to dock the ligand into the protein, was prepared using the python script
prepare_dpf4.py, and default docking parameters were used, except that 50 separate
docking calculations were performed with each calculation consisting of 1,750,000
energy evaluations and an rmsd tolerance set to 2.0 angstroms (to define entry of
structure into a given cluster). The dpf files were then automatically docked using
MUGrid with Condor submission files and AutoDock4 using the Lamarckian genetic
algorithm local search method to perform the optimization of docking pose.12 The
docking results were then clustered on the basis of the root mean square deviation (rmsd)
between the coordinates of the atoms in a given ligand, and were ranked on the basis of
calculated free energy of binding. The docking log files were then analyzed using the
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python script summarize_results4.py contained in the shell script sumresults_4, which
rank orders all the dockings, by binding energy. The results were then analyzed to find
the best clustered compounds with highest free energy of binding as determined by
AutoDock.

6.2.3

Sample Preparation and NMR Spectroscopy
The compounds that were predicted to bind best, based on AutoDock calculations

of binding energy were located in our chemical library inventory and dissolved initially
into 25 mM in deuterated DMSO and diluted to 5 mM as the working stock solution for
experiments other than NMR.
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N-labeled protein (PMK and SDF1) was concentrated to

300 µM for NMR screening, and titration experiments were performed by monitoring
chemical shift changes in a 2-D 1H-15N HSQC experiment. For the titration experiments,
aliquots of 25 mM of compound were added to the protein in increasing amounts until
saturation was reached. For screening experiments, 5 compounds were pooled together
to a final compound concentration of 1.25 mM for each compound and added to the
protein. If there were any chemical shift changes in the screening experiment, each
compound was then tested individually to identify which compound had bound to the
protein. This process allows identification of best-binding compounds, with fewer NMR
experiments and less protein consumption.
Dissociation constants were obtained by measuring the chemical shift changes in
going from free to various bound states, monitoring NMR cross peaks in fast exchange in
both 1H and 15N dimensions. These changes were then combined using Equation 2:
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Δshiftobs = [(1H shift)2+(15N shift/6.51)2](1/2)

Eq. 6.1

The chemical shift change (Δshiftobs) is plotted as a function of the concentration of the
ligand, then data were fitted to a quadratic equation, to determine the dissociation
constant Kd:

Δshiftobs = (Δshiftmax/(2[Po]))*{([Lo] + [Po] + Kd) –{([Lo] + [Po] + Kd)2 – 4[Lo][Po]}1/2}

Eq. 6.2

using Sigmaplot8, where Lo is the total ligand concentration, Po is the total protein
concentration, and Δshiftmax is the maximum chemical shift change observed for the
particular peak in question. Fitting to the quadratic equation was required because [Po] >
Kd. Standard deviations are from the non-linear least squares fitting process. Note that as
Kd gets very small relative to [Po], errors will become larger because Kd become less
well-defined in the fitting process).

6.3

Results and Discussion

6.3.1

PMK
Twenty computationally selected compounds were chosen for testing using NMR

titration experiments. Ten were from the in house library and ten from the Thai natural
product library. Of those twenty, 4 compounds were found to bind to PMK and these
were all from the in house library of compounds. Those compounds are labeled as
mu_1633, mu_1750, mu_2260, and mu_2419 and shown in Figures 6.4-6.8 and
summarized in Table 6.1.
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Compound mu_1633 is a substituted anthraquinone flanked by two hydroxyls and
two amino-sulfonate toluene groups and is shown in figure 6.4A. AutoDock calculations
predicted mu_1633 to bind in the ATP – γ phosphate site (Figure 6.4B) with 25 poses in
the lowest binding cluster, and mean calculated binding energy of -10.76 kcal/mol (the
lowest in the cluster being -11.66 kcal/mol). Panel C in Figure 6.4 shows all the
predicted interactions (less than 3.2 Å) between mu_1633 (the lowest energy docked
pose) and the active site of PMK, including many ionic and hydrogen bonding
interactions between the sulfonate groups and positively charged residues (R18, K19,
R73, and R110). Following the chemical shifts of the residues in panel D of the titration
experiment of mu_1633 and PMK and fitting the data as a function of concentration of
ligand, gave a dissociation constant (Kd) of <150 µM (since the concentration of protein
is so high, accurate Kd determination cannot be made). Following that up with a
fluorescence titration (to get more accurate Kd measurement) and monitoring the
emission of the tryptophan indole ring, gave the corresponding Kd of 127 ± 10 µM.
Compound mu_1750 is substituted naphthalene with a diazo linkage to a dicarboxylic acid substituted phenyl group (Figure 6.5A). AutoDock found l_cpfm1750 to
bind in the ATP – γ phosphate site (Figure 6.5B) with the 8 poses in the lowest binding
energy cluster having a mean binding energy of -9.8 kcal/mol (lowest in the cluster being
-10.42 kcal/mol). Panel C in Figure 6.5 shows all the predicted interactions (less than
3.2 Å) between mu_1750 (the lowest docked pose) and the active site of PMK. Like the
previous compound, the sulfonate groups (and one carboxyl group) show hydrogen
bonding interactions with the basic residues R18, K22, and R73, and hydrogen bonds to
the amide protons of S20, G21, and K22. Following the chemical shifts of the residues in
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panel D in the titration experiment of mu_1750 gave a dissociation constant (Kd) of <40
µM and following the NMR titration with a fluorescence titration gave the corresponding
Kd of 3.6 ± 1.0 µM.
Compound mu_2419 is naphthalene with a diazo linkage to a phenyl group with a
single branched carboxylic acid figure 6.6A, which differs from mu_1750 by on
carboxylic acid group on the phenyl ring. AutoDock found mu_2419 to bind in the ATP
– γ phosphate site (Figure 6.6B) with the 2 poses in the lowest binding cluster with a
mean binding energy of -10.99 kcal/mol and the lowest in the cluster being -11.02
kcal/mol. Panel C in Figure 6.7 shows the all the interactions (less than 3.2 Å) between
mu_419 (the lowest docked pose) and the active site of PMK. The negatively charged
sulfonate groups are involved in ionic interactions with R18, K22, and R73, with further
hydrogen bonding to amide groups of K22 and G16. Following the chemical shifts of the
residues in panel D in the titration experiment of mu_2419 gave a dissociation constant
(Kd) of <800 µM and subsequent fluorescence titration gave a Kd of 48 ± 11 µM.
Compound mu_2260 is a tetra-substituted pyrimidine ring with three thio-ether
linked acetyl groups and a phenyl ring (Figure 6.7A). AutoDock found mu_2260 to bind
in the ATP – γ phosphate site (Figure 6.7B) with the 10 poses in the lowest binding
cluster with a mean binding energy of -9.36 kcal/mol (lowest in the cluster being -10.36
kcal/mol). Panel C in Figure 6.7 shows all the predicted interactions (less than 3.2 Å)
between mu_2260 (the lowest docked pose) and the active site of PMK. Following the
chemical shifts of the residues in panel D of the titration experiment of mu_2260 gave a
dissociation constant (Kd) of <20 µM, and subsequent fluorescence titration gave a Kd of
14.6 ± 4.6 µM.
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mu_1633

Figure 6.4. Docking and experimental data where A) summarizes the calculated binding
energy of the compound and experimental binding affinity (dissociation constants) from
NMR and fluorescence titrations. Panels B and C are active site with relevant ionic and
hydrogen bonding interactions shown, and residues labeled. Panel D is the overlay of 2D
1
H-15N HSQC spectra for the NMR titration, where black is free PMK and the cross
peaks going to red are for increasing amounts of compound titrated onto PMK. The
chemical shift changes indicate that the compound is binding to the protein, and fitting
chemical shift values versus compound concentration provide the Kd for binding.
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mu_1750

Figure 6.5. Docking and experimental data where A) summarizes the calculated binding
energy of the compound and experimental binding affinity (dissociation constants) from
NMR and fluorescence titrations. Panels B and C are active site with relevant ionic and
hydrogen bonding interactions shown, and residues labeled. Panel D is the overlay of 2D
1
H-15N HSQC spectra for the NMR titration, where black is free PMK and the cross
peaks going to blue are for increasing amounts of compound titrated onto PMK. The
chemical shift changes indicate that the compound is binding to the protein, and fitting
chemical shift values versus compound concentration provide the Kd for binding.
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mu_2419

Figure 6.6. Docking and experimental data where A) summarizes the calculated binding
energy of the compound and experimental binding affinity (dissociation constants) from
NMR and fluorescence titrations. Panels B and C are active site with relevant ionic and
hydrogen bonding interactions shown, and residues labeled. Panel D is the overlay of 2D
1
H-15N HSQC spectra for the NMR titration, where black is free PMK and the cross
peaks going to purple are for increasing amounts of compound titrated onto PMK. The
chemical shift changes indicate that the compound is binding to the protein, and fitting
chemical shift values versus compound concentration provide the Kd for binding.
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mu_2260

Figure 6.7. Docking and experimental data where A) summarizes the calculated binding
energy of the compound and experimental binding affinity (dissociation constants) from
NMR and fluorescence titrations. Panels B and C are active site with relevant ionic and
hydrogen bonding interactions shown, and residues labeled. Panel D is the overlay of 2D
1
H-15N HSQC spectra for the NMR titration, where black is free PMK and the cross
peaks going to green are for increasing amounts of compound titrated onto PMK. The
chemical shift changes indicate that the compound is binding to the protein, and fitting
chemical shift values versus compound concentration provide the Kd for binding.
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The four compounds that were found to bind to PMK bind with reasonable
affinity all have similar structural qualities, having aromatic rings substituted with
negatively charged functional groups. Table 6.1 summarizes the computational and
experimental results of the virtual screening process. Compounds l_cpfm1750 and 2260
are the tightest binding of the four, with low micromolar affinity. It is curious that
compound l_cpfm 1750 looks very similar to l_cpfm2419, but l_cfpm1750 binds nearly
10 times tighter. This could be attributed to having the negative charged carboxyl group
on the phenyl ring of l_cpfm1750 instead of two hydroxyls on l_cfpm2419. These sort
of compounds are model compounds for binding to PMK since this protein has many
positively charged amino acids (17 arginines and 6 lysines), with the majority of them in
the active site, that can neutralize the negative charge on the compounds. While these
inhibitors are of value for in vitro studies of PMK, having too much negative charge on a
molecule poses problems in vivo such as drug bioavailability, since charged molecules
will have difficulty crossing the cell membrane. This will likely represent a significant
challenge in any drug discovery effort that targets PMK.

Table 6.1. Summary of virtual and experimental screening of compounds that were
found to bind to PMK, from our in house library of compounds.

130
6.2.2

SDF1
The in house library of compounds was docked into the Sy-21 site of SDF1

(specifically, in the vicinity of R47) where the signal peptide (sulfotyrosine 21) is known
to bind, and mediate dimer formation (Figure 6.3). The top 50 scoring compounds were
ranked by calculated binding energy of the lowest energy pose in the docking cluster and
were then experimentally screened for binding to SDF1 protein in batches of 5
compounds. If any of the batches showed any chemical shift changes in NMR 1H-15N
HSQC then each compound was added individually to SDF1 to identify which compound
was indeed binding to SDF1. Since the compounds were dissolved in DMSO and DMSO
has an effect on the spectra of SDF1, each batch of compounds was compared to a
spectrum of SDF1 with only DMSO, and any chemical shift changes observed were in
reference to this spectrum. Of the 50 compounds tested against SDF1, three were found
to bind with reasonable affinity, and are shown in Figures 6.8-6.10.
The first compound coming from the batch screening process is mu_1452, which
contains phenol sulfonate substituted napthlene rings, linked through diazo groups. Since
this is a rather larger molecule (770 Da) there are a lot of torsional degrees of freedom
that cause the docking to cluster rather poorly (32 different clusters out of 50 dockings),
however the lowest energy cluster (-9.70 kcal/mol with lowest energy pose being -10.7
kcal/mol) is the most populated clustered with 5 poses within an RMSD of 2 Å. As the
docking was confined to the Sy-21 binding site95, the negatively charged sulfonate groups
are interacting with the positively charged arginine group, which is important for binding
(Figure 6.8A-B). There are also some hydrogen bonding interactions between the
hydroxyl groups of the naphthalene and phenol rings and the carbonyl of E15. The
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NMR spectra of mu_1452 shows chemical shift changes from green going to red and the
binding affinity calculated from these chemical shift changes is < 50 µM (Figures 6.8CD).

mu_1452

ΔG	
  =	
  -‐10.73	
  kcal/mol	
  

Figure 6.8. Docking and experimental data for the docking of compound l_cpfm1452
with SDF1 where panels A) and B) are the lowest energy pose of l_cpfm1452 and
relevant interactions to SDF1. Panel C are the curves generated from the chemical shifts
in panel D) to calculate the binding affinity for of the compound bound to SDF1 which
was determined to be < 50 µM. Experimental data provided by Josh Ziarek of the
Volkman lab at the Medical College of Wisconsin. SDF1 was at 50 µM in pH 6.8
predeutero MES buffer (25 mM).
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The second compound identified in the batch screening process was mu_1784,
which has an anthracene core with two amide groups stemming from it connected to a
trimethyl sulfonate phenyl group. Although this compound is relatively large, there are
less torsional degrees of freedom, so 8 clusters out of 50 poses were obtained, with 42 of
the poses in the top two clusters ( -8.35 kcal/mol and -8.95 kcal/mol for the lowest energy
pose), where most of the variation is caused by the rotation of the phenyl rings. This
compound’s sulfonate groups are also located near R47, with interactions from the
sulfonate groups to R47, N47, and D22, with some hydrogen bonding from the amide and
hydroxyl groups of mu_1784 to the carbonyl of E15 (Figure 6.9A-B). The binding
affinity, as determined from the chemical shifts (Figure 6.9C-D with chemical shifts
going from green to red as compound is added) of multiple backbone residues is Kd <
100 µM. Based on which cross peaks perturbed, binding seems to be primarily confined
to the Sy-21 site, as opposed to being at the dimer interface, as in the next case.
The last compound that was found to bind to SDF1 is mu_1661, which has
sulfonate group attached to a pyrazole ring through a diazo linkage, and is connected to a
dichloro phenyl sulfonate group. This compound’s docking results had 16 clusters, with
poor clustering due to significant rotation through the bonds coming from the pyrazole
ring. The lowest energy cluster, with a binding energy of -8.62 kcal/mol (-8.92 kcal/mol
for the lowest energy pose), had 18 of the 50 docking poses clustered into it, making it
the most probable binding geometry. Many of the interactions between the lowest energy
pose (Figure 6.10A-B) are between the sulfonate groups and the positively charged
gunaido group of R47, as well as the backbone carbonyl and the amide of the sidechain
of Q48. The binding affinity of this compound is slightly less than the previous two
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compounds, with a Kd of ~ 200 µM (6.10C-D), however the chemical shift changes upon
binding this compound are significantly greater than for the previous two compounds
tested, with more of the changes being around the dimer interface. This indicates that
this compound may cause dimerization of SDF1, which is known to occur upon binding
ligand.
The docking and experimental data provided above suggests that the three
compounds do indeed bind with reasonable affinity to SDF1. However, further testing
will be needed to determine if these compounds do indeed inhibit this protein. As
previously suggested that compound mu_1661 appears to induce dimerization based on
chemical shift changes of 1H-15N HSQC spectra for residues in the dimer interface. This
is of importance since dimerization of SDF1 causes the protein to cease cell signaling
(proliferation of cancer). Since the docking box used for AutoDock calculations was
located at this particular binding site, centered on R47, is probably the reason that the
compounds identified were comprised of sulfonates and other negatively charged groups.
Since the Sy21 binding site is another reason these compounds are so large, if we were to
dock in a smaller binding site is quite large, it is not surprising that the compounds
identified were also large. It should be noted that during titrations, protein appeared to
precipitate. Subsequent SDS PAGE analysis by the Volkman lab indicated that the
precipitate contained covalently linked SDF1 protein monomers. It is possible that the
diazo groups, associated with many of the compounds, will form free radicals in the
presence of light (when bound to protein active sites) and oligomerize the protein to the
point in which it eventually precipitates out. Further work is being done to explore this
phenomenon.
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mu_1784

Figure 6.9. Docking and experimental data for the docking of compound l_cpfm1452
with SDF1 where panels A) and B) are the lowest energy pose of l_cpfm1452 and
relevant interactions to SDF1. Panel C are the curves generated from the chemical shifts
in panel D) to calculate the binding affinity for of the compound bound to SDF1 which
was determined to be < 100 µM. Experimental data provided by Josh Ziarek of the
Volkman lab at the Medical College of Wisconsin. SDF1 was at 50 µM in pH 6.8
predeutero MES buffer (25 mM).
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mu_1661

Figure 6.10. Docking and experimental data for the docking of compound l_cpfm1452
with SDF1 where panels A) and B) are the lowest energy pose of l_cpfm1452 and
relevant interactions to SDF1. Panel C are the curves generated from the chemical shifts
in panel D) to calculate the binding affinity for of the compound bound to SDF1 which
was determined to be ~ 200 µM. Experimental data provided by Josh Ziarek of the
Volkman lab at the Medical College of Wisconsin. SDF1 was at 50 µM in pH 6.8
predeutero MES buffer (25 mM).
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6.2.3

DUSP-5
The in house library was docked into the p-loop active site region of DUSP-5,

which is the binding site for dephosphorylation of the ERK protein. The presence of
arginines 213,214, and 269 in the DUSP-5 active site make this an ideal binding site for
the many sulfonated compounds that we have identified using docking analysis.91 A
select set of compounds from the docking (based on binding energy and clustering) was
given to our collaborators (the Ramchandran group from Medical College of Wisconsin).
Those compounds were tested directly in cell-based assays, using HUVECS (Human
Umbilical Venous Endothelial Cells). Dose response experiments in these cells tests the
effect of the compounds on a cell at differing levels of compound, by changes in
phosphorylated ERK monitoring at a certain time after dosage. The HUVEC cells were
stimulated by the addition of a compound that binds to the cell surface called VEGF
receptor, which stimulates growth of blood vessels by stimulating the DUSP-5 catalytic
reaction (i.e. dephosphorylating phospho-ERK). The amount of phospho-ERK (pERK) is
monitored by a Western blot assay, in which antibodies specifically target pERK and
thereby monitor pERK concentratio, when run on an SDS PAGE gel (concentration of
pERK is related to intensity of band). If DUSP-5 has been inhibited in some way, after
VEGF stimulation, the intensity of the Western blot band (for pERK) should be high.
This intensity should decrease with time, and in the case of DUSP-5, the time it takes for
the depletion of pERK is 45 minutes. But, if DUSP-5 is inhibited, the band will remain
intense. In addition to monitoring pERK levels, ERK and DUSP-5 levels were also
monitored. All compounds tested were monitored 45 minutes past stimulation by VEGF
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and if the compounds are inhibitory, the relative concentration of pERK should be similar
to that observed 2 minutes after VEGF stimulation in the control reaction.
The first of the compounds tested was mu_1472, which is comprised of two
substituted naphthalene rings connected via a diazo group. Each naphthalene ring has a
sulfonate and hydroxyl group, with one it with one also having an exocyclic amine.
Compound mu_1472 has a median calculated binding energy of -8.60 kcal/mol in the
lowest energy cluster as determined by AutoDock ( -9.22 kcal/mol for the lowest docked
compound). Of the 50 poses docked into the active site, 25 poses were clustered in the
lowest energy cluster with the remaining 25 dispersed amongst 16 other clusters. As
mentioned previously, the negative charged sulfonate groups of mu_1472 (Figure 6.11AB) are involved in ionic interactions with the positively charged guanido groups of the
three arginines in the DUSP-5 active site (R213,R214, and R269), with further hydrogen
bonding interactions to H234 and the carbonyl of D232. The dose response curve (i.e.
titrations) shows that compound mu_1472 inhibits DUSP-5 most effectively at 6 µM
concentration (the amount of phospho-ERK after 45 minutes is nearly the same
concentration as at two minutes after stimulation).
The second compound found to inhibit DUSP-5 is mu_1693 and was intended to
be a control compound, since it was predicted to bind poorly according to AutoDock (6.52 kcal/mol). In hindsight, this compound may not have been an appropriate negative
control since it has many of the same structural features as mu_1472 and it had been
selected in a previous docking study for another protein with a positively charged active
site. This compound is rather large for a drug at 840 Da, consisting of a biphenyl bonded
to two naphthalene groups through diazo groups. Each naphthalene ring is substituted
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with two sulfonate groups as well as a hydroxyl and amine. Due to the large size of this
compound and all the possible torsions it has, AutoDock had calculated 41 different
clusters for this compound. The lowest energy pose seems to wrap around the outside of
the active site as shown in Figure 6.12A-B with interactions between the sulfonates of the
compound and R213 and R214, and hydrogen bonding from the hydroxyl to E231 and
T235. According to the dose response curve, compound mu_1693 inhibits DUSP-5 most
effectively at 3 µM.
The last compound that was found to inhibit DUSP-5 was mu_1842. This
compound appears to be a nanomolar inhibitor, and an ideal starting point drug lead
optimization project since it is smaller (404 Da), and is comprised of a reasonably druglike core, a tri-sulfonated carbazole. Since this compound is rigid with fewer torsions, it
clustered very well with the majority of the 50 poses clustering into 3 groups, with the
lowest energy pose being -8.15 kcal/mol with average cluster binding energy of -7.93
kcal/mol. Note that calculated binding energies tend to scale with the size of the ligand,
so given the small size of mu_1842 this is quite good. The lowest energy pose of the
lowest energy cluster bound similarly to the previous two compounds with the sulfonate
groups, interacting with the three arginines in the active site, with other hydrogen
bonding interactions predicted with the sidechain carbonyl of E264 and backbone
carbonyl of D232. The dose response curve in HUVEC cells indicates that at 500 nm,
there is maximum inhibition of DUSP-5 by mu_1842 with inhibition all the way down to
10 nm. These studies need to be repeated at concentrations of mu_1842 < 10 nm, since
pERK levels were still high at 10nm (Figure 6.13C). Interestingly, there appears to be
two inflections in the dose response curve with mu_1842, especially based on panel D of
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Figure 6.13. Furthermore, all compounds seem to show a loss of potency at higher
concentrations, perhaps due to aggregations. These effects will need to be further
characterized (ex. aggregation can be determined using nephelometry).

Figure 6.11. Computational and experimental results for the docking of compound
mu_1472 into DUSP-5. The lowest energy pose for the docking of compound mu_1472
to DUSP-5 is shown in panels A and B, with relevant residues interactions labeled. Panel
C is the dose response results for the compound incubated into HUVEC cells of the
specified concentrations with relevant control experimental results shown. Specifically,
NS is no VEGF stimulation, while 2 and 45 minutes after VEGF stimulation. Compound
was incubated at 0, 0.5,…25 µ, and pERK or total ERK measured at 45 minutes. Panel D
is the western blot of pERK and total ERK in all experiments, and corresponds to the data
shown in Panel C. Experimental results provided by Indranil Sinha from the
Ramchandran group at the Medical College of Wisconsin.
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Figure 6.12. Computational and experimental results for the docking of compound
mu_1693 into DUSP-5. The lowest energy pose for the docking of compound mu_1693
to DUSP-5 is shown in panels A and B, with relevant residues interactions labeled. Panel
C is the dose response results for the compound incubated into HUVEC cells of the
specified concentrations with relevant control experimental results shown. Specifically,
NS is no VEGF stimulation, while 2 and 45 minutes after VEGF stimulation. Compound
was incubated at 0, 1,3,…50 µM, and pERK or total ERK measured at 45 minutes. Panel
D is the western blot of pERK and total ERK in all experiments, and corresponds to the
data shown in Panel C. Experimental results provided by Indranil Sinha from the
Ramchandran group at the Medical College of Wisconsin.
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Figure 6.13. Computational and experimental results for the docking of compound
mu_1842 into DUSP-5. The lowest energy pose for the docking of compound mu_1842
to DUSP-5 is shown in panels A and B, with relevant residues interactions labeled. Panel
C is the dose response results for the compound incubated into HUVEC cells of the
specified concentrations with relevant control experimental results shown. Specifically,
NS is no VEGF stimulation, while 2 and 45 minutes after VEGF stimulation. Compound
was incubated at 0, 0.01,0.05,…3 µ, and pERK or total ERK measured at 45 minutes.
Panel D is the western blot of pERK and total ERK in all experiments, and corresponds
to the data shown in Panel C. Experimental results provided by Indranil Sinha from the
Ramchandran group at the Medical College of Wisconsin.
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Unlike the other tests performed on compounds docked into SDF1 and PMK,
these cell-based in-vitro assays cannot actually be used to unambiguously conclude that
these compounds are binding and inhibiting DUSP-5. Rather these compounds will have
to be tested with overexpressed and purified DUSP-5 protein, to study inhibition and
binding. These cell-based assays do however provide evidence that the introduction of
the compounds to the HUVECs have the desired cellular effect of preventing
dephosphorylation of pERK. Compounds mu_1472 and mu_1963 seem to inhibit DUSP5 with modest IC50 values of 6 µM and 3 µM, but are really no comparison to the results
obtained by compound mu_1872 which has maximum inhibition at 500 nm with potency
at as low as 10 nm. These results are very intriguing and will be investigated further not
only with other various in-vitro assays but also with DUSP-5 protein.

6.4

Conclusion
Since the active sites of all the drug targets tested are rich in basic residues it is

not surprising that most of the compounds identified using docking are rich in sulfonate
groups. This poses other kind of problems in developing these molecules as drugs, since
an excess of the negative charge makes it difficult to cross cell membranes. This problem
can sometimes be addressed by masking charges as esters, which are then hydrolyzed in
the cell. In the case of HUVEC studies, we know the compounds can make it into the
cells. The next logical step in developing these compounds as drug leads is to try and
optimize the binding of these ligands to the drug targets by changing and adding various
functional groups to the compounds until binding potency is in the < 100nm range.97, 98
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Of all the compounds tested the most promising is compound l_cpfm1842 and its
inhibition of DUSP-5. The fact this compound seems to have potency as low as 10 nm is
an exciting find and could potentially be very lucrative as a drug lead. From the results
provided, virtual screening is an effective to way to find drug leads as we are getting a
10% hit ratio of compounds that bind to the drug targets that have been screened. The
use of Condor and the resources of MUGrid have made it possible to virtual screen many
compounds (ex. > 10,000) in a reasonable amount of time. The optimization of the
virtual screening and experimental verification can lead this project down the road of
offering this as a service to those groups (ex. collaborators) who wish find inhibitors and
drug leads to their own drug targets.
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CHAPTER VII. 15N-Carboxamide NAD(H) Probes to Determine Conformational
Binding Dynamics

145
7.1

Introduction

7.1.1

Rationale for Design of Conformational Dynamics Ligand Probe
Methods for charactering protein dynamics are becoming increasingly well

developed, however dynamics from the ligand perspective has not been adequately
explored. This is in part because such studies rely on the use 13C or 15N labels, and it has
become routine to isotopically label proteins, but not ligands. Dynamic characterization
of protein-ligand complexes using NMR has focused mostly on dynamics changes to the
protein using a generalized order parameter which measures dynamics on the psec-nsec
timescale (local backbone and sidechain dynamics) and relaxation dispersion which
measures dynamics on the µsec-msec timescale (protein domain movement).8, 99-101 In
the unbound state, the ligand has a large amount of conformational entropy, which is lost
upon binding to a protein, with enthalpic gains offsetting these entropic penalties. In
certain proteins however, ligands can retain some flexibility in the bound state such as the
matrix metalloproteinase 1 (MMP-1).102, 103 It has been shown that tightly bound ligands
of MMP-1 exist in multiple conformations that exchange slowly on the chemical shift
timescale in which two sets of signals arise for the bound ligand.97
In an attempt to characterize dynamics changes from the ligand perspective, we
have designed a 15N-carboxamide ([15N-CA])-labeled NAD(P)+ and NAD(P)H cofactor
(Figure 7.1) to be used as a probe in such studies. NAD(P)H are cofactors that are
involved in redox reactions, which participate in hydride transfer to adjacently bound
substrates.104 Oxidoreductases (or dehydrogenases) are the class of enzymes that are
responsible for this kind of reaction and are the class proteins of interest in this study.
Previous bioinformatic studies from the Sem lab and others have indicated that genomes
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are 2-5% oxidoreductases, so probes to study these enzymes could be broadly useful.105,
106

Of particular interest to us for our initial studies is the protein ornithine

monoxygenase (OMO) from Aspergillus fumigates,107 which is an NADP(H) and FAD
dependant enzyme that uses NADPH as an electron source and molecular oxygen to
hydroxylate the sidechain amine of L-ornithine (Figure 7.2), an amino acid derivative of
arginine that plays a role in the urea cycle to dispose of excess nitrogen.
Such dynamics studies are important for studying the mechanism of OMO in that
cofactor immobilization/movement is a necessary part of catalysis, to permit electron
transfer. Since a number of crystal structures show the nicotinamide displaced from that
active site, sometimes showing no electron density for the nicotinamide ring, it is inferred
that some domain movement and subsequent binding interactions are needed to bring the
nicotinamide ring of the NAD(P)H cofactor into the right position for hydride transfer.72,
108, 109

Since this process is generally occurring on the µsec-msec timescale, the most

useful NMR experiment will be the relaxation dispersion experiment, using the CarrPurcell-Meiboom-Gill (CPMG) pulse sequence.32, 99, 101, 110 This pulse sequence relies on
the measurement of the transverse relaxation rate by measuring the decay of the NMR
resonance signal during the CPMG sequence. These NMR relaxation dispersion
experiments have been used to study protein folding, protein-ligand interactions, and
enzyme function, which makes them ideal experiments to study the conformational
dynamics changes that the NAD(P)(H) cofactor appears to undergo upon binding to
proteins, such as ornithine monooxygenase (OMO).
Besides studies of cofactor dynamics, the labeled NAD(P)(H) probes being
developed can be used to address a structural questions related to oxidoreductase
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function. The conformation of the carboxamide of the NAD(P)(H) cofactor when bound
to proteins is sometimes ambiguous when determining protein structure with x-ray
crystallography, since the nitrogen and oxygen of amides is not easily distinguished at
typically achieved resolutions.105 This was a problem that was recently recognized by the
Richardson lab, with regard to carboxamides of asparagine and glutamine sidechains.
Based on data compiled form crystal structures, the Sem lab has found that ~90% of the
time the carboxamides are oriented so that the carbonyl is in the direction of hydride
transfer (Figure 7.5B) with the remaining 10% of structures having the carboxamide in
the opposite direction (Figure 7.5C). Since it is difficult to distinguish the orientation of
the carboxamide, the question becomes, is the 90% number accurate? Could it be 50%
or is it closer to 100%? If it is 100%, why is this geometry preferred? Using this NMR
probe we can determine the orientation of the carboxamide when bound to proteins using
simple 15N-filtered NOE measurements. Besides addressing basic mechanistic questions
about the role of the carboxamide in oxidoreductase function, such studies can also
facilitate drug design efforts where inhibitors are rationally designed to bind cofactor
binding sites. A detailed understanding of positioning and role of hydrogen bond donors
and acceptors is needed to design inhibitors.
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Figure 7.1. Cofactors NADH and NADPH, as well as their oxidized states. NAD(P)+
and NAD(P)H shown with the 15N-labeled carboxamide shown in red.

Figure 7.2. Catalytic reaction of ornithine monooxygenase (OMO) in which molecular
oxygen is used to hydroxylate the sidechain amine of L-ornithine.
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7.2

Materials and Methods

7.2.1

Synthesis of [15N-CA]-nicotinamide
In an ice bath, 4.0 g NaOH and 60 mL deionized water was added to a 250 mL

round bottom flask with a magnetic stirrer. When the NaOH dissolved, 1.0 g 15N-NH4Cl
was added. To this solution, 3.9 g of nicotinic acid chloride was added over 20 minutes.
The reaction was kept on an ice bath for another 20 minutes, and immediately frozen and
water removed by lyophilizing. The product nicotinamide was extracted with hot
benzene. Sample purity was tested by TLC using equal parts of DMF/Chloroform as the
separating solvent. Product was 0.50 g, with a yield of 14.3%.

7.2.2

Synthesis of [15N-CA]-NAD+111-116
80 mg of [15N-CA]-nicotinamide was dissolved in 10 mL of 40 mM potassium

phosphate and brought to a pH of 7.0. 200 mg of NAD+ was dissolved in 15 mL of 40
mM potassium phosphate buffer and brought to a pH of 7.0. In the same solution, 500700 mg of the acetone dried powered form of porcine brain NADase (purchased from
Sigma Aldrich) was added and pH brought to 7.0. For control experiments, 1 mL of
NAD+ solution and 1 mL of NAD+/NADase solution were added to eppendorf tubes.
Both solutions, [15N-CA]-nicotinamide and NAD+/NADase, were added together were
incubated at 37°C, as were control reactions. The reaction mixture was tested
periodically using the cyanide method, where 20 µL of reaction was added to 980 µL of a
1 M KCN solution and monitored spectrophotometrically at 326 nm with the same molar
extinction coefficient as NADH (6220 L/mol-cm), to determine if the NADase has
exchanged all the unlabeled for labeled nicotinamide rings of NAD+, to produce [15N-
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CA]-NAD+. In the assay, CN- attacks NAD+ to produce an adduct that absorbs at 326
nm. In the control reaction that has no nicotinamide, the NADase enzyme simply
hydrolyzes the nicotinamide of NAD, rather than swapping the ring, (so absorbance at
326 nm decreases). After the reaction was complete (the control reaction lacking free
dropped to base line levels, while the test reaction maintained similar absorbance levels
as the NAD+ control reaction), the reaction mixture was heated up to 70°C for 2 min to
precipitate the protein, and spun down for 10 minutes at 4000 RPM.
The [15N-CA]-NAD+ was purified by using a BioGel P2 size exclusion column
(100 ml bed volume) and washed with water to separate the [15N-CA]-NAD+ from all the
free nicotinamide. Fractions were tested using TLC, and the same separation solvent as
before and the fractions containing only [15N-CA]-NAD+ were pooled together. [15NCA]-NAD+ concentration was determined in an enzymatic endpoint assay. An aliquot of
this solution was mixed 20 mM of ethanol and 20 mM semicarbazide and 100 units of
yeast alcohol dehyrogenase at pH 7.3. Absorbance increase was monitored at 340 nm,
with the molar extinction coefficient of 6220 L/mol-cm. If [15N-CA]-NAD+ was the
desired product, the solution was then flash frozen and lyophilized overnight. A 2D 1H15

N HSQC spectrum was acquired to confirm the 15N labeling of the cofactor.

7.2.3

Synthesis of [15N-CA]-NADH
[15N-CA]-NADH was prepared by reduction of [15N-CA]-NAD+ using yeast

alcohol dehydrogenase (ADH) and ethanol (Figure 7.3). The reaction was run at room
temperature in the presence of excess alcohol (20 mM) in pH 7.3, 100 mM phosphate
(KPi) buffer and monitored at 340 nm until reaction was complete. After the reaction was
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done the ADH enzyme was denatured by heating at 70°C for two minutes, and then
removed by filtration using an Amicon Ultra filtration device (Millipore, cutoff 10 kDa).
The solution was then flash frozen in liquid nitrogen and lyophilized over night.

7.2.4

NMR Study of [15N-CA]-NAD+ in Complex with Ornithine Monooxygenase
OMO was obtained from the DuBois lab at Purdue University and concentrated to

600 µM in 200 mM KCl and 100 mM KPi buffer at pH 7.8. To this, 500 µM of [15NCA]-NAD+ was added, and pH measured to be 7.5. To determine the orientation of the
carboxamide on the nicotinamide ring, a 2D 15N-filtered [1H-1H] NOESY experiment,
was run with a mixing time of 150 ms. To determine possible conformational exchange,
CPMG measurements were taken with 10 measurements, with a total delay of 30 µsec.
The intensities of the NH protons were measured using the VNMRJ program, and fitted to
Eq. 7.1, to obtain R2 = 1/T2, where I is intensity of a given measurement, Io is the control
intensity and τcp is the delay that surrounds the 180° pulse in the CPMG sequence. R2 and τcp

was fit using GraphPad Prism to the fast exchange equation (Eq. 7.2)99,

I = Io*e(-τcp/T2)

Eq. 7.1

R2 = R20 + Rex*(1-2tanh(kex*τcp/2)/(kex*τcp)), Rex = p1p2Δω2/kex

Eq. 7.2

Rex = (p1p2*Δω)/kex

Eq. 7.3
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where p1 and p2 are the relative site populations (concentration) of the two states that are
in exchange, Δω is the chemical shift difference between the two states (s-1), and kex is
the exchange rate constant for the two states. R2o represents the transfer relaxation rate,
in the absence of exchange between states.

7.3

Results and Discussion

7.3.1

Preparation and Analysis of [15N-CA]-NAD(H)
[15N-CA]-NAD(H) was synthesized according to Figure 7.3 and characterized

with UV-Vis spectroscopy to determine concentration and viability as a cofactor with the
ADH enzymatic endpoint assay, and NMR to ensure 15N labeling. Two crosspeaks are
observed at 5°C in a 2D 1H-15N HSQC experiment, one for each proton on the
carboxamide of NAD+ (Figure 7.4). Analysis of a 1D slice 1H-15N HSQC experiment
reveals that the crosspeak at 8.6 ppm (anti N-H) has 2/3 of the intensity of the crosspeak
at 7.8 ppm (syn N-H), and previous studies showed that at higher temperature and pH, the
crosspeak at 8.6 ppm significantly line broadens due to exchange with water because of
the relatively higher acidity of this anti NH proton (however binding to a protein
decreases the exchange, and permits the anti N-H to be observable). For this reason it
was necessary to run all the experiments at 5°C and at neutral or slightly acidic pH, to
decrease proton exchange with water, while keeping the necessary buffer requirements of
the protein in mind.
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Figure 7.3. Synthetic scheme for preparation 15N-nicotinamide and [15N-CA]-NAD(H).
ADH is alcohol dehydrogenase from yeast.
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Figure 7.4. 2D 1H-15N HSQC spectrum of [15N-CA]-NAD+ with 1D slice taken at the
15
N chemical shift indicated, showing the relative intensity of Ha (downfield) and He
(upfield) protons. Spectrum was take at pH 7.0 and 5°C.

7.3.2

15

N-edited NOESY studies of [15N-CA]-NAD+

A useful application of the [15N-CA]-NAD+ probe is that it can be used to
determine the orientation of the carboxamide group when binding to protein. The
carboxamide, in the unbound state, should be able to rotate around the bond connecting to
the pyridine ring of the nicotinamide group to sample two states (Figure 7.5). But, when
bound to the protein, the amide protons are probably involved in hydrogen bonding to
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amino acids in the active site, to stabilize the cofactor and permit hydride transfer. Since
the 15N isotope is on the amide group, the orientation of the amide can be determined
with the 15N-edited NOESY experiment, where NOEs are observed within 5 Å of the
proton(s) stemming from the 15N. NOE intensity is much greater, the closer two atoms
are to each other, with intensity decreasing as 1/(distance)6. So if the amide is oriented
like Figure 7.5B then we should see an NOE around 9.3 ppm corresponding to the proton
H2, however if its oriented like Figure 7.5C the NOE should be around 9.0 ppm,
corresponding to proton H4.117 The 15N-[1H-1H] NOESY experiment of [15N-CA]-NAD+
bound to OMO shows the two characteristic diagonal cross peaks of the carboxamide
protons of the cofactor at ~7.8 ppm (NH syn) and ~8.65 ppm (NH anti)with NOEs to
each other. The strong peaks at approximately 4.9 ppm are due to magentization transfer
with water, as this sample had to be in water (vs. D2O) so the amide protons would be
visible. At the bottom of the spectra there are NOE cross peaks correlating the amide
protons (7.8, 8.6 ppm) with the H2 protons at 9.26 ppm, indicating the carboxamide
protons of [15N-CA]-NAD+ close to the H2 proton of the nicotinamide ring. This
information suggest the structure in Figure 7.5B is the relevant structure of [15N-CA]NAD+ when bound to OMO. This chemical probe and NMR experiment provides a
relatively simple test to verify the correct carboxamide geometry of any NAD(P)(H)
cofactor when bound to an oxidoreductase. Further work will entail testing the cofactors
with other oxidoreductases in literature and to confirm or disprove the reported geometry
of the carboxamide in the crystal structure of cofactor/protein complexes.
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Figure 7.5. A) 2D 15N-filtered [1H-1H}NOESY spectrum of [15N-CA]-NAD+ bound to
OMO, and B) the two possible orientations of the carboxamide group of [15N-CA]-NAD+
The carboxamide could be oriented with the protons closer to the H2 proton (B) or to H4
proton (C). The NOE data indicates NAD+ binds OMO in the orientation shown in panel
B.
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7.3.3

Relaxation Dispersion Study to Determine Conformational Exchange of

Bound [15N-CA]-NAD+ Cofactor
Conformational exchange is a phenomenon in which nuclei sample multiple
conformations/environments, and is measured by the rate term Rex, which is associated
with transverse relaxation effects (T2). Biological processes of proteins that undergo
conformational exchange include protein folding, substrate binding, and catalysis, which
often occur on the µsec-msec time-scale. One way to measure such motional processes is
with NMR spectroscopy using relaxation dispersion experiments with the CPMG pulse
sequence. These experiments measure the transverse relaxation rates while partially or
fully suppressing the relaxation rate due to exchange Rex, by a series of 180° refocusing
pulses (or spin-echo’s) known as CPMG.20, 99, 118 The intensity of the peaks (i.e. the NH
protons) are measured to get the transverse relaxation rates (R2 = 1/T2) using Eq.1, and
are then plotted as a function of the delay (τcp) between successive spin-echo’s and fit to
Eq.2 to get Rex. If there are Rex contributions, the curve will demonstrate exponential
decay in which the asymptote is the transverse relaxation rate (R2). If there are no Rex
contributions, then only a flat line is observed.
Since OMO utilizes the cofactor FAD for electron transfer to its substrate, with
NAD(P)H transferring a hydride ion to FAD, NAD+ had to be used in place of NADH to
avoid catalytic turnover. To study the conformational exchange effects of binding
cofactor, relaxation dispersion profiles were acquired for unbound [15N-CA]-NAD+ and
bound to OMO protein (in a 3:4 ratio so that all [15N-CA]-NAD+ was bound to OMO).
The same relaxation dispersion experiments were used with both samples, except that the
TROSY (Transverse Relaxation Optimized Spectroscopy)119, 120 version of HSQC spectra
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was acquired for OMO to sharpen the signals. Since the [15N-CA]-NAD+ is bound to a
large protein OMO is (55 kDa), the slow rotation of the bound [15N-CA]-NAD+ would
cause the signals to broaden, and TROSY compensates for this effect. For each
experiment, a control experiment was run to determine the amide proton intensity (Io) in
the absence of delay (no CPMG) and was used in Eq.1 to determine R2 and plotted
against 1/τcp and fit to Eq.2, with fitted curve shown in Figure 7.6.

Figure 7.6. Relaxation dispersion plot for unbound [15N-CA]-NAD+ and [15N-CA]-NAD+
bound to OMO. Spectra were taken at pH 7.8 and 5°C with 500 µM [15N-CA]-NAD+.
R2 is the transverse relaxation rate for the amide protons, and τcp is the delay used in the
CPFM pulse sequence.

The dispersion profile for unbound [15N-CA]-NAD+ in Figure 7.6 shows no
conformational exchange occurs in this state, indicated by the flat line with an apparent
transverse relaxation rate (R2o) of 9 s-1. Upon binding to OMO the dispersion profile
shows the exponential decay associated with conformational exchange due to binding
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with a Rex value of 67 ± 6 s-1, an exchange rate constant (kex) of 922 ± 104 s-1, and an R2o
of 88 s-1. The significant increase in R2o (9 to 88 s-1) from unbound to bound states is
most likely due to the slow tumbling of the bound labeled cofactor, which would lead to
significant transverse relaxation. In effect, signal that is observed is like that of a large
molecule (protein), even though we are still only observing the [15N-CA]-NAD+ amide
protons. Since we also observe a transverse relaxation rate due to conformational
exchange (Rex) in the bound state of the cofactor, this is likely indicative of adopting
multiple conformations in the bound state, perhaps due to domain motion for OMO to
bind its other substrate (ornithine). If ornithine were bound to OMO in the presence of
the [15N-CA]-NAD+, we would assume that the cofactor would then be locked down
rigidly, for catalysis to occur, and would suppress most, if not all, of the Rex contribution
to R2.

7.4

Conclusion
The 15N-labeled cofactor NAD+ probes, and their application described herein, are

a useful tool for studies of NAD(P)(H) binding proteins, since they can be used to explore
effects of complex formation and protein binding. We have shown that these probes can
be used to determine carboxamide geometry (which crystallography often cannot) using
the 15N-filtered NOESY experiment. They can also be used to study cofactor binding
dynamics, using CPMG-based relaxation dynamics methods. The synthesis of these
probes is relatively straightforward and can be easily extended to the phosphorylated
cofactor, since NAD+ can be converted to NADP+ using the protein NAD+ kinase.117
There are many ways that this probe can be used, for future experiments of binding [15N-
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CA]-NADP+ to M. tb thioredoxin reductase. For example, it can be used to monitor the
NADPH domain rotation (FO and FR states) in absence and presence of protein substrate
thioredoxin C. This can be done with reduced and oxidized states of the cofactor
(NADPH vs. NADP+), of thioredoxin C, and of thioredoxin reductase.
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APPENDIX
Scripts and Procedure for NMR Structure Calculation
A) The files necessary to begin structure calculation coming from experimental data.
1) Protein sequence file (the exact sequence of the protein expressed, even if residues
could not be assigned) called nameofprotein.seq with the format;
MET 1
THR 2
ASP 3
SER 4
GLU 5
LYS 6
SER 7
ALA 8
THR 9
ILE 10
LYS 11
VAL 12
THR 13
ASP 14
ALA 15
SER 16
PHE 17
ALA 18
THR 19
ASP 20
VAL 21
LEU 22
SER 23
SER 24
ASN 25
LYS 26
PRO 27
VAL 28
LEU 29
VAL 30
ASP 31
PHE 32
TRP 33
ALA 34
THR 35
TRP 36
CYSS 37
GLY 38
PRO 39
CYSS 40
LYS 41
MET 42
VAL 43
ALA 44
PRO 45
VAL 46
LEU 47
GLU 48
GLU 49
ILE 50
ALA 51
THR 52
GLU 53
ARG 54
ALA 55

THR 56
ASP 57
LEU 58
THR 59
VAL 60
ALA 61
LYS 62
LEU 63
ASP 64
VAL 65
ASP 66
THR 67
ASN 68
PRO 69
GLU 70
THR 71
ALA 72
ARG 73
ASN 74
PHE 75
GLN 76
VAL 77
VAL 78
SER 79
ILE 80
PRO 81
THR 82
LEU 83
ILE 84
LEU 85
PHE 86
LYS 87
ASP 88
GLY 89
GLN 90
PRO 91
VAL 92
LYS 93
ARG 94
ILE 95
VAL 96
GLY 97
ALA 98
LYS 99
GLY 100
LYS 101
ALA 102
ALA 103
LEU 104
LEU 105
ARG 106
GLU 107
LEU 108
SER 109
ASP 110

In which cysteines involved in disulfides have the name CYSS, and prolines in the cis
conformation have the cPRO. This file is created manually.

169
2) The chemical shift list called nameofprotein.prot is every assignment that could be
made from all backbone and sidechain spectra, and is written using the xe command in
sparky. (note: every time a prot file is written, sparky should be closed and re-opened as
sparky retains all chemical shift information and this can cause problems later on) This
file will have the format;
1 55.063 0.000 CA 3
2 41.232 0.000 CB 3
3 4.698 0.000 HA 3
4 2.627 0.000 HB2 3
5 2.760 0.000 HB3 3
6 58.682 0.000 CA 4
7 63.603 0.196 CB 4
8 8.414 0.001 H 4
9 4.393 0.007 HA 4
10 3.847 0.008 HB2 4
11 4.023 0.004 HB3 4
12 116.388 0.014 N 4
13 56.626 0.011 CA 5
14 29.908 0.144 CB 5
15 36.218 0.031 CG 5
16 8.394 0.010 H 5
17 4.271 0.009 HA 5
18 1.937 0.012 HB2 5
19 2.038 0.007 HB3 5
20 2.225 0.010 HG2 5
21 2.267 0.006 HG3 5
22 122.604 0.079 N 5
23 56.050 0.000 CA 6
24 33.182 0.087 CB 6
25 29.023 0.000 CD 6
26 42.302 0.000 CE 6
27 24.474 0.000 CG 6
28 8.241 0.011 H 6
29 4.341 0.002 HA 6
30 1.727 0.005 HB2 6
31 1.808 0.014 HB3 6
32 122.518 0.029 N 6
33 1.394 0.003 QD 6
34 2.982 0.000 QE 6
35 1.672 0.000 QG 6
36 57.132 0.180 CA 7
37 64.338 0.000 CB 7
38 8.260 0.001 H 7
39 4.551 0.006 HA 7
40 3.896 0.005 HB2 7
41 3.652 0.002 HB3 7
42 117.134 0.030 N 7
43 52.590 0.033 CA 8
44 20.124 0.000 CB 8
45 9.691 0.006 H 8
46 4.454 0.001 HA 8
47 129.351 0.089 N 8
48 1.378 0.013 QB 8
49 61.020 0.047 CA 9
50 70.889 0.050 CB 9
51 21.194 0.072 CG2 9
52 8.335 0.006 H 9
53 4.531 0.004 HA 9
54 3.843 0.010 HB 9
55 111.119 0.009 N 9
56 0.863 0.008 QG2 9
57 59.562 0.042 CA 10
58 40.114 0.000 CB 10
59 13.430 0.064 CD1 10
60 26.463 0.000 CG1 10
61 17.374 0.000 CG2 10
62 8.695 0.005 H 10
63 4.651 0.002 HA 10
64 1.800 0.010 HB 10
65 116.239 0.135 N 10
66 0.642 0.010 QD1 10
67 1.311 0.007 QG1 10
68 0.843 0.007 QG2 10
69 56.240 0.001 CA 11
70 33.245 0.000 CB 11
71 29.625 0.000 CD 11
72 42.143 0.000 CE 11
73 25.259 0.020 CG 11
74 8.643 0.004 H 11
75 4.735 0.006 HA 11
76 126.201 0.107 N 11
77 1.790 0.005 QB 11
78 1.618 0.004 QD 11
79 3.014 0.000 QE 11
80 1.226 0.010 QG 11
81 59.077 0.082 CA 12

82 35.040 0.055 CB 12
83 22.622 0.074 CG1 12
84 20.256 0.000 CG2 12
85 8.576 0.002 H 12
86 4.687 0.009 HA 12
87 1.969 0.010 HB 12
88 120.675 0.056 N 12
89 0.820 0.009 QG1 12
90 0.748 0.007 QG2 12
91 58.711 0.004 CA 13
92 73.893 0.000 CB 13
93 8.135 0.002 H 13
94 4.778 0.006 HA 13
95 4.777 0.004 HB 13
96 110.422 0.032 N 13
97 1.205 0.005 QG2 13
98 58.096 0.059 CA 14
99 40.722 0.128 CB 14
100 9.093 0.007 H 14
101 4.328 0.004 HA 14
102 2.705 0.007 HB2 14
103 2.814 0.015 HB3 14
104 120.389 0.011 N 14
105 54.086 0.014 CA 15
106 18.715 0.079 CB 15
107 8.225 0.005 H 15
108 4.310 0.009 HA 15
109 119.446 0.028 N 15
110 1.450 0.007 QB 15
111 58.955 0.002 CA 16
112 65.303 0.030 CB 16
113 8.132 0.003 H 16
114 4.701 0.009 HA 16
115 4.360 0.006 HB2 16
116 3.619 0.008 HB3 16
117 115.620 0.070 N 16
118 64.042 0.038 CA 17
119 39.999 0.048 CB 17
120 131.972 0.114 CD1 17
121 130.748 0.071 CE1 17
122 128.638 0.082 CZ 17
123 8.172 0.005 H 17
124 3.603 0.004 HA 17
125 3.541 0.014 HB2 17
126 3.038 0.005 HB3 17
127 6.444 0.006 HZ 17
128 126.834 0.083 N 17
129 6.926 0.003 QD 17
130 6.675 0.009 QE 17
131 55.676 0.034 CA 18
132 17.528 0.016 CB 18
133 9.142 0.005 H 18
134 3.937 0.010 HA 18
135 120.418 0.027 N 18
136 1.558 0.007 QB 18
137 65.254 0.001 CA 19
138 69.205 0.032 CB 19
139 21.777 0.027 CG2 19
140 7.864 0.005 H 19
141 3.911 0.003 HA 19
142 4.076 0.004 HB 19
143 113.363 0.032 N 19
144 1.192 0.007 QG2 19
145 56.648 0.049 CA 20
146 42.156 0.042 CB 20
147 8.576 0.006 H 20
148 4.274 0.007 HA 20
149 119.229 0.025 N 20
150 2.271 0.009 QB 20
151 63.365 0.023 CA 21
152 32.031 0.010 CB 21
153 20.602 0.040 CG1 21
154 20.830 0.000 CG2 21
155 7.640 0.004 H 21
156 3.843 0.008 HA 21
157 0.581 0.001 HB 21
158 113.358 0.015 N 21
159 -0.438 0.007 QG1 21
160 0.001 0.007 QG2 21
161 58.022 0.031 CA 22
162 39.425 0.048 CB 22

163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243

22.621 0.050
25.294 0.006
7.149 0.002
3.738 0.010
2.312 0.012
1.608 0.008
1.205 0.005
115.492 0.037
0.741 0.010
58.077 0.159
63.339 0.051
7.068 0.002
4.551 0.007
4.043 0.015
4.059 0.010
109.764 0.014
57.924 0.035
63.904 0.010
6.552 0.005
4.270 0.006
3.693 0.005
3.787 0.003
112.853 0.044
54.597 0.000
38.476 0.001
8.943 0.002
4.787 0.002
2.893 0.013
2.920 0.005
127.681 0.019
53.783 0.000
33.680 0.000
29.604 0.000
41.790 0.056
24.239 0.000
7.820 0.006
4.790 0.003
1.652 0.009
1.544 0.012
1.443 0.002
1.559 0.009
120.623 0.133
2.793 0.008
1.416 0.013
63.912 0.034
32.082 0.054
50.983 0.016
28.689 0.000
4.867 0.006
1.966 0.018
2.132 0.011
3.962 0.006
2.361 0.002
60.187 3.187
35.213 0.039
22.495 0.193
20.783 0.112
8.638 0.010
5.016 0.016
1.910 0.010
120.208 0.065
0.637 0.009
1.064 0.009
53.023 0.003
44.474 0.001
23.741 0.064
26.249 0.009
26.967 0.000
9.398 0.006
4.932 0.006
2.126 0.011
1.167 0.008
1.407 0.014
130.791 0.011
0.784 0.012
0.811 0.012
61.461 0.053
33.043 0.034
22.307 0.029
24.538 0.000
9.595 0.004

CD2 22
CG 22
H 22
HA 22
HB2 22
HB3 22
HG 22
N 22
QD2 22
CA 23
CB 23
H 23
HA 23
HB2 23
HB3 23
N 23
CA 24
CB 24
H 24
HA 24
HB2 24
HB3 24
N 24
CA 25
CB 25
H 25
HA 25
HB2 25
HB3 25
N 25
CA 26
CB 26
CD 26
CE 26
CG 26
H 26
HA 26
HB2 26
HB3 26
HD2 26
HD3 26
N 26
QE 26
QG 26
CA 27
CB 27
CD 27
CG 27
HA 27
HB2 27
HB3 27
QD 27
QG 27
CA 28
CB 28
CG1 28
CG2 28
H 28
HA 28
HB 28
N 28
QG1 28
QG2 28
CA 29
CB 29
CD1 29
CD2 29
CG 29
H 29
HA 29
HB2 29
HB3 29
HG 29
N 29
QD1 29
QD2 29
CA 30
CB 30
CG1 30
CG2 30
H 30

244 4.587 0.006 HA 30
245 2.337 0.008 HB 30
246 127.755 0.045 N 30
247 0.217 0.012 QG1 30
248 0.914 0.010 QG2 30
249 52.327 0.012 CA 31
250 40.487 0.127 CB 31
251 9.169 0.007 H 31
252 5.024 0.013 HA 31
253 2.226 0.004 HB2 31
254 2.929 0.006 HB3 31
255 125.859 0.036 N 31
256 58.094 0.056 CA 32
257 38.298 0.121 CB 32
258 132.812 0.116 CD1 32
259 127.776 0.072 CZ 32
260 9.266 0.007 H 32
261 5.292 0.006 HA 32
262 3.626 0.009 HB2 32
263 2.647 0.011 HB3 32
264 6.865 0.006 HZ 32
265 128.566 0.030 N 32
266 7.374 0.007 QD 32
267 7.001 0.002 QE 32
268 54.545 0.046 CA 33
269 32.813 0.000 CB 33
270 126.151 0.092 CD1 33
271 124.582 0.074 CH2 33
272 114.248 0.051 CZ2 33
273 121.359 0.117 CZ3 33
274 8.604 0.008 H 33
275 5.192 0.007 HA 33
276 3.061 0.003 HB2 33
277 3.404 0.004 HB3 33
278 7.232 0.008 HD1 33
279 10.368 0.005 HE1 33
280 7.125 0.010 HH2 33
281 7.484 0.003 HZ2 33
282 6.863 0.005 HZ3 33
283 122.476 0.055 N 33
284 129.830 0.012 NE1 33
285 51.299 0.000 CA 34
286 22.663 0.003 CB 34
287 7.032 0.003 H 34
288 3.728 0.013 HA 34
289 116.614 0.023 N 34
290 0.348 0.007 QB 34
291 21.858 0.046 CG2 35
292 9.334 0.003 H 35
293 4.232 0.005 HA 35
294 3.972 0.009 HB 35
295 115.455 0.052 N 35
296 1.314 0.009 QG2 35
297 54.193 0.098 CA 36
298 29.479 0.000 CB 36
299 129.058 0.066 CD1 36
1015 121.133 0.022 CE3 36
300 115.188 0.094 CZ2 36
301 121.116 0.000 CZ3 36
302 6.564 0.006 H 36
303 4.564 0.015 HA 36
304 3.692 0.007 HB2 36
305 3.167 0.009 HB3 36
306 7.390 0.004 HD1 36
1016 7.385 0.002 HE3 36
307 7.165 0.000 HH2 36
308 7.360 0.002 HZ2 36
309 7.384 0.000 HZ3 36
310 114.739 0.018 N 36
311 58.287 0.069 CA 37
312 26.869 0.003 CB 37
313 6.521 0.009 H 37
314 4.629 0.011 HA 37
315 1.550 0.010 HB2 37
316 2.468 0.004 HB3 37
317 122.120 0.018 N 37
318 49.232 0.026 CA 38
319 4.012 0.006 HA2 38
320 4.307 0.010 HA3 38
321 65.819 0.000 CA 39
322 32.618 0.000 CB 39

323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
773

51.759 0.044 CD 39
28.036 0.107 CG 39
4.423 0.004 HA 39
2.515 0.009 HB2 39
1.779 0.008 HB3 39
4.553 0.008 HD2 39
3.770 0.007 HD3 39
2.056 0.007 HG2 39
2.276 0.009 HG3 39
64.025 0.037 CA 40
27.621 0.003 CB 40
7.875 0.003 H 40
4.121 0.011 HA 40
3.410 0.002 HB2 40
3.607 0.013 HB3 40
114.401 0.029 N 40
58.954 0.093 CA 41
32.060 0.000 CB 41
29.237 0.000 CD 41
42.167 0.124 CE 41
25.469 0.000 CG 41
8.116 0.005 H 41
4.121 0.010 HA 41
1.980 0.004 HB2 41
2.034 0.009 HB3 41
1.780 0.008 HD2 41
1.741 0.000 HD3 41
1.512 0.002 HG2 41
1.642 0.000 HG3 41
119.964 0.081 N 41
3.052 0.006 QE 41
57.324 0.001 CA 42
32.204 0.000 CB 42
32.115 0.007 CG 42
7.397 0.004 H 42
4.328 0.005 HA 42
2.571 0.005 HG2 42
2.674 0.011 HG3 42
116.264 0.045 N 42
2.195 0.007 QB 42
62.943 0.007 CA 43
33.395 0.167 CB 43
20.769 0.000 CG1 43
22.306 0.095 CG2 43
7.236 0.007 H 43
4.143 0.007 HA 43
2.098 0.011 HB 43
115.791 0.029 N 43
0.998 0.010 QG1 43
1.158 0.013 QG2 43
57.560 0.031 CA 44
15.381 0.031 CB 44
7.369 0.008 H 44
3.916 0.006 HA 44
123.443 0.010 N 44
1.368 0.007 QB 44
65.892 0.062 CA 45
30.930 0.055 CB 45
50.571 0.052 CD 45
28.218 0.085 CG 45
4.323 0.005 HA 45
1.933 0.005 HB2 45
2.315 0.008 HB3 45
3.734 0.011 HD2 45
3.625 0.007 HD3 45
2.053 0.010 HG2 45
2.028 0.010 HG3 45
65.533 0.058 CA 46
31.690 0.004 CB 46
21.243 0.070 CG1 46
22.201 0.027 CG2 46
6.742 0.002 H 46
3.731 0.004 HA 46
2.363 0.011 HB 46
118.790 0.011 N 46
0.854 0.011 QG1 46
1.157 0.008 QG2 46
57.447 0.044 CA 47
40.806 0.059 CB 47
22.211 0.000 CD1 47
2.981 0.003 HB3 88

170
403 26.583 0.064
404 26.558 0.000
405 7.722 0.005
406 3.841 0.010
407 1.212 0.010
408 1.886 0.008
409 1.720 0.011
410 117.775 0.050
411 0.634 0.009
412 0.697 0.010
413 58.952 0.001
414 28.890 0.004
415 34.875 0.000
416 7.573 0.002
417 3.864 0.005
418 2.135 0.006
419 2.044 0.013
420 117.254 0.049
421 2.315 0.007
422 59.829 0.030
423 29.693 0.039
424 36.677 0.004
425 7.498 0.003
426 4.059 0.004
427 2.029 0.009
428 2.182 0.010
429 2.533 0.006
430 2.121 0.004
431 118.949 0.035
432 66.070 0.039
433 38.343 0.000
434 29.625 0.093
435 16.530 0.040
436 8.169 0.009
437 3.491 0.007
438 1.686 0.008
439 118.486 0.023
440 0.816 0.021
441 1.858 0.007
442 0.627 0.011
443 54.679 0.052
444 19.160 0.026
445 8.497 0.003
446 3.832 0.010
447 119.695 0.025
448 1.332 0.011
449 65.423 0.074
450 69.350 0.014
451 21.510 0.068
452 7.563 0.006
453 4.060 0.003
454 4.265 0.010
455 110.660 0.035
456 1.279 0.007
457 59.040 0.109
458 30.696 0.003
459 36.682 0.029
460 8.578 0.005
461 4.097 0.007
462 2.100 0.009
463 1.996 0.005
464 2.274 0.005
465 2.492 0.008
466 121.274 0.039
467 52.424 0.000
468 27.725 0.043
469 42.008 0.011
470 26.283 0.049
471 8.328 0.002
472 4.943 0.007
473 1.804 0.008
474 2.185 0.007
475 3.197 0.007
476 3.127 0.010
477 1.478 0.007
478 1.621 0.004
479 114.925 0.019
480 55.476 0.000
481 19.174 0.003
482 6.758 0.003
483 4.366 0.006
484 122.065 0.036
485 1.610 0.011
486 69.088 0.000
487 22.027 0.018
488 8.201 0.002
489 4.165 0.000
490 4.014 0.002
491 107.259 0.023
492 1.225 0.003
493 55.276 0.000
494 44.260 0.000
495 7.772 0.002

CD2 47
CG 47
H 47
HA 47
HB2 47
HB3 47
HG 47
N 47
QD1 47
QD2 47
CA 48
CB 48
CG 48
H 48
HA 48
HB2 48
HB3 48
N 48
QG 48
CA 49
CB 49
CG 49
H 49
HA 49
HB2 49
HB3 49
HG2 49
HG3 49
N 49
CA 50
CB 50
CG1 50
CG2 50
H 50
HA 50
HB 50
N 50
QD1 50
QG1 50
QG2 50
CA 51
CB 51
H 51
HA 51
N 51
QB 51
CA 52
CB 52
CG2 52
H 52
HA 52
HB 52
N 52
QG2 52
CA 53
CB 53
CG 53
H 53
HA 53
HB2 53
HB3 53
HG2 53
HG3 53
N 53
CA 54
CB 54
CD 54
CG 54
H 54
HA 54
HB2 54
HB3 54
HD2 54
HD3 54
HG2 54
HG3 54
N 54
CA 55
CB 55
H 55
HA 55
N 55
QB 55
CB 56
CG2 56
H 56
HA 56
HB 56
N 56
QG2 56
CA 57
CB 57
H 57

496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588

4.746 0.008
2.459 0.004
2.573 0.005
118.403 0.103
54.675 0.076
45.758 0.001
26.361 0.000
7.960 0.003
4.764 0.013
1.621 0.006
1.269 0.005
1.417 0.007
117.425 0.053
0.654 0.011
61.446 0.215
70.758 0.000
22.454 0.000
8.510 0.002
4.396 0.008
3.906 0.007
122.451 0.031
1.188 0.012
61.309 0.004
33.159 0.003
22.000 0.000
20.865 0.050
9.452 0.008
4.925 0.011
1.827 0.004
128.019 0.125
0.824 0.008
0.797 0.009
48.742 0.038
24.366 0.022
9.321 0.006
5.487 0.006
129.933 0.022
0.974 0.007
55.192 0.043
34.618 0.049
28.643 0.011
24.481 0.160
8.960 0.007
4.970 0.008
119.181 0.029
1.733 0.003
1.326 0.006
1.162 0.011
53.557 0.018
44.364 0.000
25.451 0.055
28.071 0.006
9.000 0.004
4.716 0.010
1.251 0.013
0.783 0.008
1.310 0.012
126.402 0.087
0.718 0.010
0.850 0.013
52.420 0.026
40.566 0.041
8.532 0.006
3.861 0.011
2.357 0.012
2.487 0.007
126.637 0.058
64.463 0.030
31.372 0.000
18.710 0.024
23.428 0.000
9.014 0.004
3.816 0.008
2.227 0.009
123.712 0.066
0.932 0.010
1.204 0.008
57.094 0.150
40.647 0.111
8.045 0.002
4.553 0.009
2.702 0.005
2.904 0.011
119.681 0.036
61.223 0.208
69.637 0.009
22.766 0.029
6.870 0.002
4.403 0.012
4.315 0.007
106.834 0.058
1.224 0.005
40.448 0.077

HA 57
HB2 57
HB3 57
N 57
CA 58
CB 58
CG 58
H 58
HA 58
HB2 58
HB3 58
HG 58
N 58
QD1 58
CA 59
CB 59
CG2 59
H 59
HA 59
HB 59
N 59
QG2 59
CA 60
CB 60
CG1 60
CG2 60
H 60
HA 60
HB 60
N 60
QG1 60
QG2 60
CA 61
CB 61
H 61
HA 61
N 61
QB 61
CA 62
CB 62
CD 62
CG 62
H 62
HA 62
N 62
QB 62
QD 62
QG 62
CA 63
CB 63
CD2 63
CG 63
H 63
HA 63
HB2 63
HB3 63
HG 63
N 63
QD1 63
QD2 63
CA 64
CB 64
H 64
HA 64
HB2 64
HB3 64
N 64
CA 65
CB 65
CG1 65
CG2 65
H 65
HA 65
HB 65
N 65
QG1 65
QG2 65
CA 66
CB 66
H 66
HA 66
HB2 66
HB3 66
N 66
CA 67
CB 67
CG2 67
H 67
HA 67
HB 67
N 67
QG2 67
CB 68

589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679

7.113 0.004
2.227 0.006
119.223 0.106
64.195 0.000
32.587 0.018
50.379 0.033
27.275 0.018
4.440 0.008
1.958 0.005
2.370 0.002
3.764 0.006
3.237 0.004
2.065 0.004
59.716 0.127
28.650 0.000
36.101 0.000
9.240 0.003
4.019 0.007
2.187 0.002
2.321 0.009
121.728 0.023
1.885 0.005
67.925 0.040
67.953 0.030
20.512 0.024
9.444 0.004
3.774 0.009
3.717 0.004
119.177 0.012
0.432 0.006
55.707 0.021
17.895 0.006
6.925 0.004
3.932 0.019
120.366 0.015
1.511 0.008
59.163 0.080
30.012 0.000
43.370 0.078
27.412 0.003
7.849 0.010
4.105 0.006
1.728 0.006
1.555 0.005
117.280 0.016
1.917 0.004
3.210 0.004
55.601 0.001
38.168 0.133
8.618 0.004
4.216 0.003
2.208 0.010
2.656 0.008
120.076 0.045
58.431 0.000
38.105 0.000
131.856 0.050
131.891 0.050
129.886 0.022
7.218 0.003
4.650 0.001
2.273 0.007
3.319 0.002
7.628 0.007
113.044 0.031
7.501 0.012
7.448 0.011
56.756 0.000
25.873 0.001
34.265 0.000
7.819 0.002
3.854 0.004
2.076 0.006
2.196 0.003
2.195 0.004
2.310 0.002
116.553 0.066
8.390 0.012
3.830 0.000
1.703 0.013
120.482 0.064
-0.046 0.009
61.669 0.174
33.349 0.036
18.675 0.066
8.033 0.011
4.391 0.009
2.228 0.004
121.955 0.042
0.815 0.011
56.994 0.126

H 68
HB2 68
N 68
CA 69
CB 69
CD 69
CG 69
HA 69
HB2 69
HB3 69
HD2 69
HD3 69
QG 69
CA 70
CB 70
CG 70
H 70
HA 70
HG2 70
HG3 70
N 70
QB 70
CA 71
CB 71
CG2 71
H 71
HA 71
HB 71
N 71
QG2 71
CA 72
CB 72
H 72
HA 72
N 72
QB 72
CA 73
CB 73
CD 73
CG 73
H 73
HA 73
HG2 73
HG3 73
N 73
QB 73
QD 73
CA 74
CB 74
H 74
HA 74
HB2 74
HB3 74
N 74
CA 75
CB 75
CD1 75
CE1 75
CZ 75
H 75
HA 75
HB2 75
HB3 75
HZ 75
N 75
QD 75
QE 75
CA 76
CB 76
CG 76
H 76
HA 76
HB2 76
HB3 76
HG2 76
HG3 76
N 76
H 77
HA 77
HB 77
N 77
QG2 77
CA 78
CB 78
CG1 78
H 78
HA 78
HB 78
N 78
QQG 78
CA 79

680 64.785 0.013
681 7.879 0.008
682 4.706 0.009
683 117.284 0.044
684 3.698 0.006
685 56.994 0.129
686 40.133 0.049
687 14.042 0.000
688 18.610 0.000
689 8.468 0.006
690 4.702 0.003
691 1.883 0.003
692 120.767 0.036
693 0.451 0.008
694 0.796 0.007
695 63.334 0.003
696 35.033 0.041
697 24.909 0.065
698 5.113 0.007
699 1.989 0.011
700 2.791 0.003
701 1.513 0.014
702 1.783 0.010
703 3.615 0.013
704 63.911 0.017
705 73.148 0.075
706 21.417 0.107
707 5.022 0.010
708 3.918 0.005
709 1.087 0.012
710 53.091 0.000
711 42.011 0.000
712 26.431 0.024
713 9.680 0.005
714 6.089 0.002
715 1.351 0.007
716 1.823 0.006
717 0.881 0.004
718 127.551 0.082
719 60.201 0.010
720 41.735 0.000
721 17.709 0.041
722 28.237 0.000
723 13.350 0.056
724 9.136 0.005
725 5.039 0.008
726 1.760 0.022
727 120.368 0.048
728 0.148 0.005
729 0.800 0.013
730 0.637 0.012
731 52.736 0.001
732 44.058 0.000
733 23.718 0.064
734 27.658 0.000
735 8.719 0.008
736 5.183 0.008
737 1.871 0.011
738 1.052 0.004
739 1.423 0.007
740 129.362 0.051
741 0.786 0.011
742 57.087 0.042
743 41.684 0.063
744 132.073 0.098
745 130.815 0.155
746 128.598 0.110
747 9.859 0.006
748 5.187 0.004
749 2.792 0.013
750 2.734 0.011
751 5.790 0.005
752 128.109 0.081
753 6.825 0.008
754 6.945 0.014
755 56.019 0.000
756 36.456 0.000
757 29.668 0.000
758 42.172 0.080
759 25.193 0.107
760 8.736 0.003
761 4.618 0.006
762 1.460 0.006
763 1.784 0.010
764 119.947 0.075
765 1.675 0.006
766 3.049 0.005
767 1.377 0.005
768 55.688 0.143
769 39.709 0.024
770 9.444 0.007
771 4.534 0.001
772 2.750 0.003

CB 79
H 79
HA 79
N 79
QB 79
CA 80
CB 80
CD1 80
CG2 80
H 80
HA 80
HB 80
N 80
QD1 80
QG2 80
CA 81
CB 81
CG 81
HA 81
HB2 81
HB3 81
HG2 81
HG3 81
QD 81
CA 82
CB 82
CG2 82
HA 82
HB 82
QG2 82
CA 83
CB 83
CG 83
H 83
HA 83
HB2 83
HB3 83
HG 83
N 83
CA 84
CB 84
CD1 84
CG1 84
CG2 84
H 84
HA 84
HB 84
N 84
QD1 84
QG1 84
QG2 84
CA 85
CB 85
CD1 85
CG 85
H 85
HA 85
HB2 85
HB3 85
HG 85
N 85
QD1 85
CA 86
CB 86
CD1 86
CE1 86
CZ 86
H 86
HA 86
HB2 86
HB3 86
HZ 86
N 86
QD 86
QE 86
CA 87
CB 87
CD 87
CE 87
CG 87
H 87
HA 87
HB2 87
HB3 87
N 87
QD 87
QE 87
QG 87
CA 88
CB 88
H 88
HA 88
HB2 88

774 127.788 0.081
775 46.187 0.029
776 9.156 0.004
777 4.367 0.008
778 3.855 0.005
779 103.729 0.023
780 52.038 0.050
781 30.836 0.064
782 32.783 0.018
783 7.861 0.002
784 5.197 0.006
785 1.929 0.008
786 2.157 0.008
787 117.288 0.013
788 2.435 0.008
789 61.840 0.055
790 30.886 0.040
791 50.447 0.017
792 27.680 0.042
793 3.878 0.012
794 1.259 0.006
795 1.697 0.012
796 2.450 0.007
797 2.148 0.008
798 3.983 0.008
799 62.061 0.103
800 33.332 0.036
801 21.979 0.000
802 20.481 0.035
803 8.982 0.004
804 4.394 0.004
805 2.224 0.004
806 119.911 0.054
807 0.991 0.005
808 0.836 0.010
809 55.782 0.141
810 36.090 0.098
811 42.059 0.113
812 25.019 0.000
813 7.194 0.002
814 4.538 0.006
815 1.558 0.004
816 1.810 0.007
817 118.773 0.011
818 3.065 0.012
819 1.356 0.011
820 54.972 0.009
821 33.173 0.002
822 43.369 0.067
823 28.070 0.002
824 8.828 0.006
825 5.076 0.005
826 1.653 0.006
827 1.690 0.005
828 1.303 0.009
829 1.379 0.014
830 126.303 0.048
831 3.200 0.005
832 60.780 0.007
833 40.922 0.000
834 14.432 0.133
835 27.475 0.000
836 17.847 0.000
837 9.593 0.001
838 4.347 0.008
839 1.826 0.005
840 127.824 0.028
841 0.681 0.012
842 1.053 0.009
843 0.839 0.010
844 62.070 0.068
845 33.415 0.003
846 20.586 0.000
847 21.321 0.000
848 8.898 0.002
849 4.533 0.004
850 2.013 0.005
851 127.788 0.013
852 0.949 0.014
853 0.932 0.007
854 43.717 0.038
855 8.013 0.003
856 3.589 0.004
857 4.394 0.013
858 113.977 0.022
859 52.512 0.023
860 19.273 0.004
861 8.359 0.003
862 4.065 0.006
863 120.317 0.032
864 1.299 0.010
865 54.282 0.035
866 36.401 0.014

N 88
CA 89
H 89
HA2 89
HA3 89
N 89
CA 90
CB 90
CG 90
H 90
HA 90
HB2 90
HB3 90
N 90
QG 90
CA 91
CB 91
CD 91
CG 91
HA 91
HB2 91
HB3 91
HG2 91
HG3 91
QD 91
CA 92
CB 92
CG1 92
CG2 92
H 92
HA 92
HB 92
N 92
QG1 92
QG2 92
CA 93
CB 93
CE 93
CG 93
H 93
HA 93
HB2 93
HB3 93
N 93
QE 93
QG 93
CA 94
CB 94
CD 94
CG 94
H 94
HA 94
HB2 94
HB3 94
HG2 94
HG3 94
N 94
QD 94
CA 95
CB 95
CD1 95
CG1 95
CG2 95
H 95
HA 95
HB 95
N 95
QD1 95
QG1 95
QG2 95
CA 96
CB 96
CG1 96
CG2 96
H 96
HA 96
HB 96
N 96
QG1 96
QG2 96
CA 97
H 97
HA2 97
HA3 97
N 97
CA 98
CB 98
H 98
HA 98
N 98
QB 98
CA 99
CB 99
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867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
104
917
918
919
920
921
922
923
924
925
926
927
105
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956

28.825 0.049
42.328 0.000
24.548 0.000
7.285 0.003
4.546 0.008
1.516 0.006
1.823 0.007
1.431 0.001
1.590 0.002
2.788 0.003
2.867 0.001
1.261 0.002
1.358 0.000
120.852 0.017
43.980 0.027
8.231 0.003
3.863 0.004
4.171 0.010
105.881 0.021
61.261 0.060
33.361 0.079
30.102 0.035
41.807 0.039
25.219 0.119
8.658 0.003
3.549 0.010
1.820 0.007
1.906 0.005
1.678 0.005
1.761 0.007
2.685 0.005
2.893 0.008
1.343 0.012
1.148 0.009
119.193 0.069
55.381 0.010
17.648 0.037
8.484 0.002
4.012 0.005
118.726 0.045
1.411 0.010
54.750 0.047
18.703 0.083
8.022 0.007
4.050 0.012
120.668 0.024
1.442 0.006
58.304 0.004
41.804 0.000
24.901 0.000

CD 99
CE 99
CG 99
H 99
HA 99
HB2 99
HB3 99
HD2 99
HD3 99
HE2 99
HE3 99
HG2 99
HG3 99
N 99
CA 100
H 100
HA2 100
HA3 100
N 100
CA 101
CB 101
CD 101
CE 101
CG 101
H 101
HA 101
HB2 101
HB3 101
HD2 101
HD3 101
HE2 101
HE3 101
HG2 101
HG3 101
N 101
CA 102
CB 102
H 102
HA 102
N 102
QB 102
CA 103
CB 103
H 103
HA 103
N 103
QB 103
CA 104
CB 104
CD1

8.426 0.007
3.868 0.008
1.422 0.004
1.613 0.006
1.498 0.001
119.833 0.023
0.692 0.014
0.700 0.014
58.225 0.000
40.868 0.047
22.510 0.000

H 104
HA 104
HB2 104
HB3 104
HG 104
N 104
QD1 104
QD2 104
CA 105
CB 105
CD1

8.421 0.001
3.836 0.010
1.891 0.003
1.390 0.010
117.284 0.040
0.782 0.008
0.862 0.005
59.670 0.126
29.892 0.000
43.311 0.052
27.418 0.000
7.899 0.004
4.021 0.010
1.724 0.021
1.600 0.010
119.038 0.106
1.955 0.004
3.211 0.003
58.984 0.081
29.632 0.044
36.165 0.001
7.899 0.002
4.126 0.007
2.131 0.007
2.044 0.004
2.357 0.008
2.278 0.007
119.217 0.109
55.545 0.008

H 105
HA 105
HB2 105
HB3 105
N 105
QD1 105
QD2 105
CA 106
CB 106
CD 106
CG 106
H 106
HA 106
HG2 106
HG3 106
N 106
QB 106
QD 106
CA 107
CB 107
CG 107
H 107
HA 107
HB2 107
HB3 107
HG2 107
HG3 107
N 107
CA 108
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The first value in the list is the atom number associated with the chemical shift which is
the second value with the standard deviation of chemical shifts assigned to that particular
atom of a residue which is the fourth and fifth lines. The chemical shift list that will be
used for structure calculation can only consist of assignments made on the NOESY
peaklists (more on this later). This is done so that there is less inconsistency in chemical
shifts.
3) Peaklists, the ones which are needed for structure calculation come from the three
NOESY spectra (c13no.peaks, c13ar.peaks, and n15no.peaks). The protocol for
generating these peaklists goes as follows.
-Open all sidechain spectra in Sparky (CBCA(CO)NH, CC(CO)NH, HBHA(CO)NH,
HCC(CO)NH) as well as the HCCH-TOCSY if you made any assignments using it.
-Write the chemical shift list (.prot) in xeasy format using the command xe.
-Need to convert this chemical shift list into peaks that correspond to the HCCH-TOCSY.
This is done so that we can easily assign and pick peaks in the c13 aliphatic NOESY.
This is done on the Mac workstation in room 530 using the program called GARANT.
The terminal command is:
garant genPeaks HCCH24 sequence_file_name prot_file_name new_peak list
-This peak can then be read on the HCCH-TOCSY peaklist by using the command cg/cy
in Sparky. One should then go through and fix any peaks that are not on the actual peak.
-This peaklist should be saved in sparky format so that it can be read onto the 13C
aliphatic NOESY.
-Once this peaklist is read onto the 13C aliphatic NOESY, one should then go through all
the planes and pick each peak that isn’t already picked. Its best to do this using strips in
Sparky with the command sp and click all assigned peaks which generate stripts
according to residue number. This should give strips in a format so that w1 is the xdimension (1H), w2 is the y-dimension (1H), and w3 in the z-dimension (13C). This
should yield around 2000-4000 peaks depending on the size of the protein.
-The 15N-NOESY should also be hand picked with the only assignments being from the
1
H-15N HSQC. This should yield around 1500-3000 peaks.
-The 13C aromatic NOESY can be assigned using either the 2D experiments, which
correlate Hδ or Hη to the Cβ (cbcgcdhd/cbcgcdcehe experiments) or by actually
assigning them based on the Hδ protons or observed in the aliphatic 13C NOESY and
working through the aromatic ring. The rest of the peak should be manually assigned.
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After all the peaks are assigned and picked in the NOESY experiments, the peaklists are
written using the command xe and should have the following format.
# Number of dimensions 3
#CYANAFORMAT HhC
1 4.508 3.615 59.401 1 U 1.35e+05
2 0.627 3.323 13.364 1 U 1.8e+04
3 0.787 5.201 20.846 1 U 1.05e+04
4 0.711 1.823 23.030 1 U 1.5e+05
5 1.772 3.057 42.102 1 U 1.6e+05
6 4.102 1.282 59.019 1 U 4.73e+04
7 1.384 4.484 40.852 1 U 1e+04
8 0.710 0.462 24.901 1 U 1.54e+05
9 0.828 0.449 22.000 1 U 3.59e+04
10 4.626 3.747 58.214 1 U 9.56e+03
11 6.312 3.208 42.066 1 U 1.66e+03
12 0.941 4.782 22.385 1 U 2.4e+04
13 1.511 0.688 17.899 1 U 9.06e+04
14 1.508 1.360 17.958 1 U 2.62e+05
15 0.937 3.727 22.385 1 U 3.66e+04
16 0.937 3.603 22.385 1 U 2.51e+04
17 1.511 1.676 17.890 1 U 1.79e+05
18 0.933 2.392 22.385 1 U 2.5e+04
19 4.497 3.734 64.083 1 U 1.32e+04
20 4.499 3.573 64.083 1 U 2.01e+04
21 1.938 3.983 30.931 1 U 2.7e+04
22 4.499 1.718 64.083 1 U 1.13e+04
23 2.330 3.715 32.285 1 U 4.3e+04
24 4.130 2.801 64.123 1 U 1.07e+04
25 4.139 3.871 64.011 1 U 5.3e+04

0e0 0 0 0
0e0 0 0 0
0e0 0 0 0
0e0 0 0 0
0e0 0 0 0
0e0 0 0 0
0e0 0 0 0
0e0 0 0 0
0e0 0 0 0
0e0 0 0 0
0e0 0 0 0
0e0 0 0 0
0e0 0 0 0
0e0 0 0 0
0e0 0 0 0
0e0 0 0 0
0e0 0 0 0
0e0 0 0 0
0e0 0 0 0
0e0 0 0 0
0e0 0 0 0
0e0 0 0 0
0e0 0 0 0
0e0 0 0 0
0e0 0 0 0

3811
3812
3813
3814
3815
3816
3817
3818
3819
3820
3821
3822
3823
3824
3825
3826
3827
3828
3829
3830
3831
3832
3833
3834
3835
3836
3837

0.923
0.923
0.930
0.925
0.925
0.930
0.923
0.904
0.899
0.889
0.893
0.893
0.893
0.893
0.868
4.502
4.504
4.503
4.503
4.503
4.503
4.503
4.503
4.504
2.102
2.089
2.114

2.081 22.112
0.923 22.112
0.930 22.385
0.917 21.740
0.930 21.740
0.917 22.385
0.893 22.112
1.807 20.824
3.062 20.868
4.169 20.765
4.398 20.765
2.081 20.765
0.923 20.765
0.893 20.765
0.868 21.120
0.765 59.401
0.672 59.401
4.524 59.401
2.090 59.401
0.917 59.401
0.930 59.401
0.917 59.401
0.930 59.401
1.959 59.401
1.680 32.124
4.156 32.124
0.694 32.124

1U
1U
1U
1U
1U
1U
1U
1U
1U
1U
1U
1U
1U
1U
1U
1U
1U
1U
1U
1U
1U
1U
1U
1U
1U
1U
1U

4.76e+05
1.03e+07
8.72e+06
1.04e+07
1.04e+07
8.72e+06
1.03e+07
1.23e+05
6.08e+04
8.14e+04
1.31e+05
2.73e+05
7.8e+06
7.8e+06
6.48e+06
2.55e+04
1.07e+04
5.18e+05
4.92e+04
2.34e+05
2.34e+05
2.34e+05
2.34e+05
4e+04
6.4e+04
3.16e+04
3.78e+04

0 e 0 985 983 979
0 e 0 985 985 979
0 e 0 985 985 979
0 e 0 985 985 979
0 e 0 985 985 979
0 e 0 985 985 979
0 e 0 985 986 979
0 e 0 986 814 980
0 e 0 986 816 980
0 e 0 986 959 980
0 e 0 986 982 980
0 e 0 986 983 980
0 e 0 986 985 980
0 e 0 986 986 980
0 e 0 986 986 980
0 e 0 992 438 987
0 e 0 992 964 987
0 e 0 992 992 987
0 e 0 992 993 987
0 e 0 992 995 987
0 e 0 992 995 987
0 e 0 992 996 987
0 e 0 992 996 987
0 e 0 992 1003 987
0 e 0 993 436 988
0 e 0 993 959 988
0 e 0 993 964 988

The top two lines are needed so that CYANA can properly interpret the peaklists
(#CYANAFORMAT HhN for the 15N NOESY) and are added manually. The lines are
the chemical shifts of the peaks with the inensity/volume of the peak. If the peaks are
assigned (as in the right panel), the numbers correspond to the atoms from the chemical
shift list. These peaklists should be saved with a name that tells the nature of the
experiment (i.e. c13no.peaks, n15no.peaks, c13ar.peaks).
4) Dihedral restraints are generated using Talos+, which come from the chemical shifts of
the Cα, Cβ, Hα, Hβ, CO, and HN atoms from the sidechain, HNCO, and 1H-15N HSQC
experiments. To generate the dihedral constraints go to the Mac workstation and in the
terimanl type;
-cyana
-read prot name.prot
-taloslist newname.tab
which creates the input needed for Talos called newname.tab. Dihedral constraints are
generated by typing;
-talos+ -in newname.tab
You can look at the constraint values by typing;
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-rama+ -in newname.tab
To generate the file that can be read by Cyana type, copy the file talos+2aco into the file
and type;
-talos+2aco pred.tab > name.aco
This file has the format;
3 ASP PHI -76.7 -45.1
3 ASP PSI -63.5 0.5
4 SER PHI -96.1 -44.3
4 SER PSI -50.0 -16.4
7 SER PHI -126.5 -60.4
7 SER PSI 107.7 161.9
8 ALA PHI -105.7 -74.2
8 ALA PSI 109.1 153.7
9 THR PHI -141.5 -89.7
9 THR PSI 152.4 178.3
10 ILE PHI -183.6 -59.7
10 ILE PSI 125.1 154.6
11 LYS PHI -135.5 -83.7
11 LYS PSI 108.4 145.0
12 VAL PHI -139.4 -106.8
12 VAL PSI 151.0 171.0
13 THR PHI -123.0 -82.8
13 THR PSI 153.8 173.8
14 ASP PHI -71.6 -51.6
14 ASP PSI -50.7 -28.2
15 ALA PHI -84.2 -59.6
15 ALA PSI -53.6 -13.9
17 PHE PHI -64.5 -44.5
17 PHE PSI -62.2 -42.2
18 ALA PHI -69.8 -49.8
18 ALA PSI -52.8 -32.8
19 THR PHI -79.0 -59.0
# 19 THR PSI -51.9 -31.9
# 20 ASP PHI -77.3 -55.6
20 ASP PSI -53.6 -33.1
21 VAL PHI -78.7 -58.7
21 VAL PSI -51.0 -24.0
22 LEU PHI -73.3 -53.3
22 LEU PSI -47.5 -13.6
23 SER PHI -104.4 -62.8
23 SER PSI -32.7 -11.3
24 SER PHI -139.4 -59.8
24 SER PSI
84.7 150.4
26 LYS PHI -141.9 -90.7
26 LYS PSI 102.5 166.1
27 PRO PSI 139.1 157.4
28 VAL PHI -135.6 -105.7
28 VAL PSI 110.9 140.6
29 LEU PHI -125.5 -93.7
29 LEU PSI 114.3 134.3
30 VAL PHI -119.4 -99.4
30 VAL PSI 115.7 144.4
31 ASP PHI -106.7 -84.4
31 ASP PSI 110.0 130.0
32 PHE PHI -100.3 -69.2
32 PHE PSI 109.5 139.0
33 TRP PHI -133.9 -110.4
33 TRP PSI 148.2 172.5
34 ALA PHI -169.2 -107.3
34 ALA PSI 135.3 168.5
37 CYS PHI -136.5 -33.6
37 CYS PSI
83.9 196.8
38 GLY PHI -109.4 61.9
38 GLY PSI -210.7 -123.7
39 PRO PSI -42.4 -23.5
40 CYS PHI -73.4 -53.4

40 CYS PSI
41 LYS PHI
41 LYS PSI
42 MET PHI
42 MET PSI
43 VAL PHI
43 VAL PSI
44 ALA PHI
44 ALA PSI
45 PRO PSI
46 VAL PHI
46 VAL PSI
47 LEU PHI
47 LEU PSI
48 GLU PHI
48 GLU PSI
49 GLU PHI
49 GLU PSI
50 ILE PHI
50 ILE PSI
51 ALA PHI
51 ALA PSI
52 THR PHI
52 THR PSI
53 GLU PHI
53 GLU PSI
54 ARG PHI
54 ARG PSI
55 ALA PHI
55 ALA PSI
56 THR PHI
56 THR PSI
57 ASP PHI
57 ASP PSI
58 LEU PHI
58 LEU PSI
59 THR PHI
59 THR PSI
60 VAL PHI
60 VAL PSI
61 ALA PHI
61 ALA PSI
62 LYS PHI
62 LYS PSI
63 LEU PHI
63 LEU PSI
64 ASP PHI
64 ASP PSI
65 VAL PHI
65 VAL PSI
66 ASP PHI
66 ASP PSI
67 THR PHI
67 THR PSI
68 ASN PHI
68 ASN PSI
70 GLU PHI
70 GLU PSI
71 THR PHI
71 THR PSI
72 ALA PHI

-48.6 -28.6
-71.2 -51.2
-49.9 -29.9
-75.1 -55.1
-50.1 -30.1
-93.6 -68.5
-39.5 -17.0
-61.3 -41.3
-60.9 -40.9
-42.1 -27.4
-74.9 -54.9
-51.2 -31.2
-72.6 -52.6
-49.3 -29.3
-71.6 -51.6
-50.5 -30.5
-75.1 -55.1
-55.2 -35.2
-74.1 -54.1
-53.4 -33.4
-70.2 -50.2
-49.9 -29.9
-75.4 -55.4
-48.8 -28.8
-77.6 -57.6
-46.8 -21.9
-128.3 -82.1
-5.9 35.5
-71.1 -51.1
-49.9 -28.5
-84.0 -64.0
-46.2 -20.1
-116.9 -85.5
-39.1 -4.3
-163.5 -130.0
128.7 148.7
-136.7 -109.2
114.9 138.1
-128.5 -99.7
118.0 138.0
-143.2 -110.6
137.1 165.4
-130.5 -104.6
115.8 135.8
-134.4 -88.5
117.3 143.5
-115.4 -81.9
84.7 127.6
-70.6 -50.6
-38.0 -17.1
-78.5 -58.5
-50.1 -19.9
-118.5 -93.0
-17.9 15.6
-123.0 -63.7
78.0 141.4
-77.0 -57.0
-46.1 -26.1
-76.6 -56.6
-50.7 -30.7
-72.7 -52.7

72 ALA PSI -52.6 -32.6
73 ARG PHI -77.3 -57.3
73 ARG PSI -49.1 -23.0
74 ASN PHI -76.2 -54.0
74 ASN PSI -44.2 -23.6
75 PHE PHI -96.5 -76.3
75 PHE PSI -14.2 9.7
77 VAL PHI -139.0 -23.8
77 VAL PSI
84.2 149.5
78 VAL PHI -147.3 -80.1
# 78 VAL PSI 125.1 174.6
# 79 SER PHI -128.6 -84.7
79 SER PSI 136.3 166.8
# 80 ILE PHI -144.8 -101.2
80 ILE PSI
76.2 146.5
81 PRO PSI 142.4 161.6
82 THR PHI -135.1 -109.7
82 THR PSI 121.6 146.9
83 LEU PHI -120.4 -96.8
83 LEU PSI 119.7 139.8
84 ILE PHI -136.4 -116.4
84 ILE PSI 122.4 154.9
85 LEU PHI -123.2 -92.7
85 LEU PSI 106.8 132.8
86 PHE PHI -122.7 -97.2
86 PHE PSI 130.0 156.5
87 LYS PHI -154.0 -100.5
87 LYS PSI 111.9 137.0
89 GLY PHI
68.0 88.0
89 GLY PSI
-6.5 15.6
90 GLN PHI -125.9 -95.3
90 GLN PSI 108.6 151.8
91 PRO PSI 140.4 156.7
93 LYS PHI -163.1 -142.3
93 LYS PSI 132.6 152.6
94 ARG PHI -128.4 -91.8
94 ARG PSI 112.8 141.4
95 ILE PHI -129.3 -108.0
95 ILE PSI 122.9 145.1
96 VAL PHI -133.2 -101.8
96 VAL PSI 115.5 143.8
97 GLY PHI -203.8 -73.5
97 GLY PSI 150.2 181.8
98 ALA PHI -119.5 -59.3
98 ALA PSI 102.6 158.0
99 LYS PHI -130.0 -109.0
99 LYS PSI 131.6 175.8
100 GLY PHI -146.2 -20.2
100 GLY PSI 157.0 177.0
101 LYS PHI -65.2 -45.1
101 LYS PSI -54.3 -34.3
102 ALA PHI -70.9 -50.9
102 ALA PSI -53.1 -33.1
103 ALA PHI -75.2 -55.2
103 ALA PSI -50.7 -30.7
104 LEU PHI -74.5 -54.5
104 LEU PSI -55.0 -35.0
105 LEU PHI -75.5 -53.9
105 LEU PSI -45.6 -25.6
106 ARG PHI -74.0 -54.0
106 ARG PSI -53.7 -33.7

107 GLU
107 GLU
108 LEU
108 LEU
109 SER
109 SER
110 ASP
110 ASP
111 VAL
111 VAL
112 VAL
112 VAL
114 ASN
114 ASN

PHI -74.6 -54.6
PSI -47.5 -27.5
PHI -97.8 -62.4
PSI -45.1 -9.4
PHI -74.5 -54.5
PSI -46.6 -26.6
PHI -82.8 -60.2
PSI -44.9 -22.8
PHI -123.8 -89.2
PSI -16.4 11.5
PHI -138.3 -82.2
PSI
67.3 122.7
PHI -96.8 -50.1
PSI -50.0 -0.8
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The files needed for Cyana have now been generated (n15no.peaks, c13no.peaks,
c13ar.peaks, nameofprot.seq, and nameofprot.prot).
B) To start structure calculation one has to perform the automatic assignment of the
peaklists using the noeassign macro of Cyana.
1) Cyana is ran using the Condor submission system of Pere. So one has to log into Pere
and transfer the files from above to a new directory in Pere.
2) Transfer files from the shared folder (NMR_STRUCTURE_INFO) in the Mac
workstation to that directory.
-init.cya
-autorun.cya
-autorun.sub
3) The file init.cya is the initialization script for Cyana

Input the name of the protein as well as the rmsd range used to determine rmsd as well as
the name of the sequence file. This script is immediately called up when typing starting
the Cyana program.
4) The file autorun.cya is the script that reads in the files that Cyana uses for automatic
assignment (all those that were prepared previously).
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Input the name of your peaklists (peaks), chemical shift list (prot), and any additional
constraints (dihedral, hbonds, or ssbonds). The rmsd range should be the same as the init
file. The very last line of autorun.cya is the the noeassign macro and the flags needed to
run automatic assignment (autoaco is optional to allow temporary angle restraints to favor
Ramachandran plot).
5) To submit this to Condor on Pere to run noeassign of Cyana, one has to use
autorun.sub.

Type condor_submit autorun.sub
6) The output of noeassign is 7 cycles of refinement with one final refinement. After
every cycle a pdb file is written with an overview (.ovw) file summarizing the structural
violations, target function, and rmsd. With cycle 7, assigned peaklists and new prot file
are generated (name-cycle7.peaks and name-final.prot). The command cyanatable
(shown below) summarizes the cycles.
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As long as the initial target function is under 300 and rmsd is under 3, as well as having a
cycle 7 target function under 10, the cycle 7 structure and assignments are suitable to go
onto manual refinement. If any of these is violated, one can look at the ovw file from
cycle 7 and look for any really violated distance or dihedral restraints and delete those
and run again. Generally deleting the dihedral constraints is good enough to decrease the
target function. Automatic peak picking of NOESY peaklists can lead to a lot of peaks
being thrown out because they aren’t real which leads very high target functions. This is
why manual peak picking is preferred. The upper distance limits is the number of NOEs
used in the automatic assignments.
C) Manual refinement involves assigning the peaks that noeassign missed.
1) In a new directory copy the files cycle7.pdb, all name-cycle7.peaks, name-final.prot,
*.aco, *.seq, stereofound.cya, and init.cya.
2) (optional) Delete the ambiguous restraints the Cyana gave some peaks (if it wasn’t
sure it assigned more than one assignment to a peak) with the command;
- grep –v ‘0 e 0’ name.peaks > newname.peaks
3) In sparky bring up the clean (no peaks) NOESY spectra and put the peaklists that
noeassign from Cyana assigned onto them from step 2 by using the command cy/cg
4) As in Step 1-3 generate strips of the particular NOESY spectra and go through each
strip and make as many assignments as possible (using the cycle7.pdb as guide for close
residues, since they have to at least be within 5 Å). Go through about 10 residues and
and run through manual Cyana structure calculation.
5) Copy from the shared folder (NMR_STRUCTURE_INFO) in the Mac workstation the
scripts to run manual refinement.
- man_calc.cya
- calc.cya
- calc.sub
Where man_calc.cya is the script to calibrate the peaklists and run the structure
refinement in the initial process.
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Where the macro caliba is used to calibrate the peaklists. At the end of caliba post script
file is generated called noesyname.ps. The values must be altered until the post script file
looks like this.

The line must be just barely above the dots for it to be calibrated properly. You get a ps
file for each peaklist with backbone class, sidechain class, and methyl class, all of which
must look like the figure above. If not calibrated properly the target function will go way
up.
After the peaklists are calibrated properly, look at the overview file and delete any
severely violated distance restraints and run again…repeat until all the bad restraints are
gone and decent target functions remains. Copy these peaklists to the NOESY spectra
using cy/cg command and repeat this process until all the spectra have gone through and
many more assignments have been made.
In the case of the 15N-NOESY look for NOEs that define secondary structure such as
alpha helix peakse and beta sheets. For alpha helices the NH NOEs can be seen from i to
i+4 residue.
6) Every now and again, its worth it to upload all the peaklists and prot files to another
directory and run autoassignment again. This may make the structure look a little better.
Treat the autoassigned peaklists like earlier and quickly go through the strips you have
already gone through and make sure those peaks are still assigned.
7) When you are all done making assignments replace the man_calc.cya for calc.cya.
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8) Calc.cya is only the structure calculation script from man_calc.cya. This script is used
to get your final structure and throw out NOEs to lower your target function to an
acceptable value.
9) After you have gone through all your strips and added as many NOEs as possible you
have to replace man_calc.cya with this script and change calc.sub so that it matches
calc.cya.
10) Run this script but pay attention to the last two lines in this script;
Structures violate significant=15 delete=100
Write upl filter.upl
Structures violate will delete NOEs automatically that were violated upon structure
calculation from the upl file generated. Upl file is just the list of upper distance limits
(NOEs). This will not delete from the peaklist. Significant is the number of models in
which an NOE is violated. So if an NOE is violated in 15 of the 20 structures it is
considered significant. Delete is the percentage of NOEs that are significantly violated
that are deleted. In this case any NOE that is violated in 15 or more structures it is
deleted from the upl file and the new upl file is written to filter.upl. (significant should
start at 20 and move to 15)
11) Change the name of filter.upl to found-c.upl.
mv filter.upl found-c.upl
12) Repeat until target function is between 0-3.
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13) Once this is achieved, change calc.cya;
So that 500 structures are calculated and the 99 best structures are written out.

D) This last structure of 99 conformers is then put through water refinement using
simulated annealing and the AMBER molecular force field.
In the same directory as before, copy the files;
-mdin
-mdin_rst
-amber_anneal.sub
-amber_min1.sub
-amber_min2.sub
-anneal.in
-generate.inp
-refine.inp
-final_min.inp
1) generate.inp splits the 99 structures into individual files and performs and initial
minimization on the structure in implicit solvent using the script mdin and submitted to
Condor using amber_min1.sub.
(type ./generate.inp to run)
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generate.inp

mdin

amber_min1.sub
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This initial minimization takes about 5-10 minutes to complete.
2) The output from the initial minimization (model_min.x) is fed into the simulated
annealing refinement with the script refine.inp which calls the annealing script anneal.in
and is submitted to Condor using amber_anneal.sub.
(type ./refine.inp to run)
refine.inp
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The first part of refine.inp changes the atom names of some of the atoms in the upl file so
that AMBER can convert this to restraints it can use. The second part converts the
restraint files so that AMBER can use them and applies force constants to the restraints
which can be altered. The last part is condor submission.
anneal.in
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This script defines the temperatures and step values used. This particular file heats up to
1000K and goes through 2 cycles of 30 ps simulated annealing sessions. Restraints are
used with this.
amber_anneal.sub

This portion of water refinement takes about 4 hours to complete.
If for some reason this fails, one can try and decrease the temperature and if that still fails
look at the trajectory file and see where its failing.
3) The output from this file (model.ann.x) is fed into the last portion of water refinement,
which is a final minimization using restraints in implicit solvent, which is uses the scripts
final_min.inp which calls up mdin_rst and submits to condor using amber_min2.sub.
(./final_min.inp is how to run this)
final_min.inp
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mdin_rst

amber_min2.sub

This portion takes about 15-20 minutes to complete.
3) Once all of AMBER water refinement is completed, the statistics are written out using
the script make_collect.inp (./make_collect.inp on command line). This script turns the
output from the last minimization into a pdb file, statistics using the command for each
model are written using sviol (sviol2) and are merged together and sorted by lowest
AMBER energy.
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make_collect.inp

All 99 pdb files are written into one called ensemble.pdb.
The sorted liste (averages.txt);

Where the first line is the rank, the second line is the model number, the fourth line is the
amber energy, the fifth line is total penalty energy, and ninth and tenth lines are distance
and torsion penalty.
4) In the second line of averages.txt is the model number, which corresponds to the files
in the directory. The top 20 AMBER energy structures should be copied to a new
directory along with make_collect.inp.
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make_collect.inp should be ran again to get the top 20 structures into one file called
ensemble.pdb.
5) To get statistics on this new file, run the program called pdbstat (type pdbstat on
command line), and follow the directions on start up.
- rea coo pdb ensemble.pdb
- all
- rmsd
- coo
- backbone (or heavy)
- range of protein residues (ex 7-110)
- average
- new file name
- write
- new file name.pdb
- coo
- all
- all
- pdb
- exit
6) This can write the coordinates so that they are on top of each other as when
concatenating the proteins right after AMBER causes them to be of center.
7) pdbstat can also give other statistics about number NOEs and dihedral restraints used.
(consult this website for more details
http://www.nmr2.buffalo.edu/nesg.wiki/Main_Page)
Other program such as molmol can do similar features.
E) The new structures must be validated to make sure they are acceptable for pdb
submission. Since we don’t have procheck or whatcheck installed on any computers we
can use an online resource called Protein Structure Validation Software suite (PSVS)
from http://psvs-1_4-dev.nesg.org/, which also uses pdbstat to qualify the structure. Just
submit the ensemble written from pdbstat and selecy dyana or cyana and any other
features you want and hit submit. This takes about 5 minutes to get feedback. In general
one wants the protein to have Z scores > -3 for both Procheck G and Molprobity
Clashscore.
F) The website http://www.nmr2.buffalo.edu/nesg.wiki/Main_Page offers good details
on how to submit info to PDB and BMRB. 	
  

